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Leptin and the Leptin Receptor: Molecular and Genetic Studies
Leptin, a 16kDa protein, is secreted primarily by adipose tissue. Its effects are 
pleiotropic, with known roles in body mass regulation, haematopoiesis, immune 
function and reproduction.
Studies of the leptin system in females were undertaken to complement existing animal 
and human studies. Serum leptin levels were found to increase in the luteal phase of the 
menstrual cycle raising the possibility of a role for leptin at the time of implantation. 
RT-PCR studies showed that leptin receptors were expressed in the human 
endometrium throughout the menstrual cycle. In these preliminary studies, these 
receptors appeared to be functional in response to leptin; increasing proliferation and 
decreasing TNF-a production in cultured endometrial cells. This implies that leptin has 
a local effect at the level of the endometrium.
Many cytokines are bound to proteins in serum; a proportion of this binding can be 
attributed to a soluble cytokine receptor. Soluble receptors and binding proteins have a 
variety of roles, acting as scavengers, carriers, agonists and antagonists. In order to 
investigate this phenomenon in the leptin system, a radio-receptor assay was developed 
to measure leptin-binding activity (LBA). The leptin receptor has an extracellular 
domain that is common to all isoforms and therefore, LBA may also reflect the binding 
parameters of cell surface receptors. Serum leptin levels of LBA were found to be low 
at birth, high in early childhood, to fall steadily through puberty and remain at the post- 
pubertal levels throughout adult life. This suggests that leptin and LBA has an important 
role in the initiation of puberty. There was no significant variation in LBA during the 
menstrual cycle.
Several single nucleotide polymorphisms (SNP) exist in the leptin receptor gene. 
Studies of two of these SNPs, GLN223ARG and LYS656ASN, present in the 
extracellular domain of the receptor were undertaken to assess if  genetic changes are 
associated with differences in phenotype or effect ligand binding. Homozygosity of the 
G allele of GLN223ARG is associated with lower fat mass, BMI and leptin levels in 
postmenopausal Caucasian females. This polymorphism changes the binding 
characteristics of the receptor, with a higher LBA being associated with homozygosity 
of the G allele. This suggests that the actual binding of leptin to its receptor may be an 
important factor in the regulation of body weight and adiposity.
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Appendices
1.1 Introduction
Leptin is a 16KDa protein, secreted primarily by the adipose tissue and also by the 
stomach, brain and placenta. It is pleiotropic: having known roles in body mass 
regulation, satiety, reproduction, and the immune response. Leptin acts via the leptin 
receptor, a class I cytokine receptor of which there are at least 5 isoforms present in 
humans. This thesis aims to further investigate the role of leptin in human reproductive 
processes and to assess the effect of genetic variation within the leptin receptor on body 
weight and adiposity.
1.2 Adipose tissue
Adipose tissue is increasingly being recognised as an important organ. In recent years, 
the belief that this tissue existed only as a special storage depot for nutrients in the form 
of fat have been largely dismissed. The adipose tissue is a highly metabolic organ able 
to synthesise many proteins (Figure 1.1), including cytokines, such as tumour necrosis 
factor-a (TNF-a) (Hotamisligil et al., 1993), interleukin 6 (IL-6) (Mohamed et al., 
1997), and other proteins including adipsin, a serine protease which is identical to 
complement factor D (Napolitano et al., 1994), plasminogen activator-1 (PA-1) 
(Halleux et al., 1999) and proteins associated with the renin-angiotensin system (Engeli 
et al., 1999). The full function of the adipose tissue is still being elucidated, although 
investigations into its primaiy roles in reproduction and the development of diabetes 
and obesity are underway. The distribution and amount of both brown and white fat, 
present in both males and females is vitally important for good health. Females have 
more fat mass than males and this fat tends to be positioned on the lower body. In 
males, fat appears to accumulate around the abdomen. Central obesity, white fat tissue 
that accumulates at the abdomen, is associated with the development of cardiovascular 
disease and non-insulin dependent diabetes mellitus (NIDDM). In females, a certain 
level of fat mass is essential for reproduction.
1.3 Obesity
Obesity can be defined as at least 20% over ideal weight (Lonqvist et al., 1996) and is 
an increasing concern for many Western and developing societies. Obesity can be 
accompanied by complications such as hypertension, atherosclerosis and NIDDM. 
These disorders, in turn, can lead to heart disease, stroke and premature death. Obesity 
is also related to an increased risk in developing certain cancers, for example, cancer of
2
the colon and of the endometrium (Garfinkel, 1995). Treatment costs for the indirect 
consequences of obesity exceeded $98 million in the United States (US) in 1997 
(American Diabetes Association, 1998). A study in the US of more than 11 000 women, 
showed body mass index (BMI) to be the dominant predictor of developing type 2 
diabetes mellitus (Colditz et al., 1995). Until recently obesity has been considered a 
lifestyle disorder, with the direct cause being overeating and decreased physical activity. 
However, there is increasing awareness that metabolic factors are also important factors 
in obesity (Grossman, 1995).
1.4 The identification of leptin
The study of body mass regulation began in the 1950s. Kennedy (1953) postulated that 
circulating signals were produced, that were in proportion to body weight, and would 
provide information to the brain in order to regulate body mass. It had been observed 
that a number of inbred strains of mice were grossly obese, and infertile. Coleman 
(1973) postulated that a blood-borne factor was responsible for regulating body mass in 
normal weight mice and that in these obese mice, ob/ob {obese) mice, the blood-borne 
factor was absent or mutated. Parabiosis studies were performed. When the blood 
systems of a normal mouse and an ob/ob mouse were joined, the obese mouse began to 
lose weight. This satisfied the hypothesis that a blood-borne factor was responsible for 
the mice losing weight. Another obese strain o f mice, which developed diabetes, db/db 
{diabetes) mice, were also used in the parabiosis experiments. When their blood 
systems were joined with a normal mouse, they did not lose any weight. This allowed 
researchers to postulate that in this strain, the murine obesity was not caused by the 
absence or damage to this blood bome factor, but by another mechanism. Both ob/ob 
mice and normal mice died of starvation after being joined to db/db mice: this was most 
likely to be due to increased amounts of the effective blood bome factor being present.
3
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Figure 1.1 Adipose tissue: principal afferent and efferent signals (Adapted from Mohamed-Ali et 
al., 1998).
In 1994, Zhang et al (1994) used a positional cloning strategy to identify the ob gene in 
mice. RFLP analysis defined the relevant region on chromosome 6. The DNA between 
two markers was cloned into yeast artificial chromosomes (YAC), using 24 clones to 
construct a vector series over the ob region. Exon trapping, a relatively new technique 
for the time, was employed. This techniques allows exons to be isolated from genomic 
clones using a special vector which has splice donor and acceptor sites either side of the 
insert. Digests from the clones, containing the ob gene, were sequenced and the 
sequences matched to a genomic library. RNA from different tissues was analysed by 
northern blotting analysis and RT-PCR for any possible exons of the ob gene being 
expressed.
One exon was found to be expressed in adipose tissue, this provided a candidate for the 
ob gene. An identical product was found in 20-fold lower concentrations in non-obese 
mice. Screening of a mouse adipose tissue cDNA library enabled sequencing o f the ob 
gene itself. The ob/ob mouse has a nonsense mutation in the ob gene, resulting in a 
premature stop codon. The human ob gene was shown to be 84% homologous to the 
mouse gene. Examination of the sequence suggested that the ob gene product, leptin, 
was an 18 kDa protein with a signal peptide sequence to direct secretion, which in turn 
is cleaved to leave a 16 kDa native peptide. The presence of cysteine residues in the 
structure o f this protein indicated a secreted globular protein (Zhang et al., 1994). Using 
fluorescent in situ hybridisation (FISH), the ob gene was mapped to human 
chromosome 7q31.3 (Isse et al., 1995). The human ob gene spans 20 kb, encoding 167 
amino acids. The open reading frame reveals three exons and two introns (Niki et al., 
1996). The first intron is approximately 10.6 kb in length, and occurs in the 5’ 
untranslated region (Isse et al., 1995). Madej et a l (1995) suggested that leptin 
belonged to the family of helical cytokines, on the basis that the leptin gene sequence is 
very similar to the IL-2 gene sequence when using threading analysis. This family 
includes interleukin-2 (IL-2) and growth hormone (GH).
He et al. (1995) described the genomic organisation of the murine obese gene, including 
its promoter. The promoter contains several consensus sequences for transcription 
factors, notably, a stimulatory protein-1 (Spl) motif and a CCAAT/enhancer binding 
protein (C/EBPa) motif. Similar studies have been performed on the human leptin gene. 
Isse et al. (1995) performed analysis of the human leptin gene and identified the 
promoter region using rapid amplification of cDNA ends (RACE). They demonstrated
the presence of czs-regulatory elements including GC boxes, an AP-2 binding site and a 
C/EBPa motif. Gong et al. (1996) investigated a large area (3.5 Kb) of the 5' region of 
the obese gene including the area containing the promoter. They identified a number of 
putative binding sites for known transcription factors such as Sp-1 sites, cAMP response 
element, a glucocorticoid response element and C/EBPa sites. These are of interest as 
other workers have reported leptin gene expression changes in response to both insulin 
(Saladin et al., 1995) and dexamethasone (Murakami et al., 1995). Both o f these 
studies, performed in rats, caused increases in leptin mRNA expression. These effects 
may be transmitted through one or more of the transcription factor binding sites present 
in the obese gene promoter.
1.5 Expression of leptin protein in human tissues
Leptin is primarily expressed and secreted by the adipose tissue in rodents and humans. 
Circulating levels of leptin correlate well with adiposity (Takahashi et al., 1996). Leptin 
expression has also been described in several other tissues. Bado et al. (1998) state that 
the stomach is a source o f leptin. There experiments found that both leptin mRNA and 
leptin protein were present in rat gastric epithelium. They suggest that the presence of 
leptin in the stomach may be involved in the cholecystokinin- mediated effects after 
food intake and possibly in invoking satiety. Breidert et al. (1999) confirm these results 
in humans, showing leptin expression in the gastric epithelial glands and leptin receptor 
isoforms in the epithelium and the mucosa.
Skeletal muscle is also a tissue that expresses leptin. Wang et al., (1998) found ob gene 
expression to be induced by glucosamine in skeletal muscle. This suggests an important 
biochemical link between availability o f nutrients and leptin gene expression. Rat 
hepatic stellate cells have also been identified as a source of leptin (Potter et al., 1998). 
The cells were only found to express leptin after 14 days in culture.
In humans, the placenta and the breast epithelial cells are sites of leptin expression. 
Several studies have shown the leptin production by the placenta (Hassink et al., 1997, 
Masuzaki et a/., 1997, Senaris et al., 1997). Placental leptin may serve to regulate foetal 
growth and development. Smith-Kirwin et al (1998) used RT-PCR analysis to identify 
leptin transcript in total breast tissue, pinpointing the leptin expression to the ductal 
epithelial cells using immunocytochemistiy. They also state that leptin is carried in the 
breast milk to the infant to continue the regulation of growth and development.
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Another source of leptin that has recently been proposed is the brain. Wesiner et al., 
(1999) measured leptin levels in blood taken from the jugular vein and an artery in the 
forearm: they report that leptin levels are higher in the blood sampled from the jugular 
vein and this may suggest release or production of leptin by the brain. Further to this, 
they have calculated the cerebral contribution to the circulating leptin level. Their 
assessment was that the brain contributed 13% and 41% of the circulating leptin levels 
in lean men and women respectively. At present, there are no reports that leptin mRNA 
is present in the brain. This may be due to many o f the studies performed to identify 
leptin mRNA in the brain have used whole brain tissue and not a restricted neuronal 
area or section of brain. The tissue closest to the brain where leptin has been found to be 
expressed is the pituitary gland (Jin et al., 1999). These workers used human normal 
and neoplastic pituitaries to detect leptin mRNA expression by RT-PCR. Their studies 
provide evidence for an auto/paracrine loop in the production of leptin in the pituitary 
gland.
1.6 Identification and cloning of the leptin receptor
Tartaglia et al. (1995) identified the leptin receptor (Ob-R) in mouse choroid plexus. 
They used [125I]-leptin and leptin-alkaline phosphatase fusion proteins to identify the 
receptor. The leptin receptor is a single membrane spanning receptor, o f the class I 
cytokine receptor family. The leptin receptor is similar in structure to the receptors for 
interleukin-6 (IL-6) and leukaemia inhibitory factor (LIF), although Ob-R does not 
utilise the gpl30 signalling accessory chain. Initial experiments predicted that the 
extracellular domain of the receptor was large and that the intracellular domain was 
short, suggesting that this receptor may not have signalling capabilities. Screening of 
cDNA libraries revealed that there are multiple forms o f the leptin receptor. Lee et al. 
(1996) furthered this work by identifying six alternatively spliced forms of the leptin 
receptor in mice and pinpointed a mutation that causes the db {diabetes) phenotype. 
Sequencing of RT-PCR products of Ob-Rb from the db/db mouse showed a 106bp 
insertion between the splice donor site at codon 889 and the splice acceptor site at 
codon 890. The sequence inserted here was identical to the first 106bp of the c-terminal 
end of Ob-Ra exon. This mutant protein then has a termination codon five amino acids 
down after the splice, resulting in a receptor lacking most of the cytoplasmic domain, 
including the essential "box 2" motif which is essential for Jak/STAT signalling.
All forms of the leptin receptor share common N-terminal exons that code for the 
extracellular and transmembrane domains. The C-terminal exon generates mRNA that 
can be alternatively spliced to make the various intracellular domains o f the leptin 
receptor. Several of the isoforms are identical until a lysine residue at position 889, 
beyond this point the receptors have differing cytoplasmic portions and have been 
designated Ob-Ra, Ob-Rb, Ob-Rc, Ob-Rd and Ob-Re. In mice, the isoform Ob-Re 
differed after a histidine residue at position 796: this is likely to encode a soluble form 
of the leptin receptor. Murine and human leptin receptors are very similar in amino acid 
sequence: the extracellular sequence having 74% homology and the intracellular 
sequence 71% homology. In humans four major membrane-bound isoforms of the 
receptor have been reported (Figure 1.3). There is a long form, Ob-Rb or hOB- 
R/B219.2, which has Jak/STAT signalling capabilities, and three short forms, which 
have various length intracellular chains, some of which may be able to signal using 
MAPK (Barr et al., 1999). There is also evidence for a soluble form of the receptor, 
which consists o f only the extracellular domain (Liu et al., 1997).
1.7 Signalling by the leptin receptor
The binding of leptin to the long form of the leptin receptor initiates a complex cascade 
of signalling molecules similar to those resulting from stimulation o f the gpl30 
cytokine receptor family, which includes LIF and IL-6. This family o f receptors 
activates gene transcription using the Janus tyrosine kinases (Jak) and signal transducers 
and activator of transcription (STAT) pathway. On ligand binding, the Jak proteins 
associated with the receptor are auto- and trans-phosphorylated. This induces kinase 
activity which in turn, causes phosphorylation of a tyrosine residue on the receptor 
itself. This area of phosphorylation attracts STAT proteins. These are then 
phosphorylated by the kinase activity. STAT proteins form homo- or heterodimers and 
undergo nuclear translocation. In the nucleus, the STAT complex can bind to DNA and 
alter transcriptional activity (Schindler and Darnell 1995) (Figure 1.4).
Two Jak binding boxes have been identified in the long form of the leptin receptor. Jaks 
are associated with intracellular domain binding sites and phosphorylate the intracellular 
domain on binding (Tartaglia, 1997). Transfections of cell lines with the long form of 
the leptin receptor have identified that STAT 1, 3, 5, and 6 respond to ligand binding. 
Two reports show that STAT 3 and 5 are stimulated in COS cells on ligand binding. 
Only STAT 3 has been identified as a response to ligand binding in vivo (Vaisee et al., 
1996).
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The signalling function of the leptin receptor is similar to that of the EL-6 family of 
receptors, which requires the gpl30 chain to signal. The gpl30 chain is a signal 
transducing receptor component that is required to allow signalling. Baumann et al. 
(1996) carried out an investigation using anti-gpl30 antibodies. These antibodies are 
capable of blocking IL-6 receptor signalling, which requires the gpl30 component. The 
antibodies did not inhibit the leptin receptor signalling, thus, it can be concluded that the 
leptin receptor does not utilise the gpl30 component in its signalling. The leptin 
receptor may utilise a second transmembrane component in its signalling. Growth 
hormone receptors and the G-CSF receptors both undergo homo-oligomerization in 
order to signal. Chimeric receptors were constructed using the intracellular domain of 
the G-CSF receptor and the leptin receptor and vice versa. Both of these constructs were 
able to signal (White et al., 1997). The leptin receptor may not need an accessory 
binding chain and it is postulated that intracellular homodimerization may provide the 
key to leptin signalling (White et al., 1997). Barr et al. (1999) investigated leptin 
receptor internalisation after lignand binding. All forms of the leptin receptor were 
internalised using a clathrin-mediated process, however the rate of internalisation 
varied; the long form o f the receptor was internalised in the shortest time. Ghilardi et al. 
(1996) has shown that the long form of the leptin receptor (Ob-Rb) is able to activate 
STAT 3, STAT 5 and STAT 6, although no other leptin receptor isoform has been 
identified to signal using this pathway. At least two isoforms of the leptin receptor (Ob- 
Ra and Ob-Rb) are believed to be able to activate the mitogen activated protein kinase 
(MAPK) pathway. Yamashita et al. (1998) have demonstrated that the short form of the 
leptin receptor is able to induce the MAPK pathway whereas the long form of the leptin 
receptor was able to induce both MAPK and Jak/STAT pathways. A summaiy of leptin 
rceptor signalling is shown in figure 1.4.
Other workers have suggested the induction of other signalling cascades by leptin. 
Bouloumie et al. (1999) have shown that leptin activated the terminal c-Jun kinase of 
the stress activated protein kinase pathway whilst Zhao et al (1998) report a novel leptin 
signalling mechanism using phosphoinositide-3-kinase dependent activation of cyclic 
nucleotide phosphodiesterase 3B in the decrease of insulin secretion.
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Figure 1.3 Illustration of membrane-bound human leptin receptor isoforms. (Adapted from Barr et 
al., 1999).
Although much is known about cytokine signalling, receptor aggregation, activation of 
the Jak/STAT and MAPK pathways and alteration of gene transcription, the mechanism 
by which cytokine signal transduction is switched off is only now being investigated. 
Starr et al. (1997) described 3 proteins involved in the inhibition of cytokine signalling. 
These proteins are known as suppressors of cytokine signalling (SOCS). Leptin is 
known to activate SOCS-3 in the human hypothalamus (Bjorbaek et al., 1999). As 
SOCS-3 is able to inhibit Jak 2 phosphorylation, it is postulated that excessive SOCS-3 
expression may be a potential mechanism for leptin resistance (Bjorbaek et al., 1999, 
Emilsson et al., 1999).
1.8 Expression of the leptin receptor isoforms in human tissues
Leptin receptor expression varies with isoform. The short isoform of the leptin receptor 
is expressed almost ubiquitously in all tissues, being found in the brain, specifically the 
hypothalamus and choroid plexus, kidney, lung, liver, spleen, stomach, testes and ovary. 
The long form of the leptin receptor is preferentially expressed in the hypothalamus, but 
also in the lung, liver, testes, ovary and adrenal gland. Jin et al. (1999) report the 
presence of both the long and the short forms o f the leptin receptor to be present in 
normal and neoplastic pituitaries. In the human adrenal gland, once again, all three 
membrane-bound iso forms of the leptin receptor were found (Glasow et al., 1999). The 
placenta is a site of leptin receptor expression and is a known site of expression of the 
soluble form of the leptin receptor in mice (Gavrilova et al., 1997). Leptin receptor 
isoforms have been identified in murine foetal tissues, including bone, cartilage, brain, 
lung and kidney (Hoggard et al., 1998). There was no identifiable expression of the 
receptor in foetal heart, liver adrenal gland or pancreas. More recently, the long form of 
the leptin receptor has been identified in human platelets (Nakata et al., 1999). This 
receptor is functional; the effect on the platelets in the presence of leptin is to induce 
platelet aggregation. The workers hypothesise that this may be a linking factor between 
cardiovascular disease and obesity. The long form of the receptor identified in the 
human lung also has a functional effect, this time on cell proliferation (Tsuchiya et al.,
1999). Using RT-PCR, the presence of Ob-Rb was confirmed in both human lung tissue 
and a lung cell line; the proliferative response was observed in the cell line. To 
complement the presence of leptin gene expression in the stomach, Breidert et al. 
(1999) reported the presence of the leptin receptor in the stomach. Specifically the long 
form and other short isoforms were pinpointed to the lower gastric epithelium and 
throughout the mucosa.
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Figure 1.4 Schematic diagram of leptin receptor signalling pathways. After leptin binding and receptor 
homodimerisation, the long form of the leptin receptor activates the Jak/STAT and MAPK pathway. On leptin binding the 
short form of the receptor is reported to activate the MAPK pathway.
1.9The action of leptin
1.9.1 Leptin, satiety and weight regulation
Long-term body weight, in healthy subjects, is well regulated throughout each 
individual’s lifetime (Horn et al, 1996). Kennedy et al. (1953) suggested the lipostatic 
theory; here the size of the body fat store is sensed by the central nervous system (CNS) 
via a factor produced by the adipose tissue itself. This is turn affects energy balance by 
interactions with the hypothalamus. The main action o f leptin, with respect to body 
mass regulation, is in the hypothalamus (Hamann &Matthaei, 1996). Stephens et al. 
(1995) noted high affinity binding of leptin to rat hypothalamus. Hypothalamic 
neuropeptide Y (NPY), released from the arcuate nucleus (Lonnqvist, 1996) stimulates 
appetite and food intake, increases insulin and glucocorticoid concentrations and 
decreases thermogenesis. Leptin binds to receptors in the ventromedial nucleus o f the 
hypothalamus and acts to directly inhibit NPY. Ob/ob and db/db mice and fa/fa  rats 
have high neuropeptide Y expression due to their lack of a fimctional leptin protein or 
receptor (Wilding et al., 1993, Schwartz et al., 1996). Neuropeptide Y is 36 amino acid 
protein, synthesised throughout the brain and at especially high levels in the neurones of 
hypothalamus.
Neurotransmitters that affect food  intake
Stimulatory Inhibitory
Neuropeptide Y 5-hydro xytrypt amine
Orexin CRF
Galanin a-MSH
CART Glucagon-like peptide-1
Melanin-concentrating hormone Interleukin 1
Table 1.1 Neuropeptides that affect feeding behaviours.
Neuropeptide Y is not the only neuropeptide involved with leptin in the maintenance of 
body weight and food intake, the melanocortin system is also of direct importance. This 
system involves proteins that are processed from a precursor, pro-opiomelanocortin 
(POMC) which is produced by neurones within the hypothalamus. Many products of the 
POMC gene, including a-melanocyte stimulating hormone (a-MSH), are involved in 
the regulation of feeding. It is believed that the melanocortin system is responsible for
mediating responses to leptin in the brain. Leptin receptor isoforms have been co­
localised with POMC neurones in the arcuate nucleus (Inui, 1999). Treatment of rats 
and oh/oh with leptin increased the expression of POMC mRNA in the hypothalamic 
area of the brain (Schwartz et al., 1997). Neuropeptides that influence feeding 
behaviours are listed in Table 1.
Treatment o f obese mice with recombinant leptin induces a dramatic weight loss. Ob/ob 
mice increased their physical activity and ate 60% less food, after four days treatment 
with leptin (Haalas et al., 1995). After four weeks, their fat mass had been reduced by 
75%. Normal mice treated in the same manner showed a reduction in their fat mass of 
12 % over the same period. Pellymounter et al. (1995) suggest a role for leptin in 
controlling energy expenditure. When ob/ob mice are treated with leptin, their energy 
expenditure increased. The group initiated a low calorie diet in two groups of ob/ob 
mice. One group was also treated with leptin; the other followed the diet only. The 
leptin-treated mice lost more weight; thus suggesting that leptin has a role in controlling 
body weight. These workers also investigated the effect of long-term leptin 
administration on insulin secretion in ob/ob and wild type mice. After 28 days of 
intraperitoneal injections of leptin, a dose-dependent decrease in insulin secretion was 
observed in the ob/ob mice, but not in the wild type mice (Pellymounter et al., 1995). 
Emilsson et al., (1997) performed in vivo and in vitro experiments on ob/ob mice to 
investigate the action of leptin on insulin secretion. RT-PCR studies showed the 
presence of the long form of the leptin receptor in the pancreatic islets of both the wild- 
type and the ob/ob mouse. Administration of leptin produced a dose-dependent 
inhibition of glucose-stimulated insulin secretion in ob/ob. They postulate that leptin 
overproduction from abdominal adipose tissue, may modify basal and glucose- 
stimulated insulin secretion. They suggest that it is by this mechanism that leptin is 
involved in the development of diabetic syndrome. Ceddia et al (1999) suggest that 
leptin modulates insulin secretion, in the rat, by changing the flux of potassium ions 
through channels in the pancreatic islets. More recent work by Ahren et al. (1999) was 
carried out to investigate the effect of leptin on insulin secretion in a rat insulinoma cell 
line. They found that leptin inhibits insulin secretion by the cell line only when levels of 
intracellular cyclic AMP (cAMP) are high. This provides evidence for a role for the 
cAMP-protein kinase A signal transduction pathway as a target for leptin to inhibit 
insulin secretion in insulin-producing cells.
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1.9.2 Leptin and its relationship with hypothalamic-pituitary-gonadal function
Yu et al. (1997) provided evidence for a role for leptin in hypothalamic-pituitary 
function. These workers performed in vitro studies on rat pituitary glands and on 
median eminence-arcuate nuclear explants form the same animals. Incubation of the 
tissue with various concentrations of leptin caused a dose-related increase in follicle 
stimulating hormone (FSH) and luteinising hormone (LH) in the pituitary and an 
increase in LH-releasing hormone in the arcuate nuclear explants. These data indicated 
that leptin was important in controlling gonadotropin secretion by stimulatory 
hypothalamic and pituitary actions. In both human and rodent anterior pituitaries, leptin 
and leptin receptor isoforms, both the long and short forms, have been identified (Jin et 
al, 2000). This provides further evidence that leptin may have an effect on the 
hormones produced by the anterior pituitary. Both male and female ob/ob mice are 
infertile. Administration of leptin restores the fertility of female ob/ob mice and 
increases luteinising hormone in these mice (Chehab et al., 1997, Ahima et al., 1997). 
Leptin has been shown to induce the onset of puberty in normal female mice (Ahima et 
al., 1997), with leptin initiating earlier opening of the vaginal tract, earlier onset of first 
oestrus cycle and an increase in the weight of the uterus and ovaries when compared to 
the organs of untreated animals. In male ob/ob mice, administration of leptin caused an 
increase in testicular weight when compared to untreated ob/ob controls. Leptin 
appeared to increase cellular activity in the seminiferous tubules, associated with an 
increase in testosterone levels (Barash et al., 1996). This provides evidence that leptin 
has an effect at the hypothalamo-pituitary-gonadal level. Leptin receptors have also 
been identified in reproductive tract tissues including the ovaries and testes. These 
receptors may be responsible for transmitting a signal directly to the organ, rather than 
via the hypothalamo-pituitary-gonadal axis. All of these studies provide strong evidence 
for a role for leptin and its receptor in primary reproductive processes, and not only as a 
secondary effect of energy balance.
1.9.3 Leptin interaction in the cytokine network
Leptin has been reported to interact with the cytokine network in a number of different 
situations. The presence of leptin is a necessary factor for the proinflammatory immune 
response (Matarese, 2000). The db/db mouse has reduced levels of T and B 
lymphocytes (Bennett et al., 1996), this suggest that leptin may have an important role 
in lymphopoiesis. Santos-Alvarez et al. (1999) report the activation of TNF-a and IL-6 
production from human monocytes. They further report that leptin enhances the
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activation and proliferation o f human circulating T lymphocytes, specifically by 
increasing the production of IL-2 and IFN-y. (Martin-Romero et al., 2000). Leptin is 
believed to be important in the neuroendocrine response to starvation (Ahima et al., 
1996. This corresponds well with murine studies carried out by Lord et al. (1998). 
These workers found that leptin modulates cell-mediated immunity in mice; starvation- 
induced immunosuppression is reversed in mice after treatment with leptin. Evidence 
now exists for the effects of leptin to be mediated by IL-1. Studies have shown that both 
IL-1 and TNF-a increase ob mRNA expression and serum leptin levels at least in 
rodents. In IL-1 p knockout mice, LPS (lipopolysaccharide) did not induce an increase in 
leptin levels, suggesting that IL-1 has an important role in mediating the effects of leptin 
(Faggioni et al., 1998). Luheshi et al. (1999) furthered this work in rats. They found that 
injection of leptin into the brain of normal rats increased the amount of IL-1 p in the 
hypothalamus, and that central injection of IL-1 receptor antagonist (IL-lra) inhibited 
the reduction in food intake caused by leptin. Furthermore, mice lacking the IL-1RI 
gene showed no response to leptin in the reduction of food intake. All these factors 
suggest that IL-1 mediates the action of leptin in the CNS.
TNF-a is a proinflammatory cytokine that is produced by macrophages and the adipose 
tissue. The effect of TNF-a on leptin production is complex. There have been 
contradictory results from adipocyte cell culture studies treated under identical 
conditions; both reporting the stimulation or inhibition o f leptin release in response to 
TNF-a (Finck et al., 1997, Yamaguchi et al., 1998). In cultured adipose tissue from 
obese subjects, TNF-a has been shown to decrease the release o f leptin (Fawcett et al.,
2000). Zhang et al. (2000) report a dual effect of TNF-a on leptin in adipose tissue. 
Firstly, TNF-a stimulates the release of leptin that is stored in mature adipocytes and 
differentiated preadipocytes. Secondly, TNF-a inhibits the synthesis of leptin in 
preadipocyte differentiation and induction of adipocyte dedifferentiation. Other workers 
have found that short term exposure does not have an effect on leptin production. 
Prolonged exposure (24 hours) results in a concentration dependent inhibition o f leptin 
expression and secretion by the adipocyte, at least in the obese subject (Medina et al, 
1999). At present the mechanism by which TNF-a evokes its effect on leptin is not 
known although it has been reported that TNF-a acts directly on the adipocyte via the 
receptor p55 TNFR to increase leptin release (Finck and Johnson, 2000). There is now
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some speculation as to the contribution of TNF-a and leptin to the development of 
insulin resistance and diabetes (Sethi and Hotamisligil, 1999)
1.10 Physiology of leptin concentrations in humans
1.10.1 Leptin concentrations in the normal, healthy human
Leptin is expressed and secreted as a 16KDa protein primarily by the by adipose tissue 
(Hassink et al., 1997, Considine et al., 1996) and also by the stomach (Bado et al.,
1998), skeletal muscle (Wang et al., 1998), brain (Weisner et al., 1999), the mammary 
gland (Smith-Kirwin et al., 1998), and by the placenta during pregnancy (Hassink, et al, 
1997). Leptin shows characteristics of both hormones and cytokines, having a circadian 
rhythm (Sinha et al., 1996a) and a pulsatile secretion (Sinha et al., 1996b). Sinha et al. 
(1996a) noted a nocturnal increase in serum leptin, with the peak being midnight and 
the early hours, the nadir being in the early afternoon. It has been postulated that this 
increase in leptin may suppress appetite during the night. The nocturnal increase in 
leptin mirrors those of prolactin and thyroid stimulating hormone (TSH). This circadian 
rhythm is now thought to be associated with the timing of meals as opposed to a true 
pattern of secretion (Sinha, 1997). Basal levels of leptin are markedly increased in obese 
subjects. As the primary source of leptin is the adipose tissue, leptin levels correlate 
well with markers of adiposity and weight such as body mass index (BMI) (Considine 
et al., 1996b) and percentage body fat. Hickey et al. (1996) provide evidence o f a 
gender dichotomy of the leptin-adiposity relationship. Leptin levels are higher in 
women than men at any level of fat mass. Schwartz et al (1996) also reported a similar 
increase in serum leptin in females as opposed to males. The sex difference in levels of 
leptin is likely to influence and be influenced by the levels of sex hormones (Elbers et 
al., 1997). Weisner et al. (1999) suggest that expression of leptin by the brain may also 
contribute to the gender difference observed. There is a decrease in levels of leptin after 
the menopause (Rosenbaum et al., 1996) this is likely to reflect a reduction of female 
sex hormones and age (Ostland et al., 1996, Elbers et al., 1997). Subjects with anorexia 
nervosa have also been studied. Grinspoon et al. (1996) measured serum leptin in 
women with BMI of 16.3 ±1.3 kg/m2. They found that serum leptin is still correlated 
with BMI even at low body weight, but, more recent studies have suggested that the 
reduction in serum leptin levels in women with anorexia nervosa is greater than can be 
accounted for by the subjects BMI (Herpetz et al., 1997). Successful refeeding of
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anorectic subjects results in an increase in leptin levels that does correlate with BMI, 
thus restoring the normal leptin/BMI relationship (Eckert et al., 1998).
1.10.2 Leptin in early childhood
The role of leptin during childhood has been investigated. It is postulated, that in 
children, leptin does not only regulate adiposity but is also an important growth factor. 
Leptin is detectable in cord blood and the levels of leptin are often extremely high just 
after birth. These then decrease dramatically in the early neonatal period. This is 
believed to be an important part of the adjustment to the extrauterine environment 
(Hytinantti et al., 1999) and in the stimulation of feeding behaviour (Schubring et al.,
1999). The sexual dimorphism of leptin concentrations seen in adults has also been 
reported in neonates: females have significantly higher leptin levels than males (Maffeis 
et al., 1999, Ong et al., 1999). In studies of healthy neonates, those who were large for 
gestational age and those who were small for gestational age, leptin levels were found to 
correlate with birthweight, placental weight and insulin levels (Varvarigou et al., 1999).
1.10.3 Leptin during pregnancy
Leptin levels are increased throughout pregnancy in humans, mice and rats, suggesting 
a significant role for leptin during pregnancy. This increase in circulating leptin 
concentration may be due to either: an increased production by the adipose tissue; the 
addition of placental leptin production or an increased level o f binding proteins present 
in the circulation causing an increase in leptin production. Kawai et al (1999) 
investigated the distribution of leptin receptors within the placenta. From their studies in 
pregnant rats, they found that the various isoforms of the leptin receptor co-localised 
with placental lactogen-II. The expression o f the receptors increased throughout the 
pregnancy and it is this fact they suggest proves an important role for leptin during the 
whole pregnancy. Mounzih et al. (1999) studied the role of leptin during the 
pregnancies of mice. Their studies indicated that leptin was not critical for implantation 
and growth in the normal mouse, but, instead was a necessary factor for a leptin 
resistance state from mid-pregnancy, in order to stimulate food intake and have 
sustained energy reserves available for the duration of the pregnancy. It is possible that 
leptin is increased in human pregnancy as a result of a leptin resistance state that has 
occurred in order to increase food intake, so that adequate reserves are available.
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1.11 Leptin in disease
Leptin levels have been studied in a variety o f disease states including cancer-induced 
cachexia, AIDS, renal disease and NIDDM.
1.11.1 Leptin, obesity and NIDDM
In humans, obesity appears to be a result o f leptin resistance, as many obese subjects 
have high circulating leptin levels. Banks et al. (1999) have demonstrated a reduction in 
the capacity of the blood brain barrier to transport leptin in obese mice. This reduction 
is not secondary to higher leptin levels being present in the serum, but to a physical 
reduction in the capacity of the BBB to transport leptin. Obesity is also associated with 
insulin resistance. It is possible that impaired or reduced leptin secretion is important in 
the development of diabetes. Hathout et al. (1999) investigated the hypothesis that 
insulin is involved in the regulation of leptin by measuring serum leptin before and 
during diabetic ketoacidosis in human subjects. During ketoacidosis, the researchers 
observed a decrease in serum leptin levels. When the patients were treated with insulin, 
the levels of leptin increased, leading these workers to postulate that insulin is the link 
between leptin and caloric intake. Several reports have suggested that leptin reduces 
insulin secretion from pancreatic beta cells (Emilsson et al., 1997, Seufert et al., 1999). 
One mechanism that has been proposed to explain the reduction in the secretion is 
through activation of a potassium channel. Harvey et al. (2000) demonstrate that 
activation of the K-ATP channels in the pancreatic islets by leptin, requires 
phosphoinositide 3-kinase (PI-3 kinase). These workers postulate that the leptin receptor 
can interact directly with PI-3 kinase (similar to the p55 TNF receptor) to activate K- 
ATP channels in the pancreatic islets. Liu et al. (1999) studied diabetic and normal 
subjects hypothesising that the leptin secretory response was an important factor in the 
development of obesity and diabetes. Their diabetic subjects showed normal leptin 
levels under basal conditions, but a poor leptin response to glucocorticoid levels. This 
may be due to the accompanying insulin secretory deficiency. Diabetes is a 
multifactoral disorder, which is unlikely to be easily explained by impaired or abnormal 
leptin secretion alone. Das (1999) proposes that it is a combination of factors including, 
TNF-a, glucose transporter-4 (GLUT-4) and leptin interact in the development of 
insulin resistance, obesity and NIDDM.
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1.11.2 Leptin and cachexia
There is debate as to whether leptin has a role in cachexia and wasting in response to 
infection. As leptin is intrinsically involved in the regulation of energy intake and 
weight control, it is possible that it may also have a role in cachexia. Other cytokines, 
such as IL-1, TNF-a and IL-6 (Mantovani et al., 1998), have an important function in 
the development o f cachexia. As TNF-a stimulates secretion o f leptin, Inui (1999) 
postulates a role for leptin in cancer-associated cachexia. Grunfeld et al. (1996) 
investigated serum leptin levels in patients with AIDS. They found that leptin levels 
were not increased, relative to body fat, in subjects with cachexia, therefore they suggest 
that leptin is not associated with infections in AIDS patients. Simons et al. (1998) 
studied leptin levels in patients with lung cancer-associated cachexia. They 
hypothesised that underlying abnormalities in the leptin feedback system in cancer may 
be the cause of cachexic wasting. The results of their studies showed that leptin was not 
associated with increased appetite or decreased energy expenditure, and therefore the 
hypotheses of a defective hypothalamic feedback loops are confirmed. Roberts et al., 
(1998) hypothesised that decreased serum leptin levels would be associated with end- 
stage liver disease (ESLD). These workers showed that serum leptin levels were lower 
than control levels in their cohort of children with ESLD; the levels in the subjects with 
ESLD did not correlate with fat mass. Moreover, after the children had undergone a 
liver transplant, serum leptin levels decreased further yet measures of body fat 
increased. The correlation observed between fat mass and serum leptin was restored. 
Roberts et al. (1998) suggest that the relative increase in serum leptin levels during 
paediatric ESLD suggests that leptin in this case, is not just a passive marker of body fat 
but, provides a link for leptin to cachexia.
1.11.3 Leptin in renal disease
Leptin receptors are abundantly expressed in the kidney. Studies performed on 
glomerular epithelial cells from rats showed that leptin induced TGF-P production and 
proliferation of renal cells. This provides evidence for a role for leptin in accelerating 
kidney damage. The kidney has a vital role in removing leptin from the circulation 
(Cumin et al., 1997, Meyer et al., 1997). Serum leptin concentrations are known to be 
elevated in renal disease (Koo et al., 1999). Landt et al. (1998) report that the 
hyperleptinaemia associated with end-stage renal disease (ESRD) is reversed after organ 
transplant. Further to this Fouque et al., (1998) showed that both growth hormone and
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IGF-1 were important in controlling leptin secretion in the dialysis patient this, 
however, may be due to a variation in insulin secretion in these subjects. Leptin is 
known to be increased above the levels expected for body fat mass in patients with renal 
disease. Subjects with renal disease often are nutritionally insufficient and their diets are 
heavily supplemented (Johansen et al., 1998). These workers showed that the increased 
leptin levels in these patients were associated with low serum albumin levels and with a 
decrease in protein catabolism. A combination of insufficient removal of leptin by the 
kidney and the concomitant damage that leptin may cause to renal tissue add to the 
hypothesis that leptin may act as a cachectic factor in renal disease.
1.11.4 Leptin and polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) is associated with insulin resistance, obesity and 
infertility (Baranowska et al., 1999). The central abnormality of polycystic ovary 
syndrome (PCOS) is hyperinsulinaemia, which, in turn, leads to ovarian overproduction 
of testosterone. These changes affect the pituitary-ovarian axis, leading to abnormal 
production of LH and FSH. The result o f the LH and FSH abnormalities is ovarian 
underproduction of oestrogen, along with abnormal production of progesterone, 
overproduction of testosterone, and amenorrhoea and infertility. There is an increased 
risk of miscarriage in women with PCOS; this is attributed to increased testosterone, 
insulin, or to low levels of progesterone and oestrogens. Baranowska et al. (1999) 
investigated the role of leptin in women with PCOS. They found that plasma leptin was 
increased in obese women with PCOS when compared with their control lean women. 
As expected, serum insulin concentration was also raised in their cohort of obese 
women with PCOS. As positive correlations exist between leptin and BMI, and leptin 
and testosterone in women with PCOS, they suggest that a disruption to the leptin 
feedback system exists in women with PCOS. Chapman et al., (1997) investigated the 
role o f leptin in 85 women with PCOS. They used specific criteria to define their cohort 
of women with PCOS. All the subjects had abnormal ovarian morphology on 
ultrasound, and at least two; increased serum testosterone; increased serum 
androstenedione and decreased sex hormone binding globulin (SHBG). Their results 
indicated that circulating leptin concentrations in women with PCOS, were strongly 
related to BMI and were not independently affected by circulating levels of insulin, 
gonadotrophins or sex hormones. Rouru et al. (1997) agree with these data, as they 
found no evidence for a difference in leptin levels between women with polycystic 
ovary syndrome and regularly cycling women. A recent study by Maliqueo et al. (1999)
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showed no difference between serum leptin levels between normal women and in 
women with PCOS. They suggest that although the two groups are metabolically 
different, in the women with PCOS, the effects of insulin resistance and increased 
androgens counteract each other. This area of research is still controversial and more 
work to elucidate if leptin has a primary role in the development and continuation of 
PCOS, needs to be undertaken.
1.12 Genetic changes within the leptin and leptin receptor genes
1.12.1 Mutations in the human leptin gene
Defects in the ob gene are rare in human obesity. Carlsson et al (1997) attempted to 
detect ob gene mutations in 100 obese patients, but did not find any such mutations. 
Changes that lead to mild abnormalities in ob gene expression may, however, reflect an 
altered set point for body mass and therefore play a smaller role in human obesity. 
Montague et al (1997) provide the first genetic evidence that leptin is an important 
regulator o f energy balance in humans. Their studies focus upon 2 children, from a 
highly consanguineous family of Pakistani origin who, although extremely obese, have 
very low leptin levels. These children, a male and a female, are not only obese, but have 
an extreme hyperphagia. The children are homozygous for a frame-shift mutation 
resulting in the deletion of a single guanine nucleotide in codon 133. The four parents 
and one of four siblings were heterozygous for this mutation, but were o f normal body 
weight and had expected leptin levels. This is the first evidence of a mutation in the 
human ob gene and is an important step in the search for a genetic cause of obesity. In 
the three years since the discovery of this mutation, no other individuals have been 
identified with this mutation of the leptin gene.
Another mutation in the leptin gene that causes extreme obesity and hyperphagia has 
been identified. This mutation was observed in consanguineous family of Turkish 
origin. The subjects also have low level of serum leptin, but the mutation in the leptin 
gene is different to that described by Montague et al. (1997). The mutation that gives 
rise to the extreme obesity and hypogonadism in this family is a missense mutation at 
codon 105, the same codon that is mutated in the ob/ob mouse. In this family, the 
mutation does not give rise to a premature stop codon, but leads to an amino acid 
substitution of an arginine for a tryptophan at position 84 of the mature protein. The 
protein itself is synthesised correctly, but is not secreted. In total, three affected
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members of this family have been identified. All are homozygous for the mutation. 
Again heterozygotes have normal levels of leptin and are not obese. Ozata et al., (1999) 
have performed a detailed assessment of the endocrine, immune and sympathetic 
systems in this affected family. All of the affected adults had hypogonadism and had not 
entered puberty. This defect appears to be at the level of the hypothalamus as all 
patients showed a normal response to gonadotrophin releasing hormone (GnRH). The 
heterozygotes, both males and females, had normal pubertal development and most 
have had children. In total 30 children were observed in the pedigree, of these, 11 were 
severely obese and homozygous for the leptin gene mutation and of these, 7 have died 
from infections. The remaining 19 non-obese children heterozygotes and homozygous 
for the functional leptin gene, are alive and healthy. This family has an odds ratio of 
death due to an obese phenotype of 25.4. This indicates that the mutation present in the 
leptin gene severely impairs the ability to survive past childhood. The authors postulate 
that this is due to due to diminished immune function which is also seen in the ob/ob 
mouse and demonstrated in vitro by Lord et al. (1998) who showed that leptin promotes 
T cell activity.
1.12.2 Polymorphisms within the leptin gene
Several polymorphisms are known to exist within the leptin gene itself. Oksanen et al. 
(1997) describes a novel single nucleotide variation in the obese gene promoter in 
cohorts of lean and obese Finnish subjects. The substitution of an A for a C occurs at 
position -188, upstream o f the start site. They did not find any significant association 
between this polymorphism and levels of leptin, BMI or other obesity markers such as 
insulin or lipids. However, this polymorphism is in close proximity to several putative 
regulatory elements and they suggest that it may be important in the regulation o f these 
elements. Karvonen et al., (1998) describe four gene variants in their study o f Finnish 
subjects:
1. an A to G change at position +19,
2. a C to T substitution 33bp downstream o f the termination codon.
3. a third base change at codon 48 which changes a G to an A,
4. a substitution at codon 110, which changes an alanine to methionine.
The latter two variants are rare polymorphisms, but are associated with low leptin levels 
in two obese subjects, who were both heterozygous for the variation. They found no
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other association between leptin levels, BMI or other markers of obesity and these 
polymorphisms.
Hager et al. (1998) documented the presence of a novel polymorphism in the 5’ 
untranslated region of the human obese gene. The A to G substitution occurs at position 
19 of untranslated exon 1. They report that a variant of this polymorphism is associated 
with lower leptin levels in a cohort of morbidly obese subjects and also in a cohort of 
randomly chosen lean and obese Caucasian women. Oksanen et al. (1998) analysed the 
effect of the C-188A polymorphism on the activity of the leptin promoter. They 
demonstrated that reporter gene constructs driven by the wild-type (-188C) or variant (- 
188A) promoters did not reveal any genotype-associated difference in the binding of 
cellular proteins and therefore, there was no direct discernible difference in promoter 
activity due to this polymorphism.
1.12.3 Mutations in the human leptin receptor gene
Recently, a single mutation in the human leptin receptor gene has been identified. 
Clement et al., (1998) investigated a consanguineous family of Kabilian origin with a 
prevalence of morbid obesity occurring in early life. These subjects have extremely 
elevated leptin levels, even when taking their obesity into account; they also have a 
complete absence of pubertal development. Using single stranded conformational 
polymorphism (SSCP) analysis, the workers identified a mutation in exon 16 o f the 
human leptin receptor. This genetic change was not present in a large cohort o f lean and 
obese controls indicating that it is a rare mutation. Sequencing of exon 16 in an affected 
subject revealed a G to A substitution in the splice donor site. Amplification of cDNA 
from the region around exon 16 (exons 15-17) was performed; this region is common to 
all transmembrane domain-containing isoforms of the leptin receptor. In those subjects 
homozygous for the mutant allele, a truncated form of the leptin receptor is produced; 
this lacks the transmembrane and intracellular domains and, as such, results in 
production of a large amount of soluble leptin receptor. Heterozygotes for this mutation 
are obese, but have normal pubertal development. This mutation shows that the leptin 
receptor is not only important in obesity, but also in pubertal development.
1.10.4 Polymorphisms within the leptin receptor gene
Considine et al. (1996) were the first to identify single nucleotide polymorphisms in the 
coding region of the leptin receptor gene. The main objective of these studies was to
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find a mutation, similar to that of the db/db mouse or the fa/fa  rat, in the human leptin 
receptor gene. In this small study of 15 African-American male subjects, using RT-PCR 
analysis of hypothalamic tissue, Considine et al. (1996) did not find any similar 
mutation. They did, however, identify the single nucleotide polymorphism at codon 223 
(GLN223ARG). This polymorphism results in the substitution of a glutamine with an 
arginine. Further studies of this and other polymorphisms have been performed by other 
workers in several populations. Echwald et al., (1997) used SSCP analysis to identify 
eight sequence variations within the long form of the leptin receptor in young Danish 
males including both lean and obese subjects. Four of these variants were present in the 
coding region, LYS109ARG, LYS204ARG, GLN223ARG, and LYS656ASN, all of 
these SNPs result in an amino acid change and, therefore, potentially result in changes 
in receptor function. No significant difference in allele frequency between the lean and 
obese subjects for any polymorphism was observed. Matsouka et al. (1997) studied 
polymorphic variation in a population of lean and obese Japanese subjects. Using 
automated sequencing, they identified 7 variants in the long form of the leptin receptor. 
Two of these, SER492THR and ALA976ASP, were novel polymorphisms in the coding 
region of the leptin receptor gene. These workers did not observe any significant 
differences in allele frequency between the lean and obese groups for any 
polymorphism.
Gotoda et al. (1997) identified five coding sequence variants, LYS109ARG, 
GLN223ARG and LYS656ASN as previously reported and two novel polymorphisms 
at codons SER343SER and PRO1019PRO, in a case control study of white British 
males aged 40-64 years. These novel variants do not result in an amino acid change. 
They demonstrated that all of these five variants were in strong linkage disequilibrium, 
as out of thirty-two possible haplotypes, just six accounted for more than 95% of all 
haplotypes in all subjects. There was no significant association between any o f the 
genotypes and BMI, skinfold thickness, plasma insulin, triglycerides and glucose in the 
obese subjects. Mean BMI in the lean subjects was significantly lower in the subjects 
homozygous for the common allele of the SNP LYS656ASN. They postulate that this 
single observation was identified as it may portend to maintenance of low body weight 
rather than obesity. Thompson et al. (1997a) observed an association between 
homozygosity of the G allele and lower leptin levels in a cohort of Pima Indians. They 
also found an association between this polymorphism and insulin secretion in NIDDM 
Pima Indians. Earlier, they reported that a gene governing the acute insulin response
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was in close proximity to the microsatellite marker, D1S198 (Thompson et al., 1995), 
on chromosome 1. The leptin receptor gene, they now postulate, may be this element 
(Thompson et al., 1997b). Recently, Chagnon et al. (2000) have identified associations 
between polymorphisms in the leptin receptor gene and adiposity in middle-aged male 
subjects. In their study, carriers of the A allele of the SNP GLN223ARG, had higher 
BMI, fat mass, percent fat mass and leptin than non-carriers. They postulate that the 
leptin receptor gene variation has a significant effect on adiposity, at least in Caucasian 
male subjects aged 44-64 years. Figure 1.5 shows the position of the polymorphisms in 
the coding region of the leptin receptor.
Another polymorphism in the 3’ untranslated region of the leptin receptor is associated 
with serum insulin levels in obese subjects (Oksanen et al., 1998). Serum insulin is 
higher in subjects homozygous for the absence of the insertion. This insertion of 
CTTTA occurs 60 nucleotides after the stop codon. They postulate that its presence 
generates an A + U rich mRNA sequence, this is also known as the A+U-destabilising 
element, that may be able to form a stem-loop structure. This feature may affect mRNA 
stability within the cell. Stem-loop structures are known to exist in other cytokine 
transcripts, for example, granulocyte-colony stimulating factor (Brown et al., 1996). It 
is suggested that these sequences are important in binding regulatory proteins, which 
may affect the translation rate or degradation of mRNA.
It is likely that leptin receptor gene variants have an important role in the maintenance 
of body weight and adiposity.
1.11 Aims of the study
Since leptin is known to be an important factor in the regulation and maintenance of 
body mass and in the maintenance and facilitation of reproductive function, studies to 
further elucidate the role of leptin in these processes were performed.
There were three main aims of the studies described in this thesis:
1. to develop and validate an assay to measure serum levels of leptin-binding activity 
and use this to examine the effect of leptin binding in serum.
2. to investigate the role of leptin and the leptin receptor in human reproductive 
processes such as pregnancy, the normal menstrual cycle and puberty
3. to identify any associations between leptin receptor polymorphisms and measures of 
body weight and adiposity, to assess the effect of genetic variation on receptor 
function and to examine the effect of linkage disequilibrium in this population.
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These studies should enable the further elucidation of leptin’s role in reproductive 
function and to assist in understanding the genetic influence of leptin in body mass 
regulation.
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2.1 Nucleic acid purification techniques
2.1.1 Genomic DNA Extraction
2.1.1.1 Buffers required fo r  DNA extraction 
Buffer A
0.32M sucrose (Sigma),
0.01M Tris base (Sigma),
0.15M MgCl2 (Sigma),
The pH was altered to 8 with concentrated hydrochloric acid. The buffer was then 
autoclaved and once cool, 1% Triton (Sigma) was added.
Buffer B 
0.4M Tris base,
0.06M EDTA (Sigma),
0.005M NaCl (BDH),
The pH was altered to 8 with concentrated hydrochloric acid. The buffer was autoclaved, 
and once cool, made-up to 1L. SDS (Sigma) was added to a final concentration of 1%.
2.1.1.2 DNA extraction protocol
20 ml of venous blood was collected into tubes anticoagulated with EDTA. To this, 
30ml of Buffer A was added to provide hypotonic lysis of the cells and thus, remove the 
haemoglobin and other cellular proteins. This was then mixed end-over-end for 4 minutes 
at room temperature (RT), and centrifuged (Sorvall RT 6000D) at RT, lOOOg for 15 
minutes. The supernatant was removed and discarded and the pellet (containing the 
white cell nuclei) resuspended in 20ml of buffer A. This was centrifuged again, at RT, 
lOOOg for 15 minutes. Again the supernatant was discarded and 1ml of buffer B was 
added to resuspend the pellet. The suspension was then transferred to an eppendorf tube; 
300pl of 5M sodium perchlorate was added, to precipitate the proteins, and the sample 
rotated end-over-end for 10 minutes followed by high speed microcentrifugation,
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lOOOOg, for 10 minutes. In a clean eppendorf tube, 600pl of supernatant was added to 
700pl of ice-cold chloroform. The sample was then mixed end-over-end for 3 minutes 
and centrifuged at high-speed (10 OOOg) for 10 minutes, in a microcentrifuge. The upper 
layer was then transferred to a clean eppendorf tube and twice the volume of ice-cold 
ethanol was added to precipitate the DNA. This was gently mixed and centrifuged 
(Sorvall Super T21) at 4°C, lOOOOg for 15 minutes. The supernatant was removed and 
the DNA pellet allowed to air-dry for 10 minutes. The pellet was resuspended in water 
(200-500pl o f water depending on the pellet size) and rotated en-over-end for 1 hour at 
4°C.
2.1.1.3 Assessment o f  DNA purity and concentration
The concentration of human genomic DNA was estimated by measurement o f the 
absorbance at 260nm (GeneQuant spectrophotometer). In a lcm-pathlength quartz 
cuvette, 1 absorbance unit at 260nm is equal to 50mg/ml of DNA. DNA samples were 
diluted (5pi of stock DNA solution in 995pl of water) and the absorbance measured at 
260nm. The stock DNA was diluted in water to a final concentration of 50ng/pl. 
Samples were stored at -20°C until required.
The purity of each of the DNA samples was assessed as the concentration was estimated. 
The absorbance was measured at 260nm and 280nm in a lcm-pathlength quartz cuvette 
and a ratio calculated. A ratio of 1.8 was considered a pure sample. The quality o f the 
DNA samples was assessed by agarose gel electrophoresis (Figure 2.1) An example of 
pure, good quality DNA is shown in Figure 2.1.
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Figure 2.1 Genomic DNA electrophoresed on a 1% agarose gel and stained with ethidiuin 
bromide. The first lane contains DNA ladder f({)174 DNA Haelll), the next three lanes (2-4) 
Contain genomic DNA.
3 3
2.1.2 RNA extraction from lymphocytes, tissue and cultured cells.
Extraction of RNA from lymphocytes, cultured cells and tissues uses a modified method 
first described by Chomczynski and Sacchi (1987). Homogenisation or lysis of the cells 
or tissue in the RNAzol (Biogenesis, Poole, Dorset) or Tri Reagent (Sigma) allows the 
integrity of the RNA to be retained whilst the cells are disrupted and the cell components 
are dissolved.
2.1.2.1 Extraction o f  RNA from Lymphocytes
Whole blood was collected into Vacutainer™Jubes anticoagulated withEDTA. 45ml o f 
lymphoprep (Nycomed, Oslo, Norway) was placed into a sterile universal tube (Falcon). 
An equal volume of blood was carefully layered oyer the jymphoprep. This was 
centrifuged (Sorvall RT 6000D) at RT, 400g, for 30 minutes. The mononuclear cells 
from the bufly coat were harvested into a sterile 50ml tube. The tube was topped up to 
50ml with lx  phosphate buffered saline (PBS) and centrifuged, as before, for 5 minutes. 
The supernatant was discarded and the cell pellet washed and resuspendedin 5jQml of lx 
PBS. Again this was centrifuged for 5 minutes. The supernatant was discarded and the 
cell pellet was vigorously resuspended in 1ml of RNAzol (Biogenesis, Poole, Dorset) or 
Tri Reagent (Sigma). At this stage the samples could be stored frozen at -80°C until the 
RNA extraction procedure was carried out.
2.1.2.2 Extraction o f  RNA from cultured cells
All cultured cells used were adherent cells that .grew in monolayers. The volume of the 
plastic flask was measured. The cell culture media was removed and the cells washed 
twice in 10ml of lx  PBS to remove any cell debris. To the flask, 1ml of RNAzol or Tri 
Reagent was added per 4 0cm3 of flask area. Por example, if  the area of the flask was 
75cm3, 7.5ml of RNAzol or Tri Reagent was added. The liquid was pipetted vigorously 
until the cells had lysed. At this stage the samples could be stored frozen at -80°C until 
the RNA extraction procedure was carried out.
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2.1.1.3 Extraction o f  RNA from tissue samples
Small pieces of tissue, approximately lg in weight, were frozen in liquid nitrogen and 
crushed with a sterile pestle and mortar. The freezing made the tissue extremely brittle 
and therefore, very easy to break into small fragments. It was extremely important to 
keep the tissue frozen, this had a dual purpose, to stop the RNA from degrading and also 
to allow the samples to be easily fragmented. Once the samples had been adequately 
crushed, 1ml of RNAzol or Tri Reagent was added. The tissue was pipetted vigorously 
until in suspension. At this stage the samples could be stored frozen at -80°C until the 
RNA extraction procedure was carried out.
2.1.1.4 RNA Extraction Protocol
Frozen samples were allowed to thaw on ice. The extraction procedure was the same for 
all sample types whether frozen or not. The samples were mixed and then incubated on 
ice for 5 minutes. To this, lOOpl of ice-cold chloroform (per ml of RNAzol) was added 
and incubated on ice for 10 minutes. The samples were then centrifuged (Sorvall Super 
T21) for 15 minutes, 10 OOOg at 4°C. The upper aqueous layer (approximately 500pl) 
was removed and an equal amount of ice-cold isopropanol was added. This was inverted 
gently and allowed to incubate on ice for 1 hour, this process allowed precipitation of the 
RNA. At the end of this time, the sample was centrifuged as before for 15 minutes. The 
supernatant was discarded and the pellet gently resuspended in 250pl of 80% ethanol. 
This was centrifuged at 4°C, 10 OOOg for 5 minutes, the ethanol removed and the pellet 
allowed to air-dry for 10 minutes. The pellet was then resuspended in 20-50pl of sterile 
(suitable for injection) water.
2.1.1.5 Assessment o f  RNA purity and concentration.
The concentration of RNA in each sample was assessed by measurement of the 
absorbance at 260nm. In a lcm-pathlength quartz cuvette, 1.0 absorbance unit at 260nm 
is equal to 40pg o f RNA. The samples were adjusted to a concentration of 1 |ig/pl with 
sterile water. Samples were stored at -80°C until required. As the concentration was 
assessed, the purity of the RNA sample was calculated by measuring the ratio of 
absorbancies at 260nm and 280nm. A ratio of 2.0 was considered pure.
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2.2 Polymorphism Analysis
2.2.1 Polymerase Chain Reaction (PCR) screening for polymorphisms in the leptin 
receptor
PCR was performed using either purified DNA or dried blood spot as a template. Three 
polymorphisms in the leptin receptor were investigated; GLN223ARG, LYS656ASN, 
LYS204ARG.
Primers to amplify the polymorphic regions of the leptin receptor were taken from 
Echwald et al., (1997). The primer sequences for the PCR analyses are listed in appendix
I.
2.2.1.1 GLN223ARG andLYS204ARG 
2.2.1.1a PCR from purified genomic DNA
PCR reactions were out carried in a 50pl volume containing; PCR buffer (a final 
concentration of 20mM Tris-HCl, 50mM KC1) (Gibco), 2.5mM magnesium chloride 
(Gibco), 0.6pM of the forward primer, 0.6pM of the reverse primer, 0.2mM 
deoxynucleotide triphosphates (dNTPs) (Gibco), lOOng of DNA template. A negative 
control was included in each batch of PCR, here the DNA template was replaced with 
2pl of water. Reaction mixes were overlaid with 40pl of mineral oil (Sigma). The tubes 
were placed onto a thermocycler (Biometra) and heated to 95°C for 10 minutes. The 
samples were cooled to 4°C and 2.5 units of Taq DNA polymerase (recombinant from 
Thermus aquaticus) (Gibco) were added to each reaction. The PCR was carried out on a 
thermocycler using the following conditions: heating to 95°C for 3 minutes, 35 cycles of 
heating to 95°C for 1 minute, annealing at 55°C for 1 minute and extension at 72°C for 1 
minute, followed by a final extension period of 72°C for 5 minutes. The PCR products 
were stored at 4°C until required for electrophoresis and restriction endonuclease 
digestion.
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2.2.1.1b PCR from dried blood spots
PCR reactions were out carried in a 50pl volume containing; PCR buffer (a final 
concentration of 20mM Tris-HCl, 50mM KC1) (Gibco), 2.5mM magnesium chloride 
(Gibco), 0.4pM of the forward primer, 0.4pM of the reverse primer, 0.2mM 
deoxynucleotide triphosphates (dNTPs) (Gibco). A very small piece of filter paper 
covered with dried blood, approximately 1mm2 was added to the tube containing the 
mix. A negative control was included in each batch of PCR, here the dried blood spot 
was replaced with 2pl of water. All the reactions were overlaid with 40pl of mineral oil 
(Sigma). The tubes were placed onto a thermocycler (Biometra) and heated to 95°C for 
10 minutes. The samples were cooled to 4°C and 2.5 units of Taq DNA polymerase 
(recombinant from Thermus aquaticus) (Gibco) were added to each reaction. PCR 
cycles were then performed as for the genomic DNA templates.
2.2.1.1c Genotyping GLN223ARG by restriction digest with MspI and 
LYS204ARG by restriction digest with Hinfl
The leptin receptor polymorphisms GLN223ARG and LYS204ARG are both in exon 4 
(Echwald et al., 1997) and both polymorphisms are contained within the 416bp PCR 
product. Therefore, the same PCR product can be used to identify both o f these 
polymorphisms. Digestion of the PCR product with MspI (Promega) allows detection of 
the alleles for GLN223ARG and digestion of the PCR product with Hinfl (Promega) 
allows detection of the alleles for LYS204ARG. Digestion reactions for both 
polymorphisms were identical, and were carried out in a total volume of 30pl, containing 
20pi of PCR product, 3 pi of buffer (final concentrations of 6mM Tris-HCl, 50mM NaCl, 
6mM MgCl2, and ImM DTT), 6pl of water and lp l (10 units) o f restriction enzyme. The 
tubes were incubated in a water bath at 37°C for 2 hours. After digestion, the samples 
underwent 2% agarose gel electrophoresis in order to visualise the different genotypes 
(Figure 6.1, 6.2 respectively In chapter 6).
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2.2.1.2 LYS656ASN
2.2.1.2a PCR from genomic DNA and dried blood spots
PCR reactions were out carried in a 50jil volume containing; PCR buffer (final 
concentrations of 20mM Tris-HCl, 50mM KC1) (Gibco), 2mM magnesium chloride 
(Gibco), 0.2pM of the forward primer, 0.2pM of the reverse primer, 0.2mM 
deoxynucleotide triphosphates (dNTPs) (Gibco), lOOng of DNA template or a small 
piece of filter paper covered in dried blood. A negative control was included in each 
batch of PCR, here the DNA template was replaced with 2pl of water. All the reactions 
were overlaid with 40pl of mineral oil (Sigma). The tubes were placed onto a 
thermocycler (Biometra) and heated to 95°C for 10 minutes. The samples were cooled to 
4°C and 2.5 units o f Taq DNA polymerase (recombinant from Thermus aquaticus) 
(Gibco) were added to each reaction. The PCR was carried out on a thermocycler using 
the following conditions: heating to 95°C for 3 minutes, 35 cycles of heating to 95°C for 
1 minute, annealing at 55°C for 1 minute and extension at 72°C for 1 minute, followed 
by a final extension period of 72°C for 5 minutes. The samples were stored at 4°C until 
analysed by SSCP (Shown in Figure 6.3 in Chapter 6).
2.3 Gene Expression Analysis
2.3.1 Reverse Transcriptase -  PCR (RT-PCR)
2.3.1.1 First strand cDNA synthesis
First strand cDNA synthesis was carried out in 40jal reaction mix containing: 5x AMV 
Reverse Transcriptase Buffer (with final concentrations of lOOmM Tris/HCl, lOmM 
magnesium chloride, lOmM DTT) (Gibco); 50mM potassium chloride (Gibco), lmM 
dNTPs (Gibco); 0.6pg of Oligo d(T) (Gibco). For each RNA sample, triplicate tubes 
were prepared, to two tubes 4pl o f lpg/pl total RNA was added. 3 units of AMV (avian 
myeloblastosis virus) reverse transcriptase (RT) (Gibco) was added to one reaction 
containing RNA, to the other RNA tube, 1.2pl of pure water, this tube acted as a control 
reaction. To the third tube, 4pl of pure water and 3 units of RT were added, this acted as 
a negative control. Each tube was overlaid with 40pl of mineral oil (Sigma) to prevent
38
evaporation whilst on the thermocycler. The samples were incubated on the thermocycler 
(Biometra) at 37.5°C for 1 hour to allow cDNA synthesis, then heated for 5 minutes at 
99°C to denature the RT enzyme. The samples were either used directly in PCR or were 
stored at -20°C until required.
2.3.1.2 Polymerase chain reaction ofleptin receptor isoforms
PCR of all leptin receptor isoforms from cDNA was carried out using identical 
conditions. PCR from cDNA was carried out in a 20pl reaction containing: 16.15pl 
sterile (suitable for injection) water, lOx PCR Buffer (with final concentrations of 20mM 
Tris-HCl, 50mM KC1) (Gibco, Life Technologies, Paisley Scotland); 1.25mM 
magnesium chloride (Gibco); 0.12pM forward primer, 0.12pM of reverse primer, 1.25 
units of Taq DNA polymerase and 5pl of appropriate cDNA sample. The samples were 
overlaid with mineral oil (Sigma) to prevent the reaction mixture evaporating.
PCR was carried out on a thermocycler (Biometra) using the following conditions: 
denaturation at 96°C for 1 minute, 40 cycles of; denaturation at 94°C for 1 minute, 
primer annealing at 60°C for 1 minute, extension at 72°C for 1 minute, and a final 
extension o f 5 minutes at 72°C. The samples were then electrophoresed on 2% agarose 
gels.
2.3.1.3 Polymerase chain reaction of7B6 gene
PCR from cDNA was carried out in a 20pl reaction containing: 15.25pi pure water, lOx 
PCR Buffer (with final concentrations of 20mM Tris-HCl, 50mM KC1) (Gibco, Life 
Technologies, Paisley Scotland); 1.25mM Magnesium chloride (Gibco); 0.3pM forward 
primer, 0.3pM of reverse primer, 1.25 units of Taq DNA polymerase and 5pl of 
appropriate cDNA sample. The samples were overlaid with mineral oil (Sigma) to 
prevent the reaction mixture evaporating.
PCR was carried out on a thermocycler (Biometra) using the following conditions: 
denaturation at 96°C for 1 minute, 35 cycles of; denaturation at 94°C for 1 minute, 
primer annealing at 58°C for 1 minute, extension at 72°C for 1 minute, and a final 
extension of 5 minutes at 72°C. The samples were then electrophoresed on 2% agarose 
gels.
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2.3.1.4Primers used for RT-PCR ofleptin receptor isoforms and 7B6
Primers used to detect three isoforms of the leptin receptor (Ob-R) were used in these 
studies. A method by Bennett et al., (1996) was modified, the primer sequences 
remained unchanged. A gene that is expressed ubiquitously, 7B6, identified by Francis 
and Duff (1993) was used as a positive control to ensure the RNA and the RT-PCR 
system was working. Appendix 2 lists the primer sequences of all RT-PCR primers.
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2.4 Electrophoretic Techniques
2.4.1 Agarose gel electrophoresis
Agarose gel electrophoresis was used to visualise genomic DNA, PCR and RT-PCR 
products. 2% agarose gels were made by adding lg  of agarose to 50ml of lx  Tris Borate 
EDTA (TBE) buffer. TBE buffer was made up at lOx concentration (0.89M Tris, 0.89M 
Boric acid, 0.025M EDTA in distilled water) for storage and diluted to lx  TBE in water 
for use. The gel was dissolved by heating, either in a microwave oven or on a heated 
stirrer. The gel was allowed to cool and 2pl of ethidium bromide (stock solution 
lOmg/ml in water) (Sigma) was added. The molten agarose was allowed to set in the gel 
apparatus (Biometra, Luton, Beds.). For PCR lOpl of product and for RT-PCR 15pi of 
product was diluted with 5pl of loading dye (1% bromophenol blue in 10% sucrose in 
50ml lx TBE). For each row o f electrophoresis, a DNA marker was electrophoresed 
alongside the samples to allow sizing of the products. In each case either PhiX174 
DNA/Haelll (Promega) or PhiX174 DNA/Hinf I (Promega) was used. Preparation of 
the marker was as follows; 0.5pl of marker (lpg/pl) was diluted with 15pl of water and 
5pl of loading dye. A total of 20pl was added to the gel. The gels were electrophoresed 
for 1 hour at 80-100V. Visualisation of the products was achieved by UV 
transillumination. Photographs were taken on a Polaroid camera or the images captured 
on a digital camera (Kodak electrophoresis documentation and analysis system, 
Rochester, NY).
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2.4.2 Single Stranded Conformational Polymorphism (SSCP) Analysis
For detection of the alleles of the polymorphism LYS656ASN, SSCP was used.
2.4.2.1 Sample preparation
Denaturation of the PCR products was achieved by incubating 2pl of PCR product with 
lOpl of water, 5pl of loading dye and 8pl of SSCP buffer (95% Formamide (Sigma) in 
lOmM EDTA/NaOH with 0.2% Blue Orange loading dye (Promega)). The samples were 
heated to 95°C on a thermocycler block for 10 minutes. Immediately after heating the 
samples were placed on ice and loaded onto a previously prepared polyacrylamide gel for 
electrophoresis.
2.4.2.2 PA GE gel preparation
For detection of the alleles in the samples PAGE separation was employed. Two PAGE 
gel systems from Bio-Rad Laboratories (Hemel Hempstead, Herts.) were used; the 
PROTEAN II xi Cell system and the Mini-PROTEAN II Cell system. For each system 
the same gel mix was used but the different gel systems required different amounts. A 
40% Acrylamide-Bisacrylamide solution (Sigma) at a ratio of 49:1 was utilised to allow 
clear definition of the single stranded products. A gel of final concentration 9% 
acrylamide-bisacrylamide with 10% glycerol (Sigma) was used. 25% ammonium 
persulphate (APS) (Sigma) was made-up fresh, each day PAGE gels were prepared. The 
addition of APS and TEMED (Sigma) was to crosslink the acrylamide/bisacryamide and 
therefore, allow polymerisation. These two components were added last.
The glass plates had been washed in distilled water and wiped with alcohol. The gel 
apparatus was set-up according to the manufacturer’s instructions and the gels allowed 
to polymerise for 40 minutes. The gels were transferred to the cold room where they 
were chilled for a minimum of one hour. Samples were loaded onto the gel in the cold 
room and the electrophoresis carried out at 4°C. The Mini-PROTEAN II gels were 
electrophoresed for 2 hours at 160V. The PROTEAN II gels were electrophoresed at 
200V for 6 hours. Visualisation of the DNA bands was achieved using silver staining.
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Mini-PROTEAN II PROTEAN II
lOx TBE 1ml 4ml
Aciylamide/Bisacrylamide 2.25ml 9ml
Water 5.75ml 23ml
Glycerol 1ml 4ml
TEMED 12.5pl 50pl
Ammonium Persulphate 
(25%)
40pl 160pl
Total gel volume 10ml 40ml
Table 2 PAGE gel components for SSCP of LYS656ASN polymorphism in the leptin 
receptor.
2.4.3 Silver Staining
The PAGE gel was fixed for 10 minutes in Gel Fixer (10% ethanol, 5% glacial acetic 
acid in water) with gentle mixing. The fixer was poured off and the 1% Silver nitrate in 
water added. The gel was mixed continuously for 15 minutes. The silver nitrate solution 
was poured off and the gel washed twice in distilled water. Developer (0.3 8M NaOH, 
3.75ml Formaldehyde in 1L of distilled water) was added to the gel and quickly mixed to 
avoid patchy development. The gel was allowed to develop until the bands were clearly 
visible or until 15 minutes had elapsed. The developer was poured away and the gel 
washed twice in distilled water. The gel was fixed in final fixer (7.5% Sodium carbonate 
in distilled water) for 15 minutes. Photographs were taken on a Polaroid camera or the 
images captured on a digital camera (Kodak electrophoresis documentation and analysis 
system, Rochester, NY).
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2.4.5 Preparation of PCR product DNA for sequencing
In order to ascertain if the genotypes of the LYS656ASN polymorphism were being 
correctly assessed, 3 samples were prepared and sent for automatic sequencing. One of 
the two samples was believed to be homozygous for the G allele, one was believed to be 
homozygous for the C allele and the other a heterozygote. Sequencing of the PCR 
product used in the SSCP analysis would be sufficient to identify the 3 allelic states.
2.4.5.1 Isolation o f  specific DNA product
A 50ml 1% agarose gel was made as before but, using lx  Tris acetate EDTA buffer 
(TAE) (lOx TAE buffer 0.4M Tris-acetate, 0.01M EDTA made up to 1L with distilled 
water, diluted as required to lx  TAE with distilled water). The gel was cooled and 2pl of 
ethidium bromide (stock solution lOmg/ml) was added. The gel was poured into the gel 
forming apparatus and a comb with large teeth positioned at one end. Each well of this 
comb could be filled with 60pl of DNA. A 50pl PCR reaction was required for 
sequencing. This total volume was mixed with lOpl of loading dye (20% sucrose 
solution in lx  TAE containing bromophenol blue), the total of 60pl was loaded onto the 
gel. Alongside this a DNA marker was also added as before to allow for product sizing. 
The gel was electrophoresed for 1 hour at 50v. After 1 hour the bands on the gel were 
visualised by UV transillumination. A clean transparency was placed underneath the gel 
to avoid any foreign DNA contaminating the gel. A sterile blade was used to cut out the 
gel surrounding the band(s) of interest. A small hole was pierced through the bottom of a 
0.5ml-eppendorf tube and a small amount o f siliconised glass wool was placed in the 
bottom of the tube. This small eppendorf was placed in a large 1.5ml eppendorf tube. 
The lid was removed from this tube. Each slab o f gel was placed into the pre-prepared 
eppendorf apparatus as described and the tubes centrifuged at 10 OOOg for 15 minutes. 
This forces the liquid containing the DNA of interest out of the gel and into the large 
eppendorf. Approximately lOOpl of liquid was recovered from each gel slab.
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2.4.5.2 Removal o f  Ethidium Bromide
To each sample an equal volume of water-saturated butanol was added. This was mixed 
vigorously and centrifuged at RT, 10 OOOg, for 30 seconds. The upper butanol layer was 
removed and the process repeated.
2.4.5.3 Precipitation o f  DNA
To the DNA sample, 2.5 times the volume of ice-cold ethanol was added (for lOOpl of 
sample 250pl o f ethanol) and one tenth of the original total volume (in this case I O j l i I )  of 
3M sodium acetate was added. The sample was mixed and the nucleic acids precipitated 
by incubation at -70°C for 30 minutes. The sample was then centrifuged at 10 OOOg for 
15 minutes at 4°C. The supernatant was removed and the pellet washed in 70% ethanol 
and allowed to air-dry for 15 minutes. The sample was then ready for automatic 
sequencing.
2.4.5.4 Automatic Sequencing
Miss Hazel Holden at the Department of Molecular and Genetic Medicine, University of 
Sheffield carried out the automatic sequencing. Forward and reverse primers (at a 
concentration of ljxM) were supplied with the DNA pellets. A total o f 3.2pl o f each 
primer was required for each sequencing reaction. The primers were the same as used in 
the PCR reaction. Sequencing reactions are listed in Appendix 3.
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2.5 Measurement of leptin and leptin-binding activity (LBA)
2.5.1 Measurement of leptin in serum, plasma and cell culture supernatants.
Serum, plasma and cell culture supernatant samples were analysed using one of two 
commercial kits: a human leptin radioimmunoassay (Linco Research Inc., St Louis Mo.) 
and Quantikine™ human leptin ELISA (R&D Systems, Abingdon, Oxon.). In both cases, 
the assays were carried out according to the manufacturers’ instructions.
For the RIA, samples were assayed in duplicate and did not require dilution unless the 
sample contained more than lOOng/ml of leptin. For the ELISA method, serum and 
plasma samples were diluted 100-fold in the supplied calibrator diluent, cell culture 
supernatants were assayed neat, diluted 2-fold, 5-fold and 10-fold. Samples were assayed 
in duplicate. Single samples were assayed when the total number of subjects in the study 
was greater than 150.
The RIA samples were counted on an automatic gamma counter (Wallac, Turku, 
Finland), the ELISA plates were measured on an automatic plate reader (Wallac Victor2 
1420 multilabel counter.) at 450nm.
Both the RIA and the ELISA methods measured free and bound leptin.
2.5.2 Assay for the measurement of Lectin-Binding Activity (LBA)
2.5.2.1 Preparation o f  serum from whole blood
Venous blood was collected into a sterile tube (without anticoagulant) and allowed to 
clot for 20 minutes at room temperature. The blood was centrifuged at lOOOg (Sorvall 
RT 6000D) for 10 minutes. The upper serum layer was carefully removed and aliquotted 
into 1.5ml eppendorf tubes. The serum was frozen at -20°C until required for analysis.
For the LBA assay, two individuals (one obese and one of normal BMI) were identified 
to use as controls each time the assay was performed. The subjects donated 100ml of 
venous blood. Serum was prepared from these samples as described above. 
Approximately 50ml of serum from each of the two subjects was obtained, this was 
divided into 250pl aliquots and stored at -20°C until required for analysis.
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2.5.2.2 Stripping o f  leptin from serum sample
To 200fil of serum, 500pl of prechilled 2% Norit A charcoal (Norit) 0.2% Dextran T70 
(Pharmacia) in assay buffer was added at room temperature, vortex mixed and 
immediately placed on ice for 5 minutes. The sample was centrifuged at 4°C for 12 
minutes at 10 OOOg. The supernatant (stripped of free leptin) was removed by pipette and 
placed in a new tube.
2.5.2.3 Measurement o f  LBA
50pl of stripped serum was incubated with 150pl of assay buffer (0.01M phosphate 
buffer pH 7.4, 0.18M MgCl2, 1% BSA), lOOpl of [I25I] Leptin 135pCi/pg (Linco 
Research Co, Research Park Drive, St Louis, USA), in the presence (to measure non­
specific binding) or absence (to measure total binding) of lpg unlabelled leptin (R&D 
Systems, Abingdon, Oxford, UK). For separation of the bound from the unbound 
fractions, 1ml of prechilled 2% charcoal-0.2% Dextran T70 slurry in assay buffer was 
added to the overnight incubation, vortexed, placed on ice for 10 minutes, and 
centrifuged at 4°C for 12 minutes at 10 OOOg. 1ml of the supernatant was aspirated by 
pipette and counted in an automatic y-counter. The specific binding (total binding minus 
non-specific binding) obtained was expressed as a percentage of the total [125I]-Leptin 
counts per minute incubated in 50ul of serum. All samples were measured in duplicate.
As mentioned above, serum samples with previously measured high and low levels of 
LBA were used as control serum and were run in each assay at the beginning and end of 
the assay.
2.5.2.4 HPLC analysis o f  LBA
The HPLC method was developed from a method used to measure GHBP by Tar et al 
(1990). HPLC separations were performed using a liquid chromatograph (model 600, 
Waters, Milford, MA) equipped with a sample injector (model U6K) fitted with a 1ml 
loop and an analytical Protein Pak 300sw column (Waters; 0.75 x 30cm). Absorbance at 
280nm was monitored with an LC spectrophotometer (Waters), and radioactivity was
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recorded on-line using a Bertold LB 504 y-detector (Bertold, Elancourt, France) 
connected to an Apple He computer.
Serum (150pl) was incubated overnight at 4°C with 30pl of assay buffer and 20pl of 
I25I-Leptin. A parallel incubation was carried out in the presence of an excess of 
unlabelled leptin (2pg). After filtration through a 0.45pm Millipore minifilter, the entire 
incubation was placed on to an HPLC Protein Pak 300sw column. Elution was 
performed autocratically using a degassed buffer (0.1M Na2S04 and 0.1M potassium 
phosphate, pH7.0) pumped at a rate of 0.5ml/minute. The column was calibrated with 
blue dextran, BSA, phosphorylase-b, aldolase, and [125I]-Leptin
This analysis was carried out in its entirety by Miss Sylvie Simon and Dr Marie-Catherine 
Postel-Vinay at the Faculte de Medicine Necker in Paris, France.
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2.6 Measurement of cotinine in serum
Serum cotinine levels were measured using an in-house RIA modified from the original 
method o f Knight et al. (1989). Assignment of smoking status in the serum samples from 
pregnant women was carried out in collaboration with Dr Robert Smith in the Division 
of Biomedical Sciences.
2.6.1 lodination o f  cotinine
In a reaction tube, lOOpl of trans-3-carboxy-cotinine (2pg in 0.5M phosphate buffer) (a 
kind gift from Dr George Knight), was added to lOpl of I25I (1.0 mCi) and mixed. To 
this 10 pi chloramine T (Sigma) (1.0 mg/ml in 0.1 M phosphate buffer) was added and 
the reaction allowed to proceed for 10 seconds. To quench the reaction, 20pl o f sodium 
metabisulphate (Sigma) (l.Omg/ml in 0.1 M phosphate buffer) was added. The entire 
reaction mixture was applied to a diethylaminoethyl (DEAE) column equilibrated to 
pH3.0. The fractions were eluted from the column using 0.1M phosphate buffer (pH3.0). 
In total 10 fractions with a volume of 0.5ml were collected into tubes containing 1.0ml 
phosphate buffer (pH 3). A small amount (lOpl) o f each fraction was diluted in 1ml of
0.1M phosphate buffer and counted on a y-counter. A peak at fractions two and three 
was present, this was the iodinated cotinine. These fractions were pooled together and 
stored at 4°C in 0.1 M phosphate buffer (pH 3) until required.
2.6.2 Measurement o f  cotinine in serum
Cotinine (Sigma) standards, with concentrations of 0, 12.5, 5, 25, 50, 100, 200, 400 and 
800ng/ml were prepared and stored at -20°C until required. To a polycarbonate tube, 
lOpl of sample or standard was added. Samples and standards were assayed in duplicate. 
To each tube, 750pl of assay buffer (5% horse serum in 0.01 M phosphate buffer, 0.15M 
sodium chloride pH7.5) lOOpl of iodinated cotinine label and lOOpl of rabbit anti- 
cotinine antibody (a kind gift from Dr G Knight) was added. Alongside the samples and 
standards, duplicate tubes containing lOOjil of iodinated cotinine label only (total tubes) 
and duplicate tubes not containing any sample or standard (non-specific binding, NSB)
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were prepared. All tubes were vortex mixed and incubated overnight at 4°C. To the 
overnight incubation, lOOpl of anti-rabbit IgG antiserum was added to each tube (except 
the total tubes). All tubes were mixed and allowed to incubate at room temperature for 2 
hours. To separate the bound and free fractions, 1ml of PEG buffer (8% polyethylene 
glycol (Sigma), XM sodium chloride (Sigma) made up in water) was added to each tube 
(except the total tubes), mixed and centrifuged at 4°C, 5000g for 40 minutes. The 
supernatant was removed by aspiration and the pellet counted on a y-counter. A batch of 
samples consisted of the zero tubes, 8 standards, total counts tubes, NSB tubes, 2 quality 
control samples with known cotinine concentration and up to 40 samples. Levels of 
cotinine were calculated using RIAcalc data analysis package.
2.7 Endometrial biopsy collection and celJ culture
2.7.1 Endometrial Cell Culture
Endometrial biopsies were collected by Mr T.C. Li at the Jessop Hospital for Women, 
from women undergoing gynaecological surgery for reasons other than the endometrium. 
The women were all aged between 24 and 40 years, with regular menstrual cycles o f 25- 
35. All subjects gave informed consent. The biopsies were prepared and the cells 
cultured by Miss Beverley Cork or Mrs Elizabeth Tuckerman at the Jessop Hospital for 
Women.
2.7.1.1 Epithelial and Stromal Cell separation
To separate the epithelial and stromal cells of the endometrial biopsies an established 
digestion and centrifugation method has been adopted (Laird et al., 1993, Laird et al., 
1997). The endometrial biopsies were collected into Hanks’ balanced salt solution 
(HBSS) (Sigma) containing penicillin and streptomycin (each at a concentration of 
lOOpg/ml). The tissue was washed twice in HBSS and chopped finely with scissors. The 
tissue was then incubated in Dulbecco’s modified Eagle medium (DMEM) (Sigma) 
containing 0.2% collagenase (typela) (Sigma) for 45 minutes at 37°C. During, and at the 
end of, the incubation the tissue was pipetted to disperse the cells. The epithelial cells 
and stromal cells were separated by centrifugation at lOOg. The supernatant containing
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the stromal cells was removed and the pellet containing mainly the epithelial cells was 
incubated in 5ml of DMEM with 0.2% collagenase (type la) for a further 45 minutes at 
37°C. The cells were dispersed again by gentle pipetting and the epithelial cells pelleted 
by centrifugation at lOOg. The stromal cells present in the supernatant were pooled with 
the first supernatant and pelleted by centrifugation at 300g.
The epithelial and stromal cells were purified further by unit density sedimentation. Each 
cell type was resuspended in 2ml of DMEM containing 10% fetal calf serum (FCS) 
(Sigma), glutamine (4mmol/l) (Sigma), penicillin and streptomycin (lOOpg/ml) 
(CDMEM) and gently pipetted onto 8ml of CDMEM in a test tube and left for 30 
minutes at RT. Stromal cells from the top 8ml were used for cell culture. Epithelial cells 
from the bottom 2ml were used for cell culture. Cells were seeded into 96-well plates or 
into flasks and grown in an incubator at 37°C, 5% carbon dioxide and 95 % air to 
confluency.
2.7.1.2 Proliferation o f  endometrial epithelial and stromal cell cultures.
Cells had previously been seeded into 96-well plates at a density of 0.8 x 105 cells per
well. The cells were grown to confluency for 48-72 hours in an incubator at 37°C, 5%
carbon dioxide and 95 % air. To assess if the cells proliferated in response to leptin a
thymidine uptake assay was performed. 60pl (60pCi) tritiated thymidine ([3H] thymidine)
(lmCi/ml, specific activity 60-90 Ci/mmol) (ICN, Basingstoke, Hants.) was added to
16ml CDMEM, mixed and divided into 4ml aliquots. Leptin were added to the medium
to give final concentrations of 0, 0.1, 1.0 and 10.0 ng/ml. To each well, 250pl o f media
was added. For each concentration of leptin, 10-15 wells of replicates were carried out.
The plates were then incubated for 48 hours in an incubator at 37°C, 5% carbon dioxide
and 95 % air. After incubation, the supernatants were collected and frozen at -20°C until
required for further analysis. The cells were washed twice in lx  PBS and lOOpl
trypsin/EDTA (Gibco BRL) was added to each well. The plates were incubated for 30
minutes at 37°C. The cells were harvested using a semi-automatic cell harvester
(Skatron, Newmarket, Suffolk). Each filter paper was added to 2ml of scintillation fluid
(Wallac Optiphase HiSafe, Wallac, Turku, Finland.) in a scintillation vial. Samples were
counted for 3 minutes each on an automatic P-counter (Tri-Carb 1900CA, Packard,
Pangboume, Berks.).
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2.8 Cytokine Assays
2.8.1 Measurement of Leukaemia Inhibitory Factor (LIF) in endometrial cell 
culture supernatants
LIF was measured using a specific kit, an enzyme amplified sensitivity immunoassay 
(EASIA) from Biosource Europe. The measurement of the cytokines in the endometrial 
cell culture supernatants was carried out according to the manufacturer’s instructions. 
The sensitivity of the LIF assay was 20pg/ml with an intra and inter-assay CVs of 4.5% 
and 6% respectively. The final absorbance o f the plates was measured on an automatic 
plate reader (Wallac, Turku, Finland.) at 450nm. The assay used to measure LIF did not 
cross-react with other cytokines or its soluble receptor. Dr Susan Laird carried out this 
analysis.
2.8.2 Cytotoxic Bioassav for the measurement of Tumour Necrosis Factor-a (TNF- 
a) in endometrial cell culture supernatants
This bioassay uses the cytotoxic effect of TNF-a present in the samples, in this case in 
the cell culture supernatants, on a pre-sensitised murine aneuploid fibrosarcoma cell line 
(L929). The cells were seeded into a 96-well plate at a density of 0.2 x 105 cells/well in 
lOOpl of RPMI (Sigma) containing 10% FCS, penicillin and streptomycin (lOOpg/ml). 
The plate was placed in an incubator at 37°C, 5% carbon dioxide, 95% air for 24 hours. 
TNF-a (R&D Systems) standards were prepared from a stock solution (lOjig/pl, 40 000 
IU/ml) to give solutions of 50, 25, 12.5, 6.25, 3.13, 1.56, 0.78, 0.39, 0.19 IU/ml. lOOpl 
of standard or samples was added to the plate in duplicate. 4pl of actinomycin D (0.1 
mg/ml) (Sigma) was added to each well to give a final concentration of 2pg/ml in each 
well, in order to sensitise the cells to TNF-a. The plate was incubated for 24 hours as 
described. The cells were washed in 200pl of PBS and fixed for 15 minutes in 200pl of 
methanol. The methanol was removed and the plate air-dried in a fume hood. To each
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well, 200pl of crystal violet (0.1% solution in 200mM boric acid) was added and the 
plates allowed to incubate for 20 minutes. The plate was washed thoroughly three times 
with water. To solubilise the cell layer, 50pl of 10% glacial acetic acid was added and 
the plate incubated for 30 minutes. The absorbance at 570nm was then read on an 
automatic plate reader (Wallac). The higher the absorbance the less TNF-a was present 
in the samples. The amount of TNF-a in the samples can be calculated from the standard 
curve. This analysis was carried out with the assistance of Dr Susan Laird.
2.9 Anthropometric Measures
2.91 Calculation o f  Body Mass Index (BMI)
BMI was calculated from the equation;
BMI = Weight in kg / Height in m2 
Weights and heights in imperial measurements were converted to metric as required.
2.92 Assessment o f  body composition
Body composition (lean and fat masses) were assessed using dual energy X-ray 
adsorpiometry (DEXA) scanning, by qualified personnel at the Northern General 
Hospital, Sheffield, UK.
2.93 Assessment o f  testicular volume
Testicular volume was assessed by an experienced paediatrician using an orchidometer.
2.10 Statistical and Other Data Analyses
Statistical analyses were performed using either Microsoft Excel™ or SPSS™ software 
packages.
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2.10.1 Hardy-Weinberg equilibrium
To calculate whether the observed genotypes are those expected from the observed allele 
frequencies the Hardy-Weinberg equation was used. The equation:
p2 + q2 + 2pq = 1
(Where p = frequency of common allele and q = frequency of rare allele.) The equation 
gives the expected frequency of homozygotes (p2 and q2) and heterozygotes (2pq). If the 
observed genotype distribution is not significantly different from the expected genotype 
distribution, then the genotypes are said to be in Hardy-Weinberg equilibrium.
2.10.2 Chi- squared (tf) analysis o f  contingency tables and Yates’ correction
The x2 analysis allows a measure of the extent to which observed numbers in a
contingency table depart from the expected values. Tables of the %2 distribution then 
show if the observed value is larger than would be expected by chance on a Null 
hypothesis that postulated no difference between observed and expected distributions. 
The value of x2 is given by the equation:
X2 = 2  (o-e)2/e
where o = observed number
and e = expected number
The number of degrees of freedom are calculated as the product of one less than the 
number of rows and one less the number o f columns. %2 tables were then used to 
generate a p-value.
A simple method to calculate %2 can be employed using a 2x2 contingency table (Table
4).
Variable 1
0 1 Total
Variable 2 0 a b a + b
1 c d c + d
Total a + c b + d a + b + c + d
Table 2.4 An example of a 2x2 contingency table.
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X2 can then be calculated from this equation:
X2 = (ad -  be)2 (a + b + c + d) / (a +b) (c + d) (b + d) (a + c)
When the values in a 2x2 contingency table are small, a correction for continuity, known 
as Yates’ correction, can be applied. It is common to use Yates’ correction when the 
total numbers in the contingency table are less than 100 or when one cell value is less 
than 10.
The modified %2 analysis is thus;
X2 = [ ( | ad -  be | )- 0.5 (a + b + c + d)]2 (a + b + c + d) / (a +b) (c + d) (b + d) (a + c)
X2 tables are then used to determine the level of significance.
2.10.3 ANOVA and the F-test
The F test allows the variance between two populations to be compared. The f  test was 
used to compare the variance between different populations. Analysis of variance 
(ANOVA) is a method of testing the null hypothesis that several group means are equal 
in the population by comparing the sample variance estimated from the group means to 
that estimated within the groups. ANOVA is an extension of the two-sample t test. Once 
the difference between means has been established, post hoc tests can be performed in 
order to find exactly where the differences lie. Bonferroni correction is a multiple 
comparison post hoc test, it allows the observed significance to be adjusted for the fact 
that multiple comparisons are being made. ANOVA was used to test for differences in 
group where a population contained more than two groups.
2.10.3 t test and the Mann-Whitney U test
The t test was used to test the difference in means between two populations. Different 
types of t test are used, depending on the sample populations; a paired t test is used to 
test paired data, a t test assuming equal variance was used when the sample data had an 
equal variance. The Mann-Whitney U test is the non-parametric equivalent to the t test 
and it is able to test whether two independent samples are from the same population. 
This test was used when the data was not normally distributed.
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2.10.4 Pearson and Spearman Rank Correlations
The degree of association is measured by Pearson’s correlation coefficient; r, which is a 
measure of linear association. Pearson’s correlation was used on normally distributed 
data, to determine linear relationships between variables. When the data set was either 
not normally distributed or when outlying points of data away from the main data set 
were present, Spearman Rank correlations were utilised. This correlation is a non- 
parametric test and replaces the observations with their ranks in the calculation of the 
correlation coefficient.
2.10.5 Regression Analysis
Linear regression estimates the coefficients of the linear equation involving one or more 
independent variables that best predict the value o f the dependent variable. Linear 
regression was used to analyse how a single dependent variable was affected by the value 
of one or more independent variables. Logistic regression was used to predict the 
presence or absence of an outcome based on several predictor variables. Logistic 
regression is suited to data sets where the dependent variable is dichotomous. Stepwise 
multiple regression analysis was used to determine which of the possible explanatory 
variables could be used to predict an outcome.
2.10.6 Scatchard Analysis o f  Receptor-Ligand Interaction
Estimation of binding characteristics from a curve is often not very meaningful, therefore
manipulation of the data to provide a linear relationship is preferred, one method by
which this can be achieved is Scatchard Analysis. The Scatchard plot is drawn by
dividing the concentration of bound ligand by free ligand and plotting this against the
concentration of bound ligand eg.
rBound Ligandl Vs [Bound Ligand]
[Free Ligand]
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From this plot the dissociation constant (Kd) can be obtained as the slope of the line will 
be:
A
IQ.
Figure 2.2 illustrates a typical Scatchard plot, showing extrapolation o f the slope to the 
x-axis. In this thesis, the Scatchard analysis was performed using LIGAND-EBDA 
software version 2.0 (Elsevier-Biosoft, Cambridge, UK.).
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Figure 2.2 A typical Scatchard plot (taken from Hancock, 1997).
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2.11 Equipment and reagent suppliers
Alexis Biochemicals
Alexis Corporation (UK) Ltd. 
3 Moorbridge Court, 
Moorbridge Road East, 
Bingham,
Nottingham,
NG13 8QG,
Bio-Rad Laboratories Ltd.,
Bio-Rad House,
Marylands Avenue,
Hemel Hempstead, 
Hertfordshire, HP2 7TD.
Biosource Europe,
Lifescreen Ltd.
Unit 15, The Metro Centre, 
Tolpits Lane,
Watford,
Herts, WD1 8SS.
Gibco BRL,
Life Technologies Ltd,
3 Fountain Drive 
Inchinnan Business Park, 
Paisley, PA4 9RF.
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ICN Pharmaceuticals Ltd,
Biomedical Research Products,
1 Elmwood,
Chineham Business Park, 
Crockford Lane,
Basingstoke,
Hants, RG2 8WG.
Linco Research Co.,
St Louis,
Mo.
USA.
NEN Life Science Products,
Hounslow,
London,
TW5 9RT.
New England Biolabs (UK) Ltd,
67 Knowl Piece,
Wilbury Way,
Hitchin,
Hertfordshire, SG4 OTY.
Packard,
Brook House,
14 Station Road,
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Chapter 3
Leptin Binding Activity: Assay Development and Validation
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3.1 Introduction
Circulating soluble receptors are a feature of a number of members of the cytokine 
family (Muller-Newen et a l, 1996), including IL-1, IL-6, TNFa and growth hormone 
(GH). Soluble receptors have a wide range of functions. These functions can include 
actions as a scavenger, a carrier, as an agonist, as an antagonist and for protection 
against cell degradation. Soluble receptors can be generated in two ways; firstly the 
extracellular domain of the receptor can be proteolytically cleaved off the cell surface 
and transported in the blood or around the interstitial fluid, this is known as shedding. 
Secondly, the receptor can be expressed as an alternately spliced transcript of the gene. 
The most widely studied with respect to the endocrine system is the growth hormone 
binding protein (GHBP). GHBP was first described by Ymer and Herington (1985) and 
has since been well characterised. In rats and mice, the generation of GHBP involves an 
alternatively spliced mRNA, whereas in rabbits, it is derived by proteolytic cleavage, 
from the extracellular domain of the growth hormone receptor. It is likely that this is the 
same mechanism in humans (Dastot et al., 1996, Ross et al., 1997) as no mRNA 
expression of the GHBP has been found in humans.
The receptor serves as a carrier protein in the case of soluble interleukin-4 receptor (sIL- 
4R) (Vitetta, 1991). For TNF-a bound to its receptor, the complex retains its bioactivity 
for a longer length of time. This complex protects against proteolysis and degradation. 
Soluble receptors can also act as antagonists. Soluble leukaemia inhibitory factor 
receptor (sLIF-R) has been shown to antagonise the action of LIF (Layton, 1992) and 
the soluble receptor for interferon y (IFNy) neutralises the antiviral activity of IFNy 
(Gentz et al., 1992).
Soluble receptors can also have agonistic effects. This is the case for the IL-6 and 
soluble IL-6 receptor (sIL-6R) complex. This complex can activate the Jak/STAT 
signalling cascade as it interacts with the gp 130 accessory chain, even in the presence of 
membrane bound receptors (Hibiet et al, 1991)
In disease situations, levels of soluble receptors can fluctuate. Soluble ciliary 
neurotrophic receptor (sCNTF-R ) is increased in the CSF after nerve injury from 10 
ng/ml to 500 ng/ml. Soluble TNF-Receptor II (sTNF-RII) is increased 2-3 fold on 
normal levels with malignancies. Soluble interleukin 1 receptor II (sIL-l-RII) is 
increased in the synovial fluid from rheumatoid arthritis patients. It has been reported
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that sIL-6R levels are increased after infection with human immunodeficiency virus 
(HIV) (Handa et al, 1991). The most work has been performed on soluble IL-2 receptor 
(sIL-2R), where levels have been demonstrated to be increased after infection by virus 
(HIV), bacteria (tuberculosis) or parasite (malaria). In many autoimmune diseases, 
levels of sIL-2R are also increased.
It has been postulated that there may be similar binding proteins present for leptin. 
Recent reports have identified binding proteins for leptin in human serum (Houseknecht 
et al, 1996, Sinha et al, 1996, Diamond et al, 1997) including a soluble form of the 
leptin receptor, Ob-Re (Diamond et al, 1997). The leptin-binding proteins are not yet 
well characterised and the full role of the proteins, including the soluble receptor has yet 
to be elucidated. A possible role for the soluble leptin receptor is as a mechanism for 
carrying leptin to the blood-brain barrier (Golden et al., 1997) although there is 
potential for this soluble receptor to act as an antagonist or agonist.
Amit et al, (1990) developed a method for the measurement o f GH-BP. This method 
involved the incubation of serum, in a phosphate buffer with magnesium chloride and 
I25I-GH, then separation of the bound radioactivity from the free using a 2% charcoal,
0 .2 .  dextran T-70 slurry. This method was the basis for the development o f the leptin- 
binding assay.
Radioligand binding experiments are based on a simple model, the law o f mass action. 
For ligand receptor interactions the law can expressed as:
Ligand + Receptor <=> Ligand.Receptor 
The law of mass action is based on four simple assumptions:
1. Binding occurs when ligand and receptor (or binding proteins) collide due to 
diffusion, this collision must be in the correct orientation and have enough energy.
2. Once bound, the ligand and receptor remain bound together for a time influenced by 
the affinity for the ligand and receptor for one another.
3. After dissociation, the ligand and receptor are the same as before binding, therefore 
there is no irreversible conformational change on binding.
4. Equilibrium is reached when the association rate equals the dissociation rate.
When the ligand-receptor system is at equilibrium, complexes form at the same rate 
they dissociate. Chilling of all reagents used in the binding assay will prevent this 
binding equilibrium being disrupted.
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3.2 Development of the assay
Modification of the basic method from measuring GHBP to leptin binding activity 
required a number of factors to be taken into consideration. The full method for the 
measurement of LBA can be found in Chapter 2, but in outline, involves incubation of 
the samples with a radioactive leptin in the presence or absence of cold (unlabelled) 
leptin. After incubation, the bound and free fractions are separated by the addition and 
incubation with charcoal dextran slurry, followed by chilled centrifugation. The 
supernatant contains the bound leptin and it is this fraction that is counted on a y- 
counter. After determination of incubation conditions and suitable sample types, the 
most important consideration in the development of this assay is the possible 
interference o f the endogenous levels of leptin. It is known that most obese subjects 
have high levels of leptin, reflecting their increased fat mass, and this excess could 
cause interference in the assay. In addition, it is possible that levels of leptin from 
normal weight subjects would interfere with the assay, by exerting some effect on the 
binding equilibrium. Removal of the endogenous levels of leptin from all samples 
allowed standardisation of the samples.
The approach taken to remove the endogenous leptin, was the same as to separate the 
bound from the free fractions. Incubation on ice with dextran-coated charcoal followed 
by centrifugation was employed. We believed this to be the most effective method of 
removing the leptin. The charcoal used in the assay was Norit A charcoal, these are 
steam activated carbon particles that are micronized so the final charcoal is in the form 
of extremely fine particles. Dextran-T70 is added to the charcoal slurry for two reasons:
1. It renders the charcoal stickier and therefore easier to pellet by centrifugation.
2. It acts as a barrier preventing large molecules (in this case the binding proteins) 
from being adsorbed to the charcoal, yet allows the small molecules to be removed.
In order to minimise loss of the binding proteins during this stripping step, the samples 
were incubated on ice, buffers were chilled, and the separation by centrifugation was 
performed at 4°C. It is possible that if the solutions were not chilled, the charcoal would 
absorb the binding proteins themselves.
Experiments were carried out in order to validate that the results of the assay reflected 
the physiological amount of serum leptin binding activity. This was achieved by:
© Homologous competitive binding curves and Scatchard analysis.
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• Confirmation of the assay’s specificity for leptin-binding activity.
• Confirmation of the reproducibility of the assay.
• Comparison of the LBA assay with HPLC analysis.
3.3 Selection of Assay conditions
3.3.1 Investigation o f  the incubation time o f  sample with radioactive ligand
3.3.1.1 Experimental Design
It was important that binding equilibrium had been reached when the samples were 
separated and the binding proteins measured. In order to ascertain the optimum time for 
equilibrium to occur at 4°C, the length of incubation time with radioactive ligand was 
investigated.
3.3.1.2 Study Design
A sample was thawed and the assay set-up as described in Chapter 2.
The incubation time with the radioactive ligand was varied. Incubation times of 10 
minutes, 30 minutes, 1, 2, 4, 24 and 48 hours were used. Samples were assayed in 
duplicate.
3.3.1.3 Results
There was no significant binding of the radioactive ligand to the binding protein until an 
incubation o f time of 4 hours was reached. At 24 hours, maximal binding was reached. 
Samples were incubated for 48 hours, but there was no further significant increase in 
LBA level, as binding equilibrium had been reached.
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Time of Incubation LBA (%)
10 minutes 0.0
30 mintes 0.4
1 hour 0
2 hours 0
4 hours 9.5
24 hours 10.8
48 hours 10.7
Table 3.1 Effect of variation of incubation time on ligand binding (n = 4 for each time 
point)
3.3.1.4 Conclusion
Binding equilibrium was reached by 24 hours incubation at 4°C and, this time point was 
chosen for the assay. Binding equilibrium would be reached more quickly at 20°C and 
37°C, but these temperatures were considered unsuitable, as the separation technique 
requires the samples and buffers to be chilled. At these higher temperatures, there may 
have been changes in the binding equilibrium causing the equilibrium to be less stable. 
At 37°C, increases in proteolytic enzyme activity would have needed to be addressed. 
Therefore, an incubation time of 24 hours at 4°C was chosen as the optimum incubation 
time.
3.3.2 Selection o f  sample type
3.3.2.1 Experimental Design:
In this study, serum samples were used. It would be useful, however, to use samples that 
had been treated with anti-coagulants. This would allow samples collected for other 
purposes than for LBA measurement to be utilised. Comparison of LBA measurements 
in blood with and without anticoagulants was carried out. Whole blood was collected 
and the samples taken from the same venepuncture were placed into sterile tubes and a 
portion of the sample was treated with two different anti-coagulants. All samples were 
subjected to the same conditions. The serum samples were allowed to clot for 30 
minutes at room temperature, the plasma samples remained on the benchtop. The serum 
and plasma were separated from the cellular components by centrifugation at lOOOg. 
The samples were aliquotted and frozen at -20°C until required. The samples were
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stripped of their endogenous leptin and LBA measured as described in Chapter 2. The 
samples were assayed in duplicate and the measures repeated twice. Means of these 
repeated measures are shown.
3.3.2.2 Results
Serum Sample Plasma Samples
Subject EDTA as anti­
coagulant
Lithium Heparin 
as anti-coagulant
A 10.0 9.4 10.1
B 11.5 11.9 11.6
C 7.8 7.2 7.6
D 7.6 8.2 7.6
E 9.6 9.5 8.9
Table 3.2 The effect of sampling conditions on LBA (%).
3.3.2.3 Conclusions
There was no significant difference in levels of LBA measured in samples that had been 
treated with anti-coagulants and samples that had not been treated with anticoagulant. 
Serum and plasma samples appear to both be suitable for the measurement of LBA.
3.4 Stripping the serum of endogenous leptin for the measurement of LBA
3.4.1 The effect o f incubation time with dextran-coated charcoal on stripping the serum 
o f leptin
3.4.1.1 Assay Design
The same sample was subjected to variation of incubation time with 2 % charcoal-0.2 % 
dextran T-70 on ice. Seven time points were used: 1, 2, 5, 10, 15, 30 and 60 minutes. A 
single sample was incubated with the charcoal dextran slurry for 24 hours. LBA and 
leptin levels (assessed by the RIA method) were measured in these samples. Samples 
were assayed in duplicate.
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3.4.1.2 Results
Time of Incubation 
(minutes)
LBA (%) Leptin (ng/ml)
1 7.3 2.6
2 8.5 1.8
5 11.5 <1
10 10.5 <1
15 10.5 <1
30 10.3 <1
60 8.3 <1
24 hours 3.4 <1
Table 3.3 Effect of prolonged stripping on leptin and LBA (n = 4). 
3.4.1.3 Conclusions
The results of this experiment show that for the maximum LBA and the minimum leptin 
level (undetectable) an incubation time of 5 minutes was sufficient. After 15 minutes 
incubation, there was a reduction in the level o f LBA. After 24 hours, the levels o f LBA 
were greatly reduced, it is likely that the binding proteins in the serum sample had been 
adsorbed to the charcoal. An incubation time of 5 minutes was chosen as the optimal 
time for incubation to retain the most binding protein and to minimise the level of 
residual leptin.
3.4.2 The effect o f  stripping serum o f  endogenous leptin in a cohort o f  men and women
3.4.2.1 Subjects
Subjects were recruited from the Division of Clinical Sciences laboratory at the 
Northern General Hospital. Basic clinical information was collected; age, height, weight 
and sex. The subjects included both men and women, aged between 20 and 50 years 
with a range of BMIs.
3.4.2.2 Sample Preparation
Venous blood was collected without anti-coagulant and was allowed to clot for 30 
minutes at room temperature. Following centrifugation for 10 minutes at lOOOg (Sorvall 
RT 6000D); the serum was removed and frozen in 500pl aliquots until required.
3.4.2.3 Experimental Design
Two aliquots of serum from each subject were thawed. One aliquot was stripped o f its 
endogenous leptin as described in Chapter 2. The other aliquot was used without pre-
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treatment in the assay. Both the stripped and unstripped serum for each subject was 
assayed for leptin by RI A.
Subject BMI
(Kg/m2)
LBA (%) Leptin (ng/ml)
Neat
Serum
Stripped
Serum
Neat
Serum
Stripped
Serum
1 26.3 11.2 11 6.1 <1
2 19.4 14.3 10 1.9 <1
3 22.2 10.2 6 12.6 <1
4 22.4 8.3 7.8 2.9 <1
5 23.1 9.8 11.5 <1 <1
6 21.4 9.8 8.5 3.4 <1
7 ' 23.9 11.7 4.5 4.3 <1
8 21.6 10.9 8.3 1.9 <1
9 26.3 9.5 7.5 3.7 <1
10 23.0 5.3 5 2.1 <1
11 27.7 5.7 4.8 4.6 <1
12 24.0 5.2 4 2.6 <1
Mean levels 23.4 9.3 7.4 3.8 <1
Table 3.4 Levels of LBA and leptin, in stripped and unstripped serum, in male subjects
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Subject BMI
(Kg/m2)
LBA (%) Leptin (ng/ml)
Neat
Serum
Stripped
Serum
Neat
Serum
Stripped
Serum
1 21.5 12.8 10.5 16.1 <1
2 22.6 5.5 10 18.6 1.3
3 22.6 12.5 12.5 11.5 1.5
4 24.3 9.4 16.5 39.2 <1
5 20.9 8.8 6.5 8.8 1.0
6 23.4 12.9 15.3 8.7 1.0
7 28.0 8.2 9.3 16.7 <1
8 22.2 17.9 16.5 8.3 <1
9 20.2 9.8 11.3 6.1 <1
10 33.0 5.3 12.8 40 <1
11 25.6 8.9 8.3 10.2 <1
12 45 4.4 10.8 106 1.2
Mean levels 25.8 9.7 11.7 24.2 <1
Table 3.5 Levels of LBA and leptin, in stripped and unstripped serum, in female 
subjects.
The mean serum leptin level was significantly lower in the male subjects than in the 
female subjects (t test, p = 0.02). After stripping the serum, leptin was undetectable in 
19 of the 24 samples. A paired t test was used to assess the difference between LBA in 
the stripped and unstripped samples. The difference in LBA was not significant in the 
male subjects. In some subjects, the levels of LBA were reduced. In females, 8 o f the 12 
subjects LBA increased after stripping the serum of its endogenous leptin. The increase 
in the stripped serum was most pronounced in subjects with high levels of leptin. The 
hypothesis that endogenous leptin might interfere with the LBA assay seems true in the 
case of women with high levels of leptin. Male subjects with increased levels of leptin 
were not available and, therefore, this observation was not made in male subjects.
3.4.2.4 Conclusion
Stripping the serum of the endogenous level of leptin was adopted in the method for 
LBA. All samples from both males and females were stripped of their endogenous 
leptin to normalise the variation in leptin level.
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3.5 Validation of the assay
3.5.1 Homologous competitive binding curves and Scatchard Analysis
3.5.1.1 Study design
In order to investigate the LBA assay and assess its validity, a competitive binding 
assay was performed. This assay used the same compound for the hot and cold ligand 
and therefore, is known as a homologous competitive binding experiment. Serum was 
stripped as described in chapter 2 and was used either undiluted or diluted 1:1, 1:2, and 
1:3 with sterile water. These samples were incubated with radioactive ligand and 
increasing amounts of cold (unlabelled) leptin (0-10pg/tube). This analysis was 
performed, to answer two questions about the actual binding that occurred in the assay. 
Firstly, could the radioactive leptin be displaced from the binding site by increasing 
amounts of unlabelled leptin? Secondly, would the amount of binding activity be 
reduced when the sample had been diluted?
Scatchard analysis is a method of analysing ligand-receptor interactions. A Scatchard 
plot is a graph of the amount o f radioligand bound divided by the amount o f radioligand 
free in the solution (B/F) (on the y-axis) versus the amount of radioligand bound 
(Bound) (on the x-axis). For the Scatchard analysis, samples were stripped of their 
endogenous leptin and incubated with increasing amounts of cold leptin (0-10p.g). The 
amounts of leptin were calculated in pMolar (0-600pM) and Scatchard analysis 
performed using LIGAND-EBDA software version 2.0 (Elsevier-Biosoft, Cambridge, 
UK).
3.5.1.2 Results
The addition of increasing amounts o f cold leptin resulted in more radioactive ligand 
being displaced (Figure 3.1). The diluted samples followed a parallel pattern each with 
successively lower counts, reflecting a differing amount of binding protein.
Scatchard analysis revealed a single binding species, with high affinity typical of a 
hormone or cytokine receptor (Gammeltoft and Kahn). The binding affinity was 1.0 -
1.4 x 109 M"1. (Figure 3.2)
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Figure 3.1. Competitive binding curve and parallel displacement of leptin in the LBA 
assay.
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3.5.1.3 Conclusion
The competitive binding experiment provides important information about the LBA 
assay. Firstly, the amount of dilution is inversely proportional to the counts seen, 
indicating the binding protein can be diluted away. This suggests that we are measuring 
a real leptin-binding activity and not a random event. Secondly, increasing the amount 
of unlabelled leptin added to the assay results in more radioactive ligand being 
displaced. This indicates that there is increased competition for the binding site.
Scatchard analysis revealed a high affinity (1.0 -  1.4 x 1 O'9 M'1) binding protein which 
would be compatible with the expected affinity of the soluble receptor (Liu et al., 1997). 
The Scatchard analysis appeared to detect only a single species of binding protein, 
although lower affinity binding proteins may not be detected by this method. It is usual 
to only see a single binding species, unless the affinities of the two sites are extremely 
different, or if one of the binding sites is in great excess. In summary, this experiment 
proves that the binding of radioactive ligand to the binding protein in serum is true. It 
can be removed with dilution and it is displaced when large amounts o f unlabelled 
leptin are added. Scatchard analysis revealed a single species of binding protein, with 
high affinity for the ligand. Using charcoal-dextran slurry as the separation method is 
likely to leave only high affinity binding sites in solution.
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Figure 3.2 Scatchard analysis of LBA in normal human serum. This analysis revealed a 
high affinity single species of binding protein (1.0-1.4 x 109 M-1).
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3.5.2 Confirmation o f  the specificity o f  the assay fo r  leptin
3.5.2.1 Study Design
Reactions were set up as for the Scatchard analysis, but using increasing amounts of 
growth hormone and IL-6 in place of leptin. Growth hormone was chosen as it is 
structurally similar to leptin and is of a comparable size. IL-6 was chosen, as the leptin 
receptor is structurally similar to the IL-6 receptor family. Samples were assayed in 
duplicate. Means of these two measures are shown.
3.5.2.2 Results
There was no displacement of the radioactive leptin by either growth hormone or IL-6. 
(Figure 3.3).
3.5.2.3 Conclusion
The binding species being assessed by the LBA assay appears to be specific for leptin. 
IL-6 and GH, similar hormones and cytokines, are not able to displace the bound ligand.
3.5.3 Reproducibility and sensitivity o f  the LBA assay
3.5.3.1 Study Design
In order to assess the reproducibility of the assay, two samples were chosen. The first 
sample, A, was taken from a normal weight female (BMI = 24.3 Kg/m2) with a leptin 
level of 12 ng/ml. The second sample, B, was taken from an obese female subject (BMI 
= 45.0 Kg/m2) with a leptin level of 106 ng/ml.
To assess intra-assay variability, 10 aliquots of the same samples were assayed together. 
The inter-assay variability was continually assessed with each batch of samples. With 
each batch of samples (n=15), both the A and B samples were assayed alongside. From 
these collective measurements, the inter-assay variability could be calculated. The assay 
sensitivity was assessed using 10 repeated measures of a sample not containing any 
serum leptin-binding proteins. Two zero samples were assayed. Firstly assay buffer was 
used as the zero samples, as it contained protein (albumin), but not binding proteins to 
leptin. Secondly, an aliquot of serum was heated to 80°C for 30 minutes and used as a 
zero sample, this would allow degradation of protein in the serum. This sample would 
show the limit at which, we could expect to measure LBA. Coefficients of variation 
were calculated (standard deviation / mean x 100, expressed as a percentage). The CV 
expresses the standard deviation as a percentage of the mean value and provides a 
simple appreciation of the precision (reproducibility) of the assay.
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3.5.3.2 Results
The sensitivity of the assay was 0.6% ± 0.44 (mean ± 2SD). Binding activity greater 
than this level can be attributed to leptin binding proteins being present in the sample. 
Sample A had a specific binding of 12%, with an intra-assay coefficient of variation 
(CV) of 3.2 % and an inter-assay variation CV of 6.4%. Sample B had a specific 
binding of 6% with an intra-assay coefficient o f variation (CV) of 4.1 % and an inter­
assay variation CV of 4.8%.
3.5.3.4 Conclusions
The LBA assay is a reproducible assay. For assays that use dextran-coated charcoal as 
the method o f separation, a CV o f less than 10% is considered appropriate. This assay 
has intra and inter-assay CVs for this assay are less than 10% and therefore are an 
indication of a highly reproducible assay.
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19SFigure 3.3 Specificity of binding of I-Leptin to normal human serum. The specific 
binding of 125I-Leptin is expressed as a percentage of the maximal binding. Growth 
hormone and IL-6 were used in place of leptin in the competitive binding assay. Values 
are the mean of duplicate determinations from a representative experiment.
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3.5.4 HPLC Analysis and comparison with the LBA assay
3.5.4.1 Study Design
Samples that had been previously used to investigate the effect of stripping the serum of 
endogenous leptin were utilised here. Samples were stripped of their endogenous leptin 
and used unstripped. Eight samples were analysed by the HPLC method described in 
Chapter 2. This analysis was carried out by Miss Sylvie Simon and Dr Marie-Catherine 
Postel-Vinay at the Faculte de Medicine Necker in Paris, France. HPLC analysis by Dr 
Postel-Vinay was utilised as a comparison to the LBA method. The measurement of 
GHBP is well established in their laboratory.
3.5.4.2 Results
Results from the LBA assays were compared with those obtained by HPLC. A 
representative profile is shown in Figure 4. HPLC revealed a single peak at the 
appropriate size for the soluble form of the leptin receptor (~85 kDa). Results of 
specific binding were comparable considering the different methodology used for the 
eight samples analysed.
After 10 minutes, a peak eluted off the column. This peak of radioactivity corresponds 
to the high affinity leptin-binding species seen in the LBA assay. The addition of cold 
leptin to the reaction mixture caused this peak to be attenuated. The second peak that 
eluted from the column, after 20 minutes, is the free radioactive leptin. As the large 
molecules are eluted from the column first, we can be sure that no further peaks will be 
seen after the large peak of free radioactivity (see discussion re a -2-macroglobulin). 
There was no detectable measure of radioactivity before 10 minutes.
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Sample Specific Binding (%)
LBA HPLC
1 8.1 6.3
2 9.7 8.1
3 6.5 11.7
4 10.5 8.8
5 9.3 7.2
6 12.5 10.4
7 16.5 12.6
8 10.5 10.3
Mean ± SEM 10.5 ± 1.07 9.4 ± 0.78
Table 3.8. Comparison of results from LBA assay and HPLC analysis.
3.5.4.3 Conclusion
The results from the LBA assay were comparable with the results from the HPLC 
analysis, confirming the validity of the data. A single peak is seen on HPLC analysis 
and this compares well with the Scatchard analysis which defined a single site high 
affinity binding protein. This analysis confirms that the LBA assay is measuring a 
defined quantity of binding protein that is easily comparable using other methods.
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Figure 3.4 Elution profile of I25I-Leptin incubated with human serum. I25I-Leptin (4 x 
104 cpm) was incubated with 150pl of serum without (thick line) and with (thin line) 
excess of native leptin. Binding was expressed as a radioactivity in the first peak over 
the radioactivity in peak 1 and peak 2 (free 125I-Leptin). For the profile shown, total 
binding was 29.0% and non-specific 13.1% radioactivity.
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3.6 Conclusion
The leptin-binding activity assay is a specific, sensitive, and reproducible method for 
assessing leptin-binding protein in human serum. It was necessary to optimise the assay 
specifically for leptin binding protein and to validate the results achieved using the 
assay. Serum samples were stripped of their endogenous leptin to lessen the interference 
from samples with high levels o f leptin. Investigation of sample type revealed that 
serum or plasma samples (using EDTA or lithium heparin as the anti-coagulant) were 
appropriate samples for the measurement of LBA in this manner. Validation 
experiments were able to confirm that:
• The assay is specific for measuring LBA and not binding of other hormones 
(growth hormone) or cytokines (IL-6).
• A single species of high affinity (1.0 -  1.4 x 10'9 M-1) binding activity was 
observed.
• The assay is reproducible.
• HPLC analysis also showed a single binding species and this is comparable with 
data gained from the LBA assay.
At present, exactly what the high affinity binding-protein(s) are has not been elucidated.
Previous reports have indicated that at least a portion of the binding activity is
attributable to a soluble form of the leptin receptor (Sinha et al, 1996, Houseknecht et
al, 1996). Reports have identified binding proteins from 85 to 240 kDa in size
(Houseknecht et al, 1996), with a putative soluble receptor reported to be around 85-90
kDa (Liu et al, 1997). Some workers have reported in-house ELISA assays for the
soluble isoform of the leptin receptor (Lewandowski et al, 1998). Diamond et al, (1997)
described a method for measuring leptin-binding proteins using gel filtration. They
observed a number of bound components, including a large protein with a high
molecular mass (-450 kDa). Birkenmeier et al (1998) have recently reported that leptin
is bound to a -2-macroglobulin in serum, a -2-macroglobulin is a major proteinase
inhibitor in human blood and tissue (Birkenmeier and Kunath, 1996). It is a large
glycoprotein, with a molecular weight of approximately 450 kDa and has the capacity to
bind cytokines with low affinity (Mather, 1996). The action of a-2-macroglobulin can
be as a carrier, as in the case of transforming growth factor-p (TGF-P) (Feige et al.,
1996) or a-2-macroglobulin can assist in sequestering TNF-a, IL-6 and IL-2 after
oxidative stress (Wu et al., 1998). Wu et al. (1998) postulate that this process allows
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differential regulation of cytokines during inflammatory responses such as those that 
occur in rheumatoid arthritis. Kratzsch et al, (1995) identified that growth hormone is 
also bound to a-2-macroglobulin in serum. It is possible that a portion of the LBA is 
attributable not only to a soluble form of the leptin receptor, but also to a -2- 
macroglobulin.
The development of the LBA assay to this stage permits its use in clinical situations. As 
the role o f leptin is pleiotropic, there are many situations, both in health and in disease, 
which would warrant measurement of LBA. After the establishment o f a “normal” 
range throughout life from early infancy to old age, pregnancy would be a next step. It 
is known that leptin has an important role in reproduction, particularly in females. 
Soluble leptin receptor is increased during pregnancy in mice; the placenta is a source of 
leptin and leptin receptor during pregnancy and it would be interesting to assess how 
important, if at all, LBA was during this process. For disease situations, the most 
obvious choice for the measurement of LBA would be obesity, cachexia and anorexic 
conditions. As leptin is known to reflect fat mass and therefore, be at high levels in most 
obese humans and at low levels in most anorexic individuals, the measurement of LBA 
would be pertinent. Any observed difference in LBA in these individuals may assist in 
the understanding of leptin’s complex role in body weight regulation. Measurement of 
LBA in other disease situations such as, diabetes, renal disease and cancer may aid in 
relating and expanding the role of leptin to other cytokine and hormonal systems.
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Chapter 4
Leptin and Leptin Binding Activity Levels During Pubertal
Development
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4.1 Introduction
Puberty, the transition from child to adult, is the result o f reactivation of the pituitary 
gonadal axis. Sex steroids reach adult levels in late gestation, driving sexual 
differentiation in the foetus, and then, shortly after birth, the pituitary gonadal axis 
switches off and lies dormant until the onset of puberty. The metabolic switches that 
program this biological clock are now being defined. The importance of body 
composition has been recognised since the 1970s when Frisch suggested that it was 
necessary for women to maintain a specific percentage of body fat to achieve menarche 
and fertility (Frisch et al., 1970).
Two recent reports of humans with mutations in the leptin receptor and leptin gene, who 
failed to progress through puberty, provide important evidence for the role of leptin in 
facilitating pubertal development (Clement et al., 1998, Strobel et al., 1998). However, 
the nature of the link between puberty and leptin is not fully established. Cross-sectional 
and longitudinal studies of leptin levels before and during puberty indicate that leptin 
levels follow changes in fat mass (Blum et al., 1997, Garcia-Mayor et al., 1997, Clayton 
et al., 1997). In males, there is an increase in leptin prior to pubertal development 
(Mantzoros et al., 1997), this lends weight to the hypothesis that leptin is a signal to the 
reproductive axis to initiate the start o f pubertal maturation. In children, age is also an 
independent determinant of leptin levels and leptin may act as a permissive signal to 
puberty over time (Clayton et al., 1997).
Marshall and Tanner (1969 and 1970) described in detail the development of secondary 
sexual characteristics in both girls and boys. From the studies, the Tanner stages of 
puberty were defined, with breast and pubic hair development the characteristics for 
girls and genital development the characteristic for boys. These developmental changes 
act as a marker to allow the assessment of how far through puberty a child is. The 
length of time from the onset of puberty to maturity varies between boys and girls. Girls 
usually complete puberty by the age of 14.5 years and boys by the age of 17.5 years. 
Growth spurts occur at different times in puberty in boys and girls. The female growth 
spurt begins in early puberty and is virtually complete by the onset of menarche. The 
male growth spurt occurs in the later stages of puberty, usually two years after the 
average female increase in growth. Pre-pubertally both boys and girls have an equal
86
lean, fat and skeletal mass. At maturity, men have one-and-a-half times more lean, 
skeletal and muscle mass than women; women have twice the fat mass as men.
4.1.2 Subjects included in the study
Neonatal cord bloods (n = 10) were collected within one hour of delivery (by natural 
delivery or caesarean section) from the labour ward at the Northern General Hospital. 
Serum was prepared and leptin levels were measured using the human leptin RIA kit 
(Linco Research Co.). Serum samples obtained from the children during puberty (n = 
132) were collected by Dr Peter Clayton at the Endocrine Science Group, University of 
Manchester. Leptin levels were measured by Dr Matthew Gill using the human leptin 
RIA kit (Linco Research Co.). Pubertal staging was performed by an experienced 
paediatrician using the Tanner stages of puberty. Serum samples from young and 
elderly adults (n = 35 and n = 19 respectively) were collected by Professor S. Shalet at 
the Department of Endocrinology at the Christie Hospital. Serum leptin levels were 
measured by Dr A Rahim using the human leptin RIA kit (Linco Research Co.). 
Clinical information, including weight, BMI, age and leptin levels are shown in table 
4.1. The birthweight of the neonate was recorded, as BMI was not measured. All 
subjects gave their informed consent, for those under 18 years of age a parent or 
guardian gave their assent and the studies had the approval of local ethical committees.
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4.3 Results
The median LBA at the different ages of life is shown in Figure 4.1. LB A was lowest at 
birth, highest in prepubertal children, fell during puberty to a mean level of 7-9 % in 
young men and women and remained at this level through to old age. There were no 
differences in LBA between males and females at any age. The sex difference in leptin 
levels observed in pubertal, younger and older males and females was not seen in pre­
pubertal children.
In adults, there was no evidence of a relationship between LBA and age, BMI or leptin 
levels (Table 4.2). In contrast, in children there was an inverse relationship between 
LBA and age, pubertal status, weight, and BMI (Table 4.2 and figure 4.2). The mean 
levels of LBA and BMI according to age for girls and boys are shown in Table 4.3 and 
for Tanner stage in Table 4.4.
In order to determine which is the most important factor in determining LBA, 
multivariate stepwise regression analysis with LBA as the dependent variable and age, 
puberty, BMI and leptin as the independent variables was performed. In boys, the model 
explained 41% of LBA, with only age significantly associated with LBA. In girls, the 
whole model explained 51% of LBA with age (46%) and BMI (5%) significantly 
associated with LBA. ANOVA showed a significant effect of pubertal status on LBA 
(F = 21.2, p< 0.0001) with LBA at all stages of puberty being significantly lower than 
levels at stage 1 of puberty, and stage 2 being different from all stages except 3. Pearson 
correlations between LBA and age, BMI or leptin at each pubertal stage were 
performed. In girls, LBA was negatively correlated with age during Tanner stage 1. In 
boys, LBA was inversely correlated with serum leptin during Tanner stage 4
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Figure 4.1 Box and Whisker plot o f levels o f leptin-binding activity through the ages. 
The median is indicated by the thick black line in the body of the box, the limits of the 
box are the upper and lower quartiles, the extended bars identify the range of the 
samples.
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Figure 4.3 Serum leptin-binding activity levels testicular volume in boys.
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Variable Umbilical
Cord
Boys Girls Men Women
Number of 
subjects
10 65 67 18 23
Age NM r = -0.64
p = 0.0001
r = -0.66
p = 0.0001
r = -0.09 
p = 0.713
r = -0.35
p = 0.226
Pubertal
Status
NM r = -0.62
p = 0.0001
r = -0.61
p = 0.0001
NM NM
Testicular
volume
NM r = -0.60
p = 0.0001
NA NM NA
BMI NM r = -0.38
p = 0.002
 ^
o ©
9 
©ii ii
j-i & r = -0.19 p = 0.47
r = -0.35
p = 0.28
Leptin r = -0.31 
p = 0.45
r = -0.03
p = 0.80
r = -0.42
p = 0.001
r = -0.21 
p = 0.41
r = -0.06 
p = 0.83
Table 4.2: Correlation analysis between different varia >les and LBA
NM not measured 
NA Not applicable
Age Girls Boys
LBA (%) BMI (kg/m2) LBA (%) BMI (kg/m2)
5-6.9 14.5 15.6 12.7 15.9
7-8.9 13.8 17.8 10.8 16.7
9-10.9 10.0 17.7 10.8 17.5
11-12.9 9.5 20.2 9.2 19.6
13-14.9 7.7 19.9 6.4 18.6
15-18.9 7.6 20.7 6.7 22.3
Table 4.3 Mean J3A and BMI for all children accorc ing to age.
Tanner Stage Girls Boys
LBA BMI LBA BMI
1 12.9 16.2 11.1 16.6
2 10.7 18.4 9.5 18.7
3 8.1 18.6 8.0 19.3
4 7.7 19.8 5.9 19.5
5 7.7 21.7 6.6 21.8
Table 4.4 Mean LBA and BMI for all children according to Tanner stage.
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4.4 Conclusion
LBA was low at birth, high in early childhood, fell during puberty and remained at the 
post pubertal level throughout adult life. These changes in LBA parallel the known 
changes in activity o f the pituitary gonadal axis with high levels of LBA being present 
during the childhood years when the pituitary gonadal axis is quiescent In pubertal 
children, LBA showed a significant relationship with age, pubertal status, BMI and 
testicular volume in boys. Multivariate analysis suggested that the most important factor 
was age. There is an absolute requirement for leptin for the initiation and progression of 
puberty as demonstrated by the hypogonadal state o f leptin resistant or deficient human 
subjects (Clement et al, 1998, Strobel et ah, 1998). However, leptin may only provide a 
tonic “background signal” on which other initiators act, as leptin levels in puberty 
primarily relate to fat mass (O’Rahilly, 1998). Our finding, of the direct inverse 
relationship between LBA and pubertal status or age, with a fall in LBA seen at the 
earliest stages of puberty, suggests that this is a link from leptin to the progression of 
puberty.
In both the children and in adult subjects, there were no differences in LBA between the 
sexes. This is in sharp contrast to the well-recognised sexual dimorphism in serum 
leptin levels (Rosenbaum et al., 1998). If the change in LBA is related to a change in 
leptin receptor subtype then this may be an alteration that occurs at puberty and remains 
unaltered through adult life. A relationship between BMI and LBA was not observed in 
the adult groups. These studies were carried out on a relatively small normal population. 
Previous studies have suggested that LBA is reduced in obesity (Sinha et al., 1996, 
Houseknecht et al., 1996, Diamond et al., 1997).
LBA has been reported to relate inversely to leptin levels, however this may have been 
an artefact due to interference in the assay by endogenous leptin (Diamond et al., 1996). 
In the present study, endogenous leptin was removed prior to assaying LBA and no 
statistical evidence of a relationship was found between leptin levels and binding 
activity except in girls. In girls, leptin increases with age and puberty as LBA is 
decreasing. The negative correlation would therefore be expected.
These data confirm that the measurement of serum LBA is biologically meaningful, and 
as such, suggest that this assay may be a useful indicator of leptin activity in other 
situations.
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In conclusion, we have demonstrated an inverse relationship between age and LBA and 
a strong correlation between puberty and a decrease in LBA. The fall in the earliest 
stages of puberty suggests that this is a primary event, not driven by changes in sex 
steroids. The fall in LBA could be explained by a change in leptin receptor expression, 
which may be the link between the leptin system and the initiation and maintenance of 
puberty.
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5.1 Introduction
Recent studies have suggested that leptin has a role in female reproduction although the 
exact nature of the role is not fully understood (Cioffi et al., 1996, Butte et al., 1997, 
Conway et al., 1997). Female ob/ob mice are infertile and their fertility is restored with 
administration of leptin (Barash et al., 1996). Circulating leptin concentrations are 
higher in females than males, even when corrected for differences in body mass index 
(BMI) (Hickey et al., 1996, Kohrt et al., 1996). Further evidence for a role for leptin in 
reproduction is that pregnancy causes changes in the serum concentration of leptin with 
levels at 36 weeks gestation higher than at 3 and 6 months postpartum (Butte et al, 
1997). Other studies have suggested that this increase in leptin may be brought about by 
the progressive increases in plasma progesterone, oestrogen and human placental 
lactogen during pregnancy (Cioffi et al, 1996, Conway et al., 1997).
It has been postulated that leptin is a peripheral signal that integrates fat stores, nutrition 
and reproductive viability. Female athletes can develop amenorrhoea; this loss of 
menstrual function often correlates directly with the proportion of weight that is lost 
(Goldfien and Monroe, 1997). Decreased leptin levels were found in undernourished 
women of reproductive age, mainly presenting with oligo- or amenorrhoea (Macut et 
al., 1998). This supports the hypothesis of Frisch (1990), that adequate fat stores are 
required for normal reproductive function to occur and that leptin acts as a peripheral 
signal, from the fat stores to the brain, indicating that the body has the ability to support 
a pregnancy.
Leptin interacts with the hypothalamo-pituitary-ovarian axis (Yu et al., 1997). In 
women undergoing pituitary down-regulation and ovarian stimulation for in vitro 
fertilisation (IVF), serum leptin levels have been shown to correlate with oestradiol and 
follicle stimulating hormone (FSH) (Butzow et al., 1997), and other studies have 
suggested that leptin may be involved in bringing about the ovarian response to 
gonadotrophin stimulation (Strowitzki et al., 1997). This hypothesis is supported by the 
presence o f leptin receptor in ovarian tissue (Cioffi et al., 1996) and the presence of 
leptin within the pre-ovulatoiy follicle and mature oocyte (Cioffi et al., 1997).
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5.1.1 Cytokines and soluble cytokine receptors through the menstrual cycle
The majority of previous investigations on the role of leptin in female reproduction have 
been carried out in pregnant women or those undergoing IVF treatment using stimulated 
cycles. Less is known about the variation in serum leptin levels and leptin binding 
activity throughout the menstrual cycle in normal fertile women. Some cytokines, such 
as IL-1 (Lynch et a l , 1994) and soluble cytokine receptors, such as the IL-6 soluble 
receptor (Gorai et al., 1998), are known to fluctuate during the menstrual cycle while 
others, such as IL-10, do not vary in this way (Maskill et al., 1998).
A report by Gorai et al (1998) suggests that there are significant fluctuations of the 
soluble IL-6 receptor during the menstrual cycle in their cohort of Japanese women. 
They demonstrated a rise in soluble IL-6 receptor in the early and late follicular phase 
of the menstrual cycle. As a proportion of the LBA is reported to be the soluble form of 
the leptin receptor, and soluble cytokine receptors have been reported to fluctuate 
during the menstrual cycle, it is possible that LBA would also fluctuate during the cycle 
in response to varying leptin levels. However, other workers do not report any 
fluctuation in soluble IL-6 receptor during the menstrual cycle (Angstwurm et al.,
1997). Other binding proteins, such as growth hormone-binding protein (GH-BP) and 
IGF-BP have also been studied during the menstrual cycle. Klein et al., (1996) 
measured GH-BP in two groups of regularly cycling women aged 20-25 years and 40- 
45 years. They found that GH-BP does not fluctuate in either of the two groups studied. 
Trainer et al. (1998) studied corticotrophin-releasing hormone binding protein, they 
found no variation of this binding protein in the menstrual cycle. Controversy surrounds 
the variation of IGF-BPs during the menstrual cycle. Many workers report no 
significant difference in levels of either IGF-BP 1 or IGF-BP 3 at any point of the 
menstrual cycle (Juul et al., 1997, Ovesen et al., 1998, Van Dessel et al., 1996). Helle et 
al. (1998) report that IGF-BP 3 is highest in the follicular phase of the cycle, but that 
there is no change in levels of IGF-BP I. Westwood et al. (1999) disagree, these 
workers found that IGF-BP I varied with the menstrual cycle, with a peak occurring in 
the late secretory phase.
5.1.2 Leptin and pregnancy
During pregnancy, there is a significant rise in leptin above those levels seen in non­
pregnant women (Butte et al., 1997, Hassink et al., 1997). Tamas et al. (1998) 
performed longitudinal analysis of leptin levels during the pregnancies of nine women.
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In each case, there was a steady rise in leptin levels throughout pregnancy until week 28 
where they observed a small decline. They report a positive correlation between BMI 
and leptin levels in the first and second trimester of pregnancy but, not in the third 
trimester; this may be due to the difficulties in obtaining an accurate BMI during 
pregnancy. Leptin is produced primarily by adipose tissue. It is now known, however, to 
be expressed and secreted by a number of tissues including the placenta. At this time, it 
is not known what contribution placental leptin production makes to the total leptin 
level during pregnancy. Leptin receptor isoforms have been identified in the placenta. 
Henson et al. (1998) localised leptin receptor transcripts to the syncytiotrophoblast 
cells. These cells produce hormones necessary for maintaining pregnancy and the 
authors postulate that placental leptin may be a factor in maintaining pregnancy. Bodner 
et al. (1999) agree with the previous studies on the placental distribution o f the leptin 
receptor. They identified the long form of the leptin receptor in the cytoplasm o f the 
syncytiotrophoblast cells and other receptor isoforms in the apical membrane o f the 
syncytiotrophoblast cells, intervillous space and in foetal vessels.
There is evidence to suggest that leptin is an important factor in foetal growth and 
development. Leptin mRNA has been identified in human foetal adipose tissue (Bernard 
et al./, 1999) and in murine foetal hair follicles, bone, and cartilage (Hoggard et al., 
1999). Cord blood leptin is associated with intrauterine growth, even after allowing for 
placental weight, adiposity, maternal leptin concentration and cord blood insulin level 
(Varvarigou et al., 1999). Harigaya et al. (1999) suggest that leptin has an important 
function in the regulation o f weight gain in early infancy. Hytinantti et al. (1999) 
investigated changes in leptin levels in the early postnatal period. Leptin is markedly 
reduced in the three days after birth and the gender difference observed in adults is 
already present in their study. It is possible that leptin, produced by the placenta, may be 
an important factor in intrauterine growth and development and thus be a mechanism by 
which poor placentation can lead to a poor pregnancy outcome. Alternatively, lower 
serum leptin levels may reflect lower production by a poorly-functioning placenta.
5.1.3 Leptin and cigarette smoking
Cigarette smoking is associated with lower BMI, smokers weigh less than age-matched 
non-smokers (Nicklas et al., 1999). A major deterrent to stopping smoking, especially 
amongst women, is weight gain (Spring et al., 1992). Leptin, expressed by adipose 
tissue, is proposed to regulate body weight via hypothalamic control of energy intake
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and expenditure. Increased energy intake is believed to be the most likely cause of 
weight gain after smoking cessation. There is some evidence that smoking increases the 
metabolic rate and that this rate may decrease on cessation of smoking (Moffatt et al., 
1991). Several groups o f workers have reported that leptin levels vary between smokers 
and non-smokers; these reports are in conflict. Nicklas et al. (1999) measured leptin 
levels in middle-aged and elderly male subjects, they found that smokers have 
significantly higher leptin levels than non-smokers whereas Hodge et al., (1997), report 
that leptin levels are lower in their Nauruan, West Samoan and Mauritian male 
population of smokers than non-smokers. Wei et al. (1997) also reports lower leptin 
levels in their population of Mexican-American smokers.
It is well documented that smoking during pregnancy can have a detrimental effect on 
the foetus and may lead to premature birth or the infant being light for gestational age 
(LGA) (Abel, 1980). Recent reports have suggested the effect of in utero exposure to 
tobacco smoke may have long term consequences on the child’s health. Smoking during 
pregnancy is a risk factor for the development o f congenital heart defects (Kallen, 1999) 
and for behavioural and neurodevelopmental difficulties such as, reduced intellectual 
ability and decreased attention span (Eskenazi and Castorina, 1999). Mathews et al., 
(1999) demonstrated that the level of cotinine, a nicotine metabolite, at week 16 of 
pregnancy was predictive of a poor outcome. At cotinine levels of greater than 225 
ng/ml, the subjects were more likely to have a pregnancy that resulted in a poor 
outcome.
5.1.4 Objectives
In order to expand current knowledge of leptin in female reproductive processes, studies 
of leptin and leptin binding activity were carried out in three cohorts of women; two 
studies within the menstrual cycle and a study o f leptin during pregnancy.
There were three main aims of these studies:
® To test the hypothesis that levels of leptin and leptin binding activity alter 
throughout the menstrual cycle.
® To aid in the elucidation of the role of LBA in adulthood and assist in understanding 
the role of leptin in reproduction.
® To provide some understanding of the role of leptin during pregnancy, the possible 
relationship with pregnancy outcome and the effect of smoking during pregnancy.
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5.2 Serum leptin and LBA levels during the menstrual cycle
5.2.1 Study Design
5.2.1.2 Cohort A
Serum samples were obtained from 17 normal fertile women, these were collected by 
Mr T.C. Li at the Jessop Hospital for Women in Sheffield. All the women were aged 
30-39 years and had a BMI of between 19.8 and 27.9 kg/m2. The subjects were not 
required to fast before sampling took place. The number of serum samples collected 
from each subject ranged from 1 to 3 in the follicular phase and 2 to 3 in the luteal 
phase. All subjects had normal menstrual cycles as confirmed by detection of luteinising 
hormone (LH) surge and luteal phase progesterone levels. Each woman had had at least 
one successful pregnancy. None of the subjects were currently prescribed oral 
contraceptives or corticosteroids.
The samples obtained were timed precisely according to the LH surge. From day 9 of 
the cycle, early morning urine or daily serum samples were collected from each subject. 
LH was measured in each sample by an established immunoenzymatic assay (Serono 
Diagnostics Ltd, Surrey, UK.) The day in which the LH surge occurred was designated 
as day LH+0 (Li et al., 1993).
Leptin levels were measured using a specific human leptin RIA from Linco Research 
Co. as described in Chapter 2. Serum progesterone had previously been measured in 
samples taken ten days after the LH surge (LH+10), at the point where progesterone is 
maximal, in 14 of the women. The progesterone was measured using a Progesterone 
EIA kit (Serozyme, Welwyn Garden City, Herts, UK.). Analysis of serum progesterone 
levels and urinary or serum LH was carried out at the Jessop Hospital for Women. All 
subjects gave informed consent and the studies had the approval of the local ethical 
committee (South Sheffield Ethics Committee).
2.5.1.3 Cohort B
Serum samples were obtained from eight women throughout the menstrual cycle; these 
were collected by Dr Melissa Westwood at the University o f Manchester. All the 
women had a BMI between 19.8 and 28.7 kg/m2 and were aged between 21 and 40 
years. The women had normal length menstrual cycles of between 25 and 35 days. 
None of the women were currently prescribed oral contraceptives or corticosteroids.
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The subjects were required to fast prior to the blood samples being taken. Menstrual 
cycle date was determined by measurement of the LH surge. The number of serum 
samples collected from each subject ranged from 1 to 3 in the follicular phase and 2 to 3 
in the luteal phase. The measurement of serum and urinary LH was carried out by Dr 
Melissa Westwood. Leptin levels were assessed using a specific human leptin ELISA 
(R&D Systems) and LBA was measured as described in Chapter 2. The women who 
provided samples for these studies gave their informed consent and the studies had the 
approval o f the local ethical committee.
Statistical Analysis
The difference between the mean levels of leptin in the follicular and luteal phases for 
each woman was assessed by a paired t test. The relationship between leptin and BMI 
was assessed using Pearson product moment testing.
5.2.2 Results
5.2.2.1 Cohort A
Levels of leptin gradually increased throughout the cycle and were maximal in the luteal 
phase. In 14 out of the 17 subjects, mean luteal levels of leptin were arithmetically 
higher than the mean follicular leptin levels. The mean follicular and luteal levels of 
leptin in the remaining 3 subjects were unchanged.
Serum follicular and luteal phase leptin levels for each individual woman is shown in 
Figure 5.1. Leptin levels were significantly higher (p<0.01) in serum obtained during 
the luteal phase than in serum collected during the follicular phase. The overall median 
serum leptin during the follicular phase was 10.0 ng/ml with a range of 4.3-32.2 ng/ml. 
The median level of leptin during the luteal phase was 11.4 ng/ml with a range o f 4.9- 
66.7 ng/ml.
BMI measurements were not available for subjects 2 and 10. For the 15 subjects whose 
values were available, a significant correlation was seen between leptin levels (mean of 
all menstrual cycle measurements) and BMI. (r = 0.54, p <0.05) (Figure 5.2). Luteal 
phase progesterone levels were obtained in 14 o f the 17 subjects. No correlation was 
seen, however between leptin and progesterone at the peak progesterone level ten days 
after the LH surge (r = -0.34, p <0.370) (Figure 5.3).
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5.2.2.2 Cohort B
Leptin levels were measured in samples from eight women throughout the menstrual 
cycle. As expected, the mean leptin level (from each subjects samples throughout the 
cycle) correlated with BMI (r = 0.892, p=0.003) (Figure 5.2). The mean leptin level for 
the 8 subjects was 13.9 ± 4.9 (mean ± SEM). The mean level of leptin in the follicular 
phase was 12.6 ± 4.5 ng/ml (mean +SEM) and in the luteal phase was 15.3 ± 5.4 ng/ml 
(mean ± SEM). Leptin levels were significantly higher in the luteal phase of the 
menstrual cycle (p = 0.04) and this agrees with the previous study. The follicular and 
luteal phase leptin levels are shown in Figure 5.1. Serum LBA was measured in 8 
subjects; LBA was higher in the luteal phase than the follicular phase in three 
individuals, lower in the luteal phase than the follicular phase in three individuals and 
remained unchanged throughout the cycle in 2 subjects (Figure 5.4). The mean level of 
LBA in the follicular phase was 8.5 ± 3.0 % (mean ± SEM) and in the luteal phase was
8.3 ± 2.9 (mean ± SEM). There was no significant difference between the mean 
follicular level of LBA and the mean luteal level o f LBA using a t test for paired data. A 
significant correlation between LBA and BMI was not seen (r = -0.693, p = 0.06) 
(Figure 5.5), although a negative trend was observed: with a higher BMI, a lower LBA 
is present.
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Figure 5.1 Levels of leptin for each individual subject in the follicular (open squares) 
and luteal (black squares) phases in cohort A and B.
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Figure 5.2 Mean serum leptin levels correlated with BMI in both cohort A and B. A 
significant correlation was seen in cohort A (r = 0.54, p< 0.05) and cohort B (r = 0.892, 
p = 0.003).
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Figure 5.3 In cohort A, there is no relationship between leptin and progesterone on day 
LH+ 10.
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Figure 5.5 Serum leptin-binding activity (%) did not show significant correlation with 
BMI in cohort B (r = -0.693, p = 0.06)
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5.3 Effect of smokin2 status and pregnancy outcome on serum leptin levels during
pregnancy
5.3.1 Study design
As leptin is known to fluctuate:
a) during the menstrual cycle;
b) in pregnancy;
c) with smoking status,
The aims of the present study were to assess if maternal serum leptin concentrations 
varied in subjects who had a poor pregnancy outcome compared to those with a normal 
pregnancy outcome, and if there was any variation in serum leptin levels in pregnant 
smokers compared to pregnant non-smokers.
Subjects used in this study were recruited by Dr Fiona Mathews at the University of 
Oxford as part of a larger study o f more than 1000 nulliparous, pregnant women 
investigating antioxidant status and birthweight. At the first antenatal booking-in 
appointment the women’s height, weight and smoking status were recorded. During 
routine antenatal blood testing (at weeks 16 and 28), samples were obtained for cotinine 
and leptin analysis. In total, 154 samples were obtained from 77 women (paired samples 
at both 16 and 28 weeks) for cotinine and leptin analysis. Poor pregnancy outcomes of 
light for gestational age and pre-term birth were chosen a priori. Data on each subject’s 
pregnancy outcome was obtained retrospectively.
Cotinine levels were measured with an in-house RIA (as described in chapter 2) to 
assign smoking status. This analysis was carried out in collaboration with Dr Robert 
Smith. Any subject with a cotinine level of >15ng/ml was considered a smoker. Serum 
leptin levels were measured using the leptin ELISA (R&D Systems), as described in 
chapter 2.
This study had the approval of the local ethical committee and all participants gave their 
informed consent.
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5.3.2 Results
In this cohort of pregnant women, mean serum leptin levels at week 16 were 24.5 ± 2.8 
ng/ml (Mean ± SEM). This increased to 25.0 ± 2.9 ng/ml at week 28. In the total cohort, 
there was no significant increase in serum leptin concentration between weeks 16 and 
28. At 16 weeks of gestation, BMI was calculated. Serum leptin levels correlated with 
BMI (r = 0.536, p = 0.001) at week 16 (Figure 5.6). Clinical data for all subjects is 
shown in Table 5.1a. Mean serum leptin levels at 16 and 28 weeks and cotinine levels 
are shown in Table 5.1b.
Mean serum leptin levels were lower in subjects who had a poor pregnancy outcome 
compared to those who had a normal pregnancy outcome at week 16 and week 28 
although this did not reach significance (Figure 5.7). Clinical details for subjects 
separated by pregnancy outcome are shown in Table 5.2a. Mean BMI was significantly 
lower in those women with poor pregnancy outcome compared to women who had a 
normal pregnancy outcome. Mean serum leptin concentrations at 16 and 28 weeks and 
serum cotinine levels for women separated according to pregnancy outcome are shown 
in Table 5.2b.
Leptin levels correlated with BMI in both the women with a normal pregnancy outcome 
(r = 0.661, p = 0.0001) and poor pregnancy outcome (r = 0.429, p = 0.004) at week 16 
of the pregnancy. By week 28, only the women with poor pregnancy outcome had leptin 
levels that correlated with BMI (taken at week 16) (r = 0.619, p = 0.0001). There was a 
significant correlation between BMI and birthweight in those subjects with a normal 
pregnancy outcome at 16 weeks (r = 0.376, p = 0.03), but this was not apparent at 28 
weeks or in subjects with a poor pregnancy outcome. A relationship between maternal 
serum leptin level and infant’s birthweight was not observed.
Mean serum leptin levels were significantly lower in pregnant smokers than in pregnant 
non-smokers at week 16 and week 28 of pregnancy (Figure 5.8), although this may be 
an effect of smokers having a lower BMI than non-smokers. BMI was significantly 
lower in those women who smoked compared to the non-smokers. Serum leptin level 
correlated with BMI at week 16 o f pregnancy in both the smokers and the non-smokers. 
However, at week 28, leptin level correlated with BMI (taken at week 16) in the non­
smoking group. There was no correlation between serum leptin level and serum cotinine 
level in these subjects. There was no significant correlation between BMI and
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birthweight at either week 16 or 28 in the smokers. In the non-smokers, BMI correlated 
with birthweight at 16 weeks but, this relationship had disappeared by week 28. There 
was no correlation between leptin levels and birthweight at week 16 or 28.
ANOVA (with Bonferroni correction) was used to determine differences between the 
groups. At week 16 there was no significant difference between the four groups of 
pregnant subjects. By week 28, however, non-smokers with normal pregnancy outcome 
had significantly higher leptin levels than normal outcome smokers (p = 0.03) and poor 
outcome smokers (p = 0.009). The change in serum leptin levels between 16 and 28 
weeks of pregnancy is shown in those with poor and normal pregnancy outcome, in 
smokers and non-smokers and subjects separated according to smoking status and 
pregnancy outcome (Figure 5.9). The individual changes in serum leptin concentration 
between 16 and 28 weeks of pregnancy in subjects separated according to smoking 
status are shown in Figure 5.10. The change in serum leptin levels between 16 and 28 
weeks separated according to pregnancy outcome and smoking status is represented in 
Figure 5.11 and Table 5.4.
I l l
Mean ± SEM Number
Age (years) 24.7 + 2.9 77
Weight (kg) 65.7 ± 7.7 76
BMI (kg/m2) 24.7 ± 2.9 76
Systolic blood pressure 
(mmHg)
125.4 ± 14.8 77
Diastolic blood pressure 
(mmHg)
78 ±9.2 77
Gestation period (weeks) 38.4 ±4.5 77
Birthweight of infant 
(kg)
2.9 ± 0.3 77
Table 5.1a Clinical details for all subjects in this study of pregnancy.
Mean ± SEM Number
Leptin at 16 weeks 
(ng/ml)
24.5 ±2.8 77
Leptin at 28 weeks 
(ng/ml)
25.6 ±3.0 77
Cotinine (ng/ml) 59.4 ± 7.0 11
Table 5.1b Mean serum leptin concentrations and cotinine levels (mean of week 16 and 
28) in all subjects in this study of pregnancy.
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Normal
Outcome
n Poor
Outcome
n p value
Age (years) 25.5 ±4.4 34 24.8 ±3.8 43 NS
Weight (kg) 68.9 ± 12 33 62.8 ± 9.5 43 0.03
BMI (kg/m2) 25.5 + 4.4 33 23.7 ±3.6 43 0.04
Systolic blood pressure 
(mmHg)
114.1 ±19.6 34 132.7 ± 
20.1
43 NS
Diastolic blood pressure 
(mmHg)
65.9 ±11.5 34 86.3 ±13.1 43 NS
Gestation period (weeks) 40.3 ±6.9 34 36.9 ±5.6 43 0.0001
Birthweight of infant (kg) 3.4 ±0.6 34 2.5 ±0.4 43 0.0001
Table 5.2a Mean clinical data ]nr subjects groupec according to pregnancy outcome
Normal Outcome n Poor Outcome n p value
Leptin at 16 weeks 
(ng/ml)
24.6 ±4.2 34 22.0 ± 3.3 43 NS
Leptin at 28 weeks 
(ng/ml)
28.0 ±4.8 34 22.6 ±3.4 43 0.08
Cotinine (ng/ml) 39.4 ± 6.8 34 82.2 ± 12.5 43 0.03
Table 5.2b Mean serum leptin concentrations and cotinine levels (mean of week 16 and 
28) grouped according to pregnancy outcome.
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Non-Smokers n Smokers n p value
Age (years) 25.9 + 4.2 38 24.3 ± 3.9 39 0.06
Weight (kg) 68.4 ±11.1 37 62.7 ±10.0 39 0.03
BMI (kg/m2) 25.5+4.2 37 23.4 ±3.8 39 0.02
Systolic blood pressure 
(mmHg)
136.8 ±22.2 38 112.4 ±18 39 NS
Diastolic blood pressure 
(mmHg)
90.0 ± 14.6 38 64.9 ± 10.4 39 NS
Gestation period (weeks) 37.8 ± 6.2 38 39.1 ±6.3 39 0.03
Birthweight of infant (kg) 2.9 ±0.5 38 2.95 ±0.5 39 NS
Table 5.3a Mean clinical data ]"or subjects groupec according to smoking status.
Non-Smokers n Smokers n p value
Leptin at 16 weeks 
(ng/ml)
27.2 ±4.4 38 19.2 ±3.1 39 0.01
Leptin at 28 weeks 
(ng/ml)
29.3 ±4.8 38 20.8 ± 3.3 39 0.009
Cotinine (ng/ml) 6.3 ±1.0 38 118.8 ±19.0 39 0.0001
Table 5.3b Mean serum leptin concentrations and cotinine levels (mean o f week 16 and 
28) grouped according to smoking status.
114
8 0 ,
70-
60-O)
~  50
40
S  30
10
Figure 5.6 Serum leptin levels correlate with BMI at week 16 of pregnancy in a cohort 
of 77 women.
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Figure 5.7 Serum leptin levels in all subjects, and separated into groups according to 
pregnancy outcome, at 16 (A) and 28 (B) weeks
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Figure 5.8 Serum leptin levels in all subjects, and separated into groups according to 
smoking status, at 16 (A) and 28 (B) weeks
117
—♦— NrhStrDters 
—A—Sirkers
Figure 5.9 The overall change in serum leptin concentration between 16 and 28 weeks, 
observed in subjects with normal and poor pregnancy outcome (A), smokers and non- 
smokers (B)
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Mean serum leptin 
concentration 
(ng/ml) 
(Mean ± SEM)
Numbers
Increased
Numbers
Decreased
16 weeks 28 weeks >2 ng/ml <2 ng/ml >2 ng/ml <2 ng/ml
Normal
Outcome
Non-
Smoker
31.1 ± 8.6 38.2 ±10.6 7 0 5 1
Normal
Outcome
Smoker
20.7 ±4.5 21.7 ±4.7 7 3 11 2
Poor
Outcome
Non-
Smoker
26.3 ± 5.5 24.4 ±5.1 6 1 14 0
Poor
Outcome
Smoker
17.0 ±3.8 20.5 ± 4.6 11 2 6 1
Table 5.4 Mean serum leptin concentrations (Mean ± SEM) according to smoking 
status and pregnancy outcome, with numbers of subjects that increased and decreased 
between 16 and 28 weeks of pregnancy.
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Figure 5.11 Histogram representation of the change in leptin between 16 and 28 weeks 
in subjects separated according to pregnancy outcome and smoking status.
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5.3.3 Conclusion
5.3.3.1 Serum leptin and LB A levels during the menstrual cycle
The results of this study indicate that circulating leptin concentrations increase after 
ovulation in the luteal phase of the menstrual cycle. This increase was seen in 14 out of 
the 17 women included in cohort A. Levels of leptin showed no change in 3 women. 
The reason for this is unknown, but it may be due to differences in levels of 
reproductive hormones. This same increase in the luteal phase of the menstrual cycle 
was also seen in cohort B. In this study, leptin levels increased in 7 of the 8 women, the 
remaining woman's leptin level remained constant throughout the cycle. In a similar 
study, Hardie et a l (1997) also found that levels of leptin increased during the luteal 
phase of the menstrual cycle. Their study was, however, limited by the fact that it 
included only 6 regularly cycling women. In addition to similar changes seen 
throughout the menstrual cycle in both studies, the absolute levels o f leptin in the serum 
were similar in both these studies and that of Hardie et al. (1997).
The observation that levels of leptin are higher during the luteal phase of the cycle than 
the follicular phase would agree with suggestions for a role for leptin in reproduction 
(Montague et al., 1997) and, possibly, implantation (Cioffi et al., 1997). The presence 
of leptin receptors in the ovary (Cioffi et al., 1997) also suggests that it may have a role 
to play in ovarian function and the rise in leptin levels seen during the luteal phase 
supports the hypothesis that it interacts with the hypothalamo-pituitary-ovarian axis to 
help maintain the corpus luteum. The corpus luteum is the glandular body that develops 
in the ovary in place of the ovum that has been released at ovulation. It produces female 
sex steroids: progesterone and oestrogen. The maintenance of the corpus luteum is 
important for implantation processes.
Several studies have shown that serum leptin levels correlate well with BMI (Butte et 
al., 1997). In this study, a significant correlation of BMI with serum leptin levels was 
also seen. The relationship between BMI and reproductive ability is well established. 
Gymnasts, marathon runners and others with low percentage body fat often have 
amenorrhoea, and puberty is delayed in females with low percentage body fat mass 
(Vogel, 1996). In addition, it has been shown that a critical fat mass (> 1 Oth centile) is 
required for ovulation in women (Frisch, 1990). In relation to this, it has been suggested
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that leptin may serve as a signal to the reproductive system to inform it that stores are 
sufficient to sustain reproduction (Barash et al., 1996).
It was noted that there was some interpersonal variation in the leptin levels measured, 
the reason for this is unknown although a study has shown that leptin levels in women 
are highly variable even when they have been normalised for BMI. However, subject 4 
of cohort A, had a far higher serum leptin level than other subjects, with only a 
moderately raised BMI of 26.5 kg/m2. A possible explanation for this anomaly is that 
she may have eaten prior to having the sample taken and hence, had a short-term change 
in metabolism. An alternative explanation may be the presence of a leptin receptor 
defect or a much greater adiposity than the other subjects. BMI is not a measure of 
adiposity but of total body weight compared with height and leptin levels have been 
shown to correlate better with measures of adiposity than with BMI (Conway et al., 
1997). In addition, there are other factors, which may effect serum leptin concentrations 
for example exercise (Friederich et al., 1995), which were not controlled for in this 
study. A number of other factors including diurnal rhythms, food intake, cytokine and 
hormones are known to influence leptin levels. We can offer no clear explanation of the 
raised levels of leptin in this subject, which were consistent in all her samples.
In contrast with other reports (Hardie et al., 1997) no correlation was seen between 
luteal phase progesterone levels and mean luteal phase leptin levels. In our study, 
progesterone measurements were only obtained at one point in the cycle, whereas they 
were obtained throughout the cycle in the study by Hardie et al (1997). Other studies, in 
women undergoing IVF have suggested levels of leptin correlate with oestradiol and 
FSH. We have not measured these in this study and it may be that leptin correlates 
better with these reproductive hormones than it does with progesterone.
In cohort B, LBA was measured. There was no significant difference between mean 
serum LBA in the follicular phase and mean serum LBA in the luteal phase of the 
menstrual cycle in this cohort of eight regularly cycling women. It is possible that a 
variation in serum LBA during the menstrual cycle may become apparent if more 
subjects were studied, although other studies investigating the fluctuation o f cytokines 
and soluble receptors during the menstrual cycle used similar numbers of subjects. A 
trend towards lower LBA in those subjects with a higher BMI was observed, although 
this did not reach a level of significance. This observation, of a negative correlation
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between serum LBA and BMI, has been reported by other workers measuring LBA by 
varying methods (Sinha et al., 1996, Houseknecht et al., 1996, Diamond et al., 1997) 
and was significant in a larger study of postmenopausal Caucasian women (reported in 
chapter 6). As there is still some disagreement concerning the fluctuation of IGF-BPs 
during the menstrual cycle, it can be postulated that serum LBA may also be as 
contentious. The possibility that the soluble leptin receptor portion of the LBA varies 
with menstrual cycle phase cannot be excluded.
In summary, we have shown, in two cohorts of normal women, that serum levels of 
leptin increase during the luteal phase of the menstrual cycle, supporting the contention 
that leptin may have a role in reproduction. In addition, this fluctuation should be taken 
into account when studies, involving the measurement of leptin, are performed in 
female subjects. There is no evidence, from this study, that LBA has a role in the human 
menstrual cycle. Perhaps in this small cohort of normal fertile women, a small 
fluctuation or variation across the menstrual cycle would not have been recognised or, 
as with IGF-BP, the full role of LBA is still to be elucidated.
5.3.3.2 Effect of smoking status and pregnancy outcome on serum leptin levels 
during pregnancy
In this study, serum leptin levels were arithmetically lower in subjects with a poor 
pregnancy outcome compared to a normal pregnancy outcome at both 16 and 28 weeks: 
this reached a level of significance at 28 weeks. Lage et al., (1999) reported that serum 
leptin levels increased throughout the first six months of pregnancy, but were low in 
women who had a spontaneous abortion in the first trimester o f pregnancy.
In this study of pregnant women, two subjects had extremely high leptin concentrations 
at week 16 of pregnancy, these levels had decreased dramatically by week 28 of 
pregnancy. Both of these women were obese with BMIs of 30.7 and 40.5 kg/m2. It is 
likely that this is the reason for their extremely high leptin level at week 16. Both of 
these women had a normal pregnancy outcome. We can conclude, therefore, that this 
decrease in leptin level by 28 weeks of pregnancy did not affect their pregnancy 
outcome.
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Leptin levels are reported to be lower in smokers than non-smokers (Wei et al., 1997). 
This study confirms that leptin is reduced in smokers compared to non-smokers even in 
pregnancy. In this study, as in others, leptin levels were higher than the reported levels 
for non-pregnant subjects. It is possible that the difference in leptin levels seen in 
smokers and non-smokers may be due to differences in BMI. Smokers have a lower 
BMI than non-smokers (Nicklas et al., 1999). This may be a direct effect of increased 
lipolysis. Smoking increases secretion of catecholamines, which in turn increases 
lipolysis and thus the breakdown of adipose tissue occurs. If there is less fat mass 
present, the amount of leptin secreted will also be less. This is complicated by the fact 
that during pregnancy, other sites of leptin production are also present. Festa et al. 
(1999) report that the increase in leptin levels in their study of pregnant women were 
independent of BMI and fasting insulin. During pregnancy, BMI is not an adequate 
measure of adiposity, however in this and other studies of pregnant subjects, BMI does 
correlate with serum leptin levels (Hassink et al., 1997, Helland et al., 1998).
Smoking during pregnancy is associated with a reduction in foetal growth and an 
increase in foetal mortality. Smoking during pregnancy, in fact, carries a low risk for 
poor pregnancy outcome, as many women who do not smoke have a poor pregnancy 
outcome. Mathews et al. (1999) have shown an increase in the likelihood o f a poor 
pregnancy outcome with a dose-dependent increase in cotinine levels. However, there is 
now evidence to suggest that smoking is responsible for adverse affects on child 
development (Trasti et al, 1999). The placentae of women who are heavy smokers are 
extremely large at delivery. The placental weight, in these cases, is primarily made-up 
of the peripheral villous tree. This section of the placenta in known to adapt to stress, 
particularly hypoxia (Kadyrov et al, 1998). As leptin is an angiogenic factor, this 
increase in the peripheral villous tree may be reflected by the amount of leptin produced 
by the placenta. Smoking causes impairment in the transport of oxygen across the 
placenta. It is speculated that the placenta, in trying to increase its surface area to 
increase oxygen exchange, in turn causes the disproportionately large placenta at birth. 
During pregnancy, nicotine metabolism is altered. Various cytochrome P450 elements 
are responsible for nicotine metabolism in the non-pregnant situation. However, these 
genes are not expressed by the placenta and therefore, metabolism of nicotine by the 
placenta is altered (Pasanen, 1999).
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In these studies, a decrease in serum leptin concentration was observed between 16 and 
28 weeks in subjects who were non-smokers but had a poor pregnancy outcome. It can 
be postulated that leptin is a necessary factor in placental development and therefore in 
having a good pregnancy outcome. Perhaps, the leptin levels were decreased in this 
group of pregnant women, as placental function, or even the foetus itself is not 
undergoing the correct developmental procedure. Poor pregnancy outcome may occur 
as a result of poor placental function. This decrease in placental function may cause a 
decrease in placental leptin production and secretion and as such a decrease in maternal 
serum leptin levels. Leptin's action as an angiogenic factor, may increase the formation 
of new blood vessels (Bouloumie et al., 1998, Sierra -Honigmann et al., 1998) and, 
therefore, it may act in an autocrine manner in the placenta. Feedback to leptin receptors 
expressed in the placenta may occur, resulting in the formation of blood vessels and 
increasing responses to the needs o f the foetus. Leptin is known to be highly elevated in 
severe pre-eclampsia, this may be the placenta responding to the hypoxic situation 
however, leptin levels in mild pre-eclampsia are not elevated (Mise et al., 1997). It is 
possible, as leptin is believed to have importance in implantation processes, that the 
change in leptin is most important in the early weeks of pregnancy, prior to this study 
being performed. The change in leptin observed between the two time-points is likely to 
be of more clinical significance. This is primarily due to the fact that starting BMI does 
not have as much influence on this measurement. By 28 weeks of gestation, the 
outcome of the pregnancy can be assessed. It is possible that measurement of leptin at 
two earlier time-points in pregnancy would be an indicator of poor pregnancy outcome, 
whether the subject does or does not smoke.
As only a small proportion (10%) of all births result in a poor pregnancy outcome, and 
of these deliveries, smoking affects only a few of these cases, it may be that a low leptin 
level is a more notable risk factor, as it will encompass all poor pregnancy outcomes, 
not just those seen in smokers. From this study we can state, that there is no single 
determinant of poor pregnancy outcome, although leptin does appear to be a constituent 
of this multifactoral disorder.
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Chapter 6
Leptin and its Receptor in the Human Endometrium
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6.1 Introduction
Numerous studies have shown that leptin has an important function in mammalian 
reproductive processes. Ob/ob mice do not produce a functional leptin protein. Both 
males and females are extremely obese and infertile. This infertility can be completely 
reversed when the mice are treated with recombinant leptin (Ahima et al., 1997). 
Supplementation of leptin allows the mice to progress through puberty and to become 
fertile. Female hamsters that are treated with recombinant mouse leptin show increased 
sexual behaviour, providing evidence for a role for leptin in female reproduction. These 
processes may be brought about by leptin signalling. Leptin binds to receptors in the 
hypothalamus, whereon a neuroendocrine signal is passed to the pituitary gland and 
onto the gonadal axis via gonadotrophin releasing hormone. However, leptin receptors 
are also expressed in many peripheral tissue including those o f the reproductive tract, 
such as the ovary and testes (Cioffi et al., 1997, Hoggard et al., 1997). The presence of 
leptin receptor isoforms, particularly the long signalling form, in the reproductive tract, 
suggests that leptin, in addition to the effect on hypothalamo-pituitaiy-gonadal axis, 
may also have a direct effect on these tissues and consequently a direct effect on 
reproductive function.
6.1.1 The endometrium
The human uterus consists of three histologically separate layers,
1. the perimetrium, the outer layer this aids in anchoring the uterus in the abdominal 
cavity
2. the myometrium, the thick middle layer of the uterus, it consists of three layers of 
smooth muscle (shown in figure 6.1)
3. the endometrium, this is the inner layer of the uterus, this layer is vitally important 
for the implantation of the embiyo and is the layer studied in this chapter (shown in 
figure 6.1).
The endometrium can be subdivided into two layers, the stratum functionalis and the 
stratum basalts (Figure 6.1). The stratum functionalis surrounds the entire lumen of the 
uterine cavity and is shed during menstruation. The stratum basalis is in direct contact 
with the myometrium and is a permanent layer; it is this layer that gives rise to the
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stratum functionalis. The stratum functionalis is made up of two types of cells, stromal 
and epithelial cells. During each cycle, the uterus prepares to receive an embryo and 
readies itself to provide nourishment for a foetus. These preparations are reflected in the 
cellular changes taking place at the level of the endometrium. The stratum functionalis 
proliferates during the menstrual cycle, the layers of cells (both stromal and epithelial) 
thicken and after ovulation, deep endometrial glands develop. The stromal and epithelial 
cells of the endometrium have very different functions. The stromal cells are destined to 
become the decidua and then the maternal side of the placenta. The epithelial 
endometrial cells are in two forms: the luminal epithelium, cells that line the surface of 
the endometrium and the glandular epithelium, cells that line the surface of the 
endometrial glands. The epithelial cells are important in the early stages o f implantation, 
as it is these cells that the blastocyst align against and then attach to. If  fertilisation and 
then implantation do not occur, the excess endometrial tissue is shed, this is 
menstruation.
The endometrium is extremely important in implantation. Implantation involves the 
attachment of the blastocyst to the uterine surface. There are two important factors 
necessary for successful implantation, the production of a blastocyst able to implant and 
the development of an endometrial surface that is receptive to the blastocyst.
It is well established that the preparation of the endometrial lining for implantation and 
pregnancy is directly influenced by hormones, specifically the female sex steroid 
hormones, oestrogen and progesterone. It is believed that these hormones act as the 
initiators of a complex molecular pathway, involving cytokines and growth factors, that 
eventually leads to successful implantation. Many of the tissues involved in 
implantation produce and/or respond to cytokines. The human endometrium actively 
secretes and reacts to cytokine stimulation. Cytokines of particular importance are the 
interleukin (IL)-l family, IL-6, tumour necrosis factor-a (TNF-a) and leukaemia 
inhibitory factor (LIF). Implantation is believed to occur at a point in the menstrual 
cycle where the endometrium is optimally receptive to receive an embryo. This is 
known as “the implantation window” (Simon et al., 1996). Cytokines and growth 
factors are thought to have important roles in controlling the receptivity of the 
endometrium for an implanting embryo.
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Figure 6.1 The histology o f  the human endometrium and myometrium. (Taken from 
Tortora, 1997)
130
Several studies have identified the importance of IL-1 in the human endometrium. IL- 
ip mRNA and protein have been detected in the endometrial layer (Simon et al., 1995), 
and IL-1 type I receptor is present throughout the menstrual cycle (Simon et a l,  1993). 
Plasma IL-1 levels increase in the luteal phase of the menstrual cycle (Cannon et al., 
1995), indicating that IL-1 may be under the control of female sex hormones. In vitro 
studies have shown that IL-1 induces IL-6 production in endometrial stromal (Semer et 
al., 1991) and epithelial cell cultures (Laird et al., 1994). TNF-a is present in the human 
endometrium, and studies have suggested that production is greatest during the late 
proliferative phase of the cycle, although a second peak during the mid-secretory phase 
has been described (Laird et al., 1996, Von Wolff et al., 1999). The production o f TNF- 
a , in epithelial endometrial cell cultures, is stimulated by IL-1 in a concentration- 
dependent manner (Laird et al., 1996b). Further to this, the production o f LIF in human 
endometrial cell cultures is controlled in part by IL-1 and TNF-a (Arici et al., 1995, 
Laird et al., 1997).
Leptin is known to interact with cytokines in other tissues. Murine studies have shown 
that leptin stimulates proliferation and TGF-p expression in the glomerular endothelial 
cells of the kidney (Wolf et al., 1999). In studies of a murine adipose cell line, 3T3-L1, 
Granowitz (1997) demonstrated that treatment of the cultures with TGF-p caused an 
increase in ob gene expression. Treatment o f the cultures with IL-ip, IL-6, IL-11 and 
TNF-a caused a decrease in ob gene expression. Luheshi et al., (1999) have 
demonstrated that leptin actions in the brain depend on IL-1. In their studies o f rats, they 
showed that leptin causes the release of IL-1 in the central nervous system (CNS). They 
state that the actions o f leptin on appetite and temperature regulation are controlled by 
two different mechanisms, with only temperature involving cyclooxygenase products.
Leptin has an important role in many female reproductive processes. As cytokines are 
important factors for successful implantation and plasma leptin levels vary throughout 
the menstrual cycle it can be postulated that leptin may also have a role in endometrial 
function and embiyo implantation. This chapter described studies which were carried 
out in order to determine if any leptin receptor isoforms were present in endometrial 
tissue, if leptin had a direct effect on the proliferation of the cells of the endometrium 
and, finally, if leptin brought about any changes in cytokine secretion from these cells.
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6.2 RT-PCR Analysis of three leptin receptor isoforms in human endometrial cells 
in culture.
RT-PCR was used to determine if the various leptin receptor isoforms were expressed in 
endometrial stromal and epithelial cells in primary culture. Endometrial biopsy samples 
were collected and cultured as described in chapter 2. The biopsies were each collected 
from a different woman, all of whom had regular menstrual cycles of 25-35 days in 
length. The biopsies, from which the endometrial cells were cultured, were collected on 
days 7, 14, 19 and 33 of the menstrual cycle. RNA from epithelial and stromal 
endometrial cells in culture was extracted, as described in the materials and methods 
chapter. Specific primers for three leptin receptor isoforms (listed in appendix II) were 
used to identify leptin receptor mRNA expression in the endometrial stromal and 
epithelial cultured cells. A positive control for each isoform of the leptin receptor was 
analysed alongside the stromal and epithelial cells. RNA extracted from human 
embryonic kidney 293 (HEK293) cells, or from normal human liver was used as the 
positive control for the short and variant forms o f the leptin receptor. For the long form 
of the leptin receptor, RNA extracted from normal human liver was used, as the HEK 
293 cells do not express this isoform of the leptin receptor. RT-PCR was carried out 
twice on mRNA extracted from stromal cell cultures and epithelial cell cultures 
prepared from the four different biopsies. Examples of expression in the cells prepared 
from biopsies taken in the early, mid and late phases of the menstrual cycle are shown.
6.2.1 Results o f  RT-PCR studies
Expression of the leptin receptor isoforms is shown in Figure 7.2. Figure 7.2a shows the 
expression of the long form of the leptin receptor. A band corresponding to the long 
form of the leptin receptor can be observed in the positive control of human liver and in 
endometrial epithelial cell cultures taken from biopsies on days 7, 14, and 33. A band 
was also observed, of the size corresponding to the long form of the leptin receptor, in 
the endometrial epithelial cell culture taken from a biopsy on day 19. There was no 
positive RT-PCR result for the long form of the leptin receptor in RNA from any o f the 
endometrial stromal cell cultures taken from biopsies on days 7,14, 19 and 33.
Figure 7.2b shows the expression of the short form of the leptin receptor in RNA 
extracted from endometrial epithelial and stromal cells in culture taken from biopsies on 
days 7, 14, and 33. A band corresponding to the short isoform of the leptin receptor can
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be seen in the positive control of HEK293 cells but, not in the human liver sample. 
Expression of the short form of the leptin receptor in this samples has been observed 
(photograph not shown). Expression of the short form of the leptin receptor was 
observed in both stromal and epithelial cell cultures prepared from biopsies taken on 
days 7, 14, and 33. Expression of the short isoform of the leptin receptor was also 
observed in endometrial stromal and epithelial cell cultures prepared from a biopsy 
taken on day 19 of the menstrual cycle.
Figure 7.2c shows the expression of the variant form of the leptin receptor. This isoform 
has an intermediate length intracellular domain. Expression of the variant form of the 
leptin receptor was been observed in human liver. Both HEK293 cells and human liver 
have been shown to express this form of the leptin receptor (photograph not shown). 
Expression o f the variant form of the leptin receptor was observed in both endometrial 
stromal and epithelial cell cultures prepared from biopsies taken on days 7, 14, and 33. 
Expression of this isoform was also observed in endometrial stromal and epithelial 
cultured cells prepared from a biopsy taken on day 19 of the menstrual cycle.
Each RT-PCR reaction contained the same amount of RNA (4pg); therefore, it is 
possible to comment on the amount of expression in each of the samples. These studies 
have shown that there is a high level of expression in the liver of the long form of the 
leptin receptor. Comparing the three endometrial epithelial cell culture samples, there is 
a higher level o f expression o f the long form of the leptin receptor in the cells cultured 
from the biopsy taken on day 7 of the menstrual cycle, than in those samples taken on 
days 14 and 33. When considering the expression of the short form of the leptin 
receptor in endometrial stromal and epithelial cell cultures, there is very little expression 
of this isoform of the leptin receptor in the epithelial cells compared to the stromal cells. 
The levels of expression appear uniform in the epithelial cells, but the level of 
expression is varied in the stromal cells. Expression of the short form of the leptin 
receptor is higher in the samples taken on days 14 and 33 than on day 7. The variant 
isoform of the leptin receptor is expressed at a consistently high level in all samples of 
stromal cells in culture. Expression of this isoform in the epithelial cells in culture were 
lower compared to the stromal cells, however there was little difference in expression in 
each individual sample, suggesting uniform expression throughout the menstrual cycle.
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Figure 6.2a. The long isoform of the
leptin receptor (Ob-Rb).
Lane Sample
1 DNA Hinf I Marker
2 Human Liver
3 Epithelial cells Day 7
4 Epithelial cells Day 14
5 Epithelial cells Day 33
6 Stromal cells Day 14
7 Negative
Figure 6.2b. The short isoform of the 
leptin receptor (Ob-Ra)._____
1 2  3 4 5 6 7 8 9
Lane Sample
1 DNA Hae III Marker
2 Human liver
3 Epithelial cells Day 7
4 Epithelial cells Day 14
5 Epithelial cells Day 33
6 Stromal cells Day 7
7 Stromal cells Day 14
8 Stromal cells Day 33
9 HEK 293 cells
Figure 6.2c. The variant isoform of the 
leptin receptor.____________
1 2 3 4 5 6 7 8 9 10
Lane Sample
1 Epithelial cells Day 7
2 Epithelial cells Day 14
3 Epithelial cells Day 33
4 HEK293 cells
5 Human Liver
6 Stromal cells Day 7
7 Stromal cells Day 14
8 Stromal cells Day 33
9 Negative
10 DNA Hae III Marker
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Day of Cycle Leptin Receptor Isoform
Short (Ob-Ra) Long (Ob-Rb) Variant
7 ++ +++ ++
14 + + +
19 + + +
33 +/- ++ ++
Table 6.1a Leptin receptor isoform expression in endometrial epithelial cells in culture.
Day o f  Cycle Leptin Receptor Isoform
Short (Ob-Ra) Long (Ob-Rb) Variant
7 +++ - ++
14 I ri - ++
19 1 1 -I - ++
33 ++-I- - ++
Table 6.1b Leptin receptor isoform expression in endometrial stromal cells in culture.
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6.3 Proliferation of endometrial cells in culture in response to leptin
Since leptin receptors were expressed by both stromal and epithelial endometrial cells in 
culture, a tritiated-thymidine uptake assay was utilised to assess if the leptin receptor 
isoforms that were expressed in the endometrium, had a functional role in endometrial 
cell proliferation. This technique assesses DNA synthesis, transport of thymidine across 
the plasma membrane and phosphorylation of the thymidine by thymidine kinase prior 
to use in DNA synthesis (Burke et al., 1995). The endometrial cells in culture (both 
stromal and epithelial) were seeded into 96-well plates, grown to confluency and 
incubated with tritiated thymidine in the absence or presence of various concentrations 
of leptin for 48 hours as described in chapter 2. There are large differences in the counts 
per minute (CPM) in two of the proliferation assays. This is due to a change in specific 
activity of the tritiated thymidine used in those assays. Statistical analyses were 
performed (f test, followed by the appropriate t test) to look at differences between 
control cells and cells stimulated with various concentrations o f leptin. P values are 
expressed as follows: p<0.05 - *, p<0.01 - **, p<0.001 - ***
6.3.1 Results
The results obtained were very varied. In two of three experiments, leptin caused a 
significant increase in tritiated thymidine uptake by endometrial epithelial cells, while 
in the third experiment no significant effect was seen (Figure 6.3). For the endometrial 
stromal cells a significant increase in cell proliferation was also seen in three o f the four 
experiments carried out (Figure 6.4). In all other experiments an increase in cell 
proliferation was also seen however, the effect was no significant. Every care was taken 
in order to keep culturing times the same; however, cells were used when they had 
reached confluence. Occasional cultures took longer to reach confluency.
In order to fully explain the effect of leptin on the expression of leptin receptor isoforms 
and on proliferation of the stromal and epithelial cells in culture, more biopsy samples 
from all stages (days) of the menstrual cycle should be studied.
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Figure 6.3 Proliferation o f endometrial epithelial cells in response to leptin.
The cells were prepared from biopsies taken on days 8 (A), 9 (B), and 25 (C).
(Mean ± SEM). Statistical analyses were performed (f  test, followed by the appropriate t test) 
to look at differences between control cells and cells stimulated with 
various concentrations of leptin.
137
30000
25000 -
20000 -
CL 15000 -
10000 -
5000 -
0.1Control
Leptin added (ng/ml)
45000 -|
40000 -
35000 -
30000 -
25000 -
20000 -
15000 -
10000 -
5000 -
0.1Control
Leptin added (ng/ml)
Figure 6.4a Proliferation o f endometrial stromal cells in response to leptin.
The cells were prepared from biopsies taken on days 8 (A), 9 (B).
(Mean ± SEM). Statistical analyses were performed ( f  test, followed by the appropriate t test) 
to look at differences between control cells and cells stimulated with 
various concentrations of leptin.
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Figure 6.4b Proliferation of endometrial stromal cells in response to leptin.
The cells were prepared from biopsies taken on days 21(C) and 25 (D).
(Mean ± SEM). Statistical analyses were performed (f test, followed by the appropriate t test) 
to look at differences between control cells and cells stimulated with 
various concentrations o f leptin.
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6.4 The effect of leptin on the production of LIF and TNF-a by epithelial
endometrial cells
As incubation of endometrial epithelial cells in culture with leptin caused an increase in 
cell proliferation, studies to investigate the effect of leptin on cytokine production by 
these cells were carried out.
The supernatants from the proliferation assays were collected and stored at -20°C until 
required; these were then utilised to assess the production of the cytokines, LIF and 
TNF-a, by the epithelial cells of the endometrium in response to leptin. TNF-a and LIF 
production were only measured in the supernatants of epithelial endometrial cells as 
TNF-a and LIF are not normally detectable in the supernatants of stromal cells (Laird et 
al., 1996, Laird et al.9 1997). Differences in TNF-a and LIF production by these cells in 
culture were assessed using an f  test, followed by the appropriate t test. P values are 
expressed as follows: p<0.05 - *, p<0.01 - **, p<0.001 - ***
6.4.1 Results
Figure 6.5 shows the effects of leptin on TNF-a production by epithelial endometrial 
cells prepared from four different biopsies. Leptin caused a concentration-dependent 
decrease in TNF-a production, with significant decreases observed over a concentration 
range of 1.0-100 ng/ml of leptin. These cells had a concentration-dependent increase in 
proliferation in response to leptin. This is in contrast to the decrease in TNF-a 
production by the epithelial endometrial cells in culture. From these data, it can be 
concluded that the decrease in TNF-a secretion is a true response and is not affected by 
cell proliferation. More TNF-a was being produced by epithelial cells taken from 
biopsies in the early menstrual cycle on days 8 and 9. A similar decrease of TNF-a in 
response to leptin was observed in the cells taken form each biopsy.
Figure 6.6 shows the effects o f leptin on LIF production by epithelial endometrial cells 
prepared from three different biopsies. In contrast to its effect on TNF-a, leptin had no 
significant effect on LIF production by endometrial epithelial cells.
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Figure 6.5 Production o f  T N F -a by the epithelial cells o f  the endometrial in response to leptin 
(0-100ng/m l) (Mean ±  SEM). Statistical analyses were performed ( f  test, followed by the 
appropriate t test) to look at differences between control cells and cells stimulated with various 
concentrations o f  leptin.
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Figure 6.6 Production o f  LIF by the epithelial cells o f  the endometrium in response to leptin (0- 
lOOng/ml) (Mean ±  SEM). Statistical analyses were performed ( f  test, followed by the 
appropriate t test) to look at differences between control cells and cells stimulated with various 
concentrations o f  leptin.).
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6.5 Conclusion
6.5.1 RT-PCR studies
The results from this study suggest that all three of the leptin receptor isoforms are 
expressed in the endometrium. The pattern of expression varies with the cell type, 
although all forms were expressed by epithelial cells while only the short and variant 
forms were expressed by the stromal cells. The results in vitro suggest that leptin 
receptor expression does vary during the menstrual cycle, although care should be taken 
between extrapolating between the in vitro and in vivo systems. These RT-PCR studies 
were not quantitative; however, as the same amount of RNA was used in each reaction, 
commenting on the response in the menstrual cycle is possible. The presence of the 
various isoforms o f the leptin receptor in both cultured stromal and epithelial cells 
suggests that the leptin receptor is expressed in vivo and therefore, that leptin may have 
a direct functional effect on endometrial function and embryo implantation. Therefore, 
further work was carried out, in order to determine if these receptors were able to 
function in human endometrial cells.
6.5.2 Proliferation o f  endometrial cells in culture
The results from this initial study suggest that leptin may increase the growth of 
epithelial and stromal endometrial cells in culture. However, there was a lot of 
variability in the response seen and only a limited number of experiments were carried 
out. One reason for the variability seen may be that the cells were not cultured to 
complete confluency, although every effort was made to use the cells in the same state. 
It is known that cell density is an important factor affecting cell growth and therefore, 
different states of confluency may effect the cells proliferative response to leptin. This 
would lead to variation in the cell number and therefore to differences in proliferative 
response. If further studies confirm these results it would suggest that leptin may effect 
cellular growth in vivo. The proliferation in response to leptin at various concentrations 
in both stromal and epithelial qgjls in culture indicates that the leptin receptors present 
in these cell types are functioi^d. Assail the endometrial cells in culture are taken from 
different women, there may be some variation in leptin receptor function. 
Polymorphisms in the leptin receptor gene have been shown to affect ligand binding 
(Chapter 6), it is possible these genetic changes would effect cell proliferation in these 
studies. These results can be tentatively associated with expression of leptin receptor 
isoforms in the stromal and epithelial cells in culture. At the time when the epithelial
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cells in culture express the long form of the leptin receptor (day 7), there was a 
significant increase in cell proliferation (day 9). When expression of the long form of 
the leptin receptor was reduced (day 14 and 19) there was a small increase in cell 
proliferation (day 25) in epithelial endometrial cells. This pattern is also seen with the 
short and variant forms of the leptin receptor in epithelial endometrial cells in culture. 
As the stromal endometrial cells do not express the long form of the leptin receptor, 
changes in cell proliferation were due to the short and variant isoforms. An increase in 
cell proliferation was observed early in the menstrual cycle (day 8 and 9), this is when 
the expression of the short isoform is low and variant isoform is high. Later in the cycle 
(day 21 and 25) when expression of the short form of the receptor increases, there is no 
increase in cell proliferation. In this situation, it can be postulated that this isoform is 
acting as a dominant negative element, with leptin binding to both the short and the 
variant forms, thus preventing cell proliferation.
6.5.3 The effect o f  leptin on the production o f  TNF-a and LIF by epithelial endometrial 
cells
Leptin caused a significant decrease in the production of TNF-a by epithelial 
endometrial cells. In these studies, epithelial cell TNF-a secretion decreases, in a 
concentration-dependent manner, in response to leptin. As leptin causes epithelial 
endometrial cells to proliferate and TNF-a secretion to decrease, it can be concluded 
that there must be a direct effect on TNF-a secretion, as a decrease in secretion would 
not reflect an increase in cell number. Laird et al. (1996) and Von Wolff et al. (1999) 
describes the production of TNF-a in epithelial endometrial cells throughout the 
menstrual cycle. TNF-a levels are maximal in the late proliferative phase, just prior to 
the LH surge and then decrease again in the secretory phase. This is in agreement with 
levels of TNF-a in serum (Brannstrom et al., 1999). This decrease in TNF-a in the 
endometrium during the secretory phase, when serum leptin levels are high, together 
with the results of this study suggest that leptin reduces the amount of TNF-a locally in 
the endometrium. It is possible that leptin may be an important factor in reducing TNF- 
a  by the endometrium in the late secretory phase, thus aiding implantation. At present, 
it is not known if leptin is expressed by human uterine tissues. Bovine studies have 
shown, by RT-PCR, the expression of leptin by uterine tissues during pregnancy 
(Takahashi et al., 1998). RT-PCR for leptin transcripts in the endometrium or the
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measurement of leptin levels in uterine flushings may allow consolidation of the 
hypothesis that leptin has a role, perhaps only indirectly, in implantation.
LIF production by epithelial endometrial cells was not affected by the addition of leptin 
to the growing cells in culture. This suggests that the effect of leptin on cytokine 
modulation in the epithelial cells o f the endometrium may be specific for TNF-a.
The effect of leptin on the proliferation of endometrial stromal and epithelial cells and 
the decrease in TNF-a production by endometrial epithelial cells in response to leptin, 
suggests that functional leptin receptor isoforms are present in the endometrium.
As the long signalling form of the leptin receptor was present in the epithelial 
endometrial cells, proliferation of these cells in response to leptin may be controlled by 
this isoform of the receptor. The stromal endometrial cells did not express the long form 
of the leptin receptor but still proliferated in response to leptin. It is possible that in 
these tissues another form of the leptin receptor, either the short or variant form, can 
signal via the Jak/STAT pathway or by some other signalling pathway. Other workers 
have suggested that the short form of the leptin receptor can cause signalling to be 
induced. Murakami et al., (1997) provide evidence of the short form of the leptin 
receptor initiating production of the early genes c-fos, c-jun and jun-B. Yamashita et al, 
(1998) detected phosphorylation of the MAP kinase pathway in cells transfected with 
the short form of the leptin receptor. Therefore, it is possible that in the endometrium, 
leptin may initiate signalling through the short or variant forms o f the leptin receptor, 
via a pathway other than Jak/STAT.
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Chapter 7
Investigation of three single nucleotide polymorphisms in the
leptin receptor
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7.1 Introduction
Single nucleotide polymorphisms (SNP) are the most common genetic variants, with 
one occurring every 100-300 kb. The National Human Genome Research Institute 
(NHGRI) in the United States has recently reported its intensive effort to identify 50 
000 new SNPs within three years. It is hoped that this will accelerate the identification 
of disease associated genetic changes. SNPs can be used to associate sequence variation 
with observed phenotypes and to investigate the functional aspects of the variation. 
Populations analysis or case-control groups can be used to identify associations between 
sequence variation and phenotype. This approach is far simpler than pedigree analysis 
as family data from successive generations is not required.
7.1.1 Linkage Disequilibrium
Linkage disequilibrium occurs when a combination of alleles of a set of genetic markers 
(a haplotype), occurs significantly more or less frequently in a population than would be 
expected. This information suggests that as the alleles have been inherited together, 
there has been less opportunity for recombination events to occur at meiosis and 
therefore, the physical distance between the alleles is small. In this case, the common 
allele of one polymorphism is inherited in combination with the common allele of the 
another polymorphism. Theoretically, a specific genotype within a population may be 
consistently associated with a phenotypic difference. As linkage disequilibrium exists, a 
haplotype of markers may also be associated with the phenotypic change. It is possible 
that polymorphisms within the leptin receptor gene are associated with phenotypic 
differences in body weight. One or more of these genetic changes may have a direct 
functional effect on phenotype or reflect linkage disequilibrium with another 
polymorphism nearby, possible in another gene.
7.1.2 Genetic studies o f  leptin receptor polymorphisms in a cohort o f  postmenopausal 
women
Inter-individual differences in BMI are highly heritable (Austin et al., 1997, Rice et al., 
1999) and a proportion of this heritability may reflect genetic variations in the leptin 
and leptin receptor genes.
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Several single nucleotide polymorphisms (SNPs) have been described in the human 
leptin receptor gene (Considine et al., 1996, Matsouka et al., 1997). Three 
polymorphisms, in the extracellular domain of the leptin receptor gene, GLN223ARG, 
LYS656ASN and LYS204ARG, have been studied in this chapter. These three SNPs 
each result in an amino acid change in the coding region and, therefore, may have an 
effect on ligand binding or receptor dimerisation. The SNP, GLN223ARG, is associated 
with circulating leptin levels but not with body mass index (BMI) in non-diabetic Pima 
Indians (Thompson et al., 1997). Homozygosity for the G allele, o f this SNP, is 
associated with lower plasma leptin levels after correction for obesity and sex. 
LYS656ASN has been reported to be associated with lower BMI in a population of lean 
males (Gotoda et al., 1997) and with waist circumference in young obese females 
(Wauters et al., 1999). Similar associations may be observed in other populations. To 
investigate this, an allelic association study on a population of postmenopausal women 
from the Sheffield area was undertaken.
There are profound differences in the leptin system between males and females. Leptin 
has an important, though not fully understood, role in reproduction. Circulating leptin 
levels are higher in females than in males, even when corrected for differences in BMI 
(Hickey et al., 1996) and vary significantly with the menstrual cycle (as discussed in 
Chapter 5 and reported by Hardie et al., 1997). This may represent an important 
confounding factor in leptin studies and, as such, postmenopausal women were used in 
these investigations in order to minimise hormonal effects. GLN223ARG and 
LYS656ASN genotypes were determined with BMI, fat mass and serum leptin levels 
measured in order to investigate whether the functional correlations reported are also 
observed in female Northern European Caucasians.
Significant genetic associations with a particular SNP may indicate a direct effect on 
protein function, or simply reflect linkage disequilibrium with other polymorphisms 
within the same gene or nearby. In order to determine whether there is a measurable 
functional difference in ligand-binding capacity of the leptin receptor associated with 
the SNPs studied here, serum leptin-binding activity (LBA) was also measured. An 
amino acid change in the extracellular region of the leptin receptor may change the 
functional characteristics of the receptor. A soluble form of the leptin receptor exists in 
serum: serum leptin binding activity has been described in both humans and rodents, at 
least a proportion of this binding is attributable to the soluble extracellular domain of
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the leptin receptor. Modulation of leptin activity by a soluble form of the receptor is 
consistent with observations in other cytokine systems, including IL-1, TNF- and 
growth hormone. Since all the receptor isoforms share the same extracellular domain, a 
difference in serum leptin-binding activity (LBA), associated with a particular allele, 
may indicate that other forms o f the leptin receptor also have altered ligand-binding 
capacity or that it may affect receptor dimerisation or the affect the production of 
soluble receptor by the cell.
7.1.3 Aims o f  the study
Three leptin receptor polymorphisms were studied, LYS204ARG, GLN223ARG and 
LYS656ASN. All o f these variations result in a change in an amino acid and therefore, 
may potentially cause variation in leptin binding to the extracellular domain of the 
receptor or in the signal transmitted on ligand binding. The aims of these studies were 
to:
• Genotype female postmenopausal subjects for the three SNPs present in the 
extracellular domain of the leptin receptor.
• To seek associations between these polymorphisms and BMI, fat mass and leptin 
levels.
• To investigate the effect of the amino acid changes on ligand-binding using the LBA 
assay.
• To determine the extent of linkage disequilibrium between these polymorphisms in 
the leptin receptor gene.
7.2 Study Design
Blood samples were collected from a community-based cohort of Caucasian 
postmenopausal women, from the Sheffield area (by Professor R Eastell from the 
Northern General Hospital, as part of an osteoporosis epidemiology study). Blood for 
genotyping studies (n = 225) was spotted onto standard neonatal blood cards and dried 
overnight before storage at room temperature. The mean age was 67.7 ± 4.6 years 
(mean ± SEM) (n = 220) and the mean BMI of the women was 26.9 ± 1.8 kg/m2 (mean 
± SEM) (n = 220). Clinical details were recorded at the time of sample collection. All 
subjects gave informed consent and the studies had the approval of the North Sheffield 
Local Research Ethics Committee local ethical committee. The women included in the 
study of leptin levels and LBA (n = 84) were selected as they were not currently
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prescribed hormone replacement therapy (HRT) or corticosteroids, neither were any of 
them diabetic. Serum leptin levels were measured by Allison Lee (at the University of 
Sheffield) using the Linco Research Co. RIA kit. Serum LBA was measured in subjects 
where sufficient serum was available for the purpose.
Genotyping was carried out as described in Chapter 2. The visualisation of the alleles 
for GLN223ARG is shown in Figure 7.1a, for LYS204ARG in Figure 7.1b and for 
LYS656ASN in Figure 7.1c.
150
GG AG AA
B
GG AG
Figure 7.1 Visualisation o f the different genotypes o f GLN223ARG (A) and 
LYS204ARG (B) single nucleotide polymorphisms o f the leptin receptor.
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Figure 7.1 Visualisation o f the genotypes o f LYS656ASN (C ) by SSCP.
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7.3 Results
7.3.1 GLN223ARG
In order to determine allele and genotype frequencies, 223 subjects have been 
genotyped for the GLN223ARG SNP. The calculated allele frequencies correspond well 
with published work (Table 7.1). The balance of homozygotes and heterozygotes 
observed was as predicted by the Hardy-Weinberg equation from these allele 
frequencies (Table 7.2).
Data on BMI was available for 220 subjects. Homozygotes for the G allele had a lower 
mean BMI (25.4 kg/m2 ± 4.5) (Mean ± SEM) than A homozygotes (27.2 kg/m2 ± 3.1) 
and heterozygotes (27.2 kg/m ± 2.6) (Figure 7.2). Levels of fat and lean mass were 
assessed in a number of subjects (n = 89) where data was available. Homozygotes for 
the G allele had a significantly lower fat mass (2202lg  ± 5505) compared to the other 
genotypes (A homozygotes (26393g ±4816) and heterozygotes (28895g ± 4405) (p = 
0.006)) (Figure 7.3a). Levels of lean mass in those homozygous for the G allele (36186g 
± 9047) did not differ when compared to the other genotypes (A homozygotes 35990g ± 
6568) and heterozygotes (36613 ± 5581) (p = NS) (Figure 7.3b).
Serum leptin levels were measured in a subset o f this cohort (n = 84). As expected, 
these correlated with BMI (n = 84, r = 0.687, p <0.001) (Figure 7.4) and with fat mass 
(n = 81, r = 0.719, p = 0.0001) (Figure 7.5). Homozygotes for the G allele had lower 
mean circulating leptin levels (12.6 ng/ml ± 3.2) than A homozygotes (18.3 ng/ml ± 3.6) 
and heterozygotes (23.8 ng/ml ± 3.6) (Figure 7.6)
In order to clarify whether the observed associations between the polymorphism 
GLN223ARG and BMI and leptin levels could be the result of a direct functional effect 
on the leptin receptor binding parameters, serum LBA was measured in a number of 
subjects in our cohort (n = 60), where sufficient serum was available. Serum LBA was 
significantly higher in individuals homozygous for the G allele (11.6% ±3.1) compared 
to those homozygous for the A allele (10.5% ± 2.3) and the heterozygotes (9.7% ± 1.9) 
(p = 0.04) (Figure 7.7). A negative correlation was observed between BMI and LBA (n 
= 58, r = -0.253, p <0.05) (Figure 7.8), although no significant correlation was observed 
between LBA and serum leptin levels (Figure 7.9). This data is summarised in table 7.3.
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Genotype P value
AA AG GG
BMI (kg/m2)
n = 220
27.2 ±3.1 27.2 ±2.6 25.4 ±4.5 0.001
Fat mass (g)
n =  89
26393 ±4816 28895 ±4405 22021 ± 5505 0.006
Lean mass (g)
n =  89
35990 ±6568 36613 ±5581 36186 ±9047 NS
Serum leptin 
concentration 
(ng/ml)
n =  84
18.3 ±3.6 23.8 ±3.6 12.6 ±3.2 0.0001
Serum LBA
(%)
n== 60
10.5 ±2.3 9.7 ±1.9 11.6 ± 3.1 0.04
Table 7.3 Mean levels of BMI, fat and lean mass, leptin and serum LBA for each 
genotype of GLN223ARG. P value is calculated by comparing those homozygous for 
the G allele with the other genotypes using the appropriate t test.
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Figure 7.2 BMI and GLN223ARG genotype in the whole population group: mean BMI
is significantly lower in those homozygous for the G allele compared to heterozygotes
and those homozygous for the A allele.
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Figure 7.3 Fat mass (A) and GLN223ARG genotype: mean BMI is significantly lower 
in those homozygous for the G allele compared to heterozygotes and those homozygous 
for the A allele. Lean mass (B) and GLN223ARG genotype: no significant difference 
was observed.
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Figure 7.4 Correlation of serum leptin levels with BMI in this cohort (r -  0.687, p -  
0 .001)
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Figure 7.5 Serum leptin concentration correlates with fat mass in this cohort (r = 0.719,
p = 0.0001)
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Figure 7.6 Serum leptin levels and GLN223ARG genotype: mean serum leptin levels
are lower in those homozygous for the G allele compared to heterozygotes and those
homozygous for the A allele (p = 0.0001).
160
p = 0.04
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Figure 7.7 Serum leptin-binding activity and GLN223ARG genotype: mean LBA levels
are higher in those homozygous for the G allele compared to heterozygotes and those
homozygous for the A allele.
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Figure 7.8 Correlation of serum leptin-binding activity with BMI (r = -0.253, p = 0.05, 
n = 58).
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Figure 7.9 No significant correlation between serum leptin levels and LBA was 
observed.
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7.3.2 LYS656ASN
In order to determine allele and genotype frequencies for this SNP, 152 subjects were 
genotyped. The calculated allele frequencies (G allele 0.69 and C allele 0.31) are shown 
in Table 7.4 with other published allele frequencies. The balance of homozygotes and 
heterozygotes was as predicted by the Hardy-Weinberg equation from these allele 
frequencies (Table 7.5).
Data on BMI was available for 137 subjects. Mean BMI for those homozygous for the C 
allele was 26.6 kg/m2 ± 6.8 (Mean ± SEM), this did not differ significantly from the 
heterozygotes (27.1 kg/m ± 3.7) or those homozygous for the G allele (27.7 kg/m ± 
3.4) (Figure 7.10). Fat and lean masses were also assessed in 76 subjects. Mean levels 
of fat mass for those homozygous for the C allele (2476lg  ± 9523) were not 
significantly different from the other genotypes (heterozygotes 27626g ± 5116, those 
homozygous for G allele 25302g ± 4081) (Figure 7.11a). Similarly, the mean lean mass 
in those homozygous for the C allele (36589g ± 14073) did not differ significantly from 
the other genotypes (heterozygotes, 35775g ± 6225 and G allele homozygotes, 36246g 
± 5846) (Figure 7.11b). Serum leptin levels were measured in 72 subjects. Mean levels 
of leptin for those homozygous for the C allele (15.3 ng/ml ± 5.9) (Mean ± SEM) did 
not differ significantly from the heterozygotes (22.3 ng/ml ± 4.3) and those homozygous 
for the G allele (18.0 ng/ml ± 2.9) (Figure 7.12).
Serum levels of LBA were measured in a subset o f the population (n = 57). As there 
were no observed associations between this SNP and BMI and leptin levels, a 
significant difference in the level of serum LBA was not expected. Mean levels of LBA 
for those homozygous for the C allele (9.9% ± 5.0) (Mean ± SEM) did not differ from 
the heterozygotes (10.4% ± 2.2) or those homozygous for the G allele (10.6% ± 1.9) 
(Figure 7.13). This data is summarised in table 7.6.
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Genotype P value
GG GC CC
BMI (kg/m2) 
n =  137
27.7 ± 3.4 27.1 ±3.7 26.6 ± 6.8 NS
Fat mass (g)
n = 76
25302 ±4081 27626 ±5116 24761 ±9523 NS
Lean mass (g) 
n = 76
36246 ± 5846 35775 ± 6225 36589 ± 14703 NS
Serum leptin 
concentration 
(ng/ml)
n = 72
18.0 ±2.9 22.3 ±4.3 15.3 ±5.9 NS
Serum LBA
(%)n =  57
10.6 ±1.9 10.4 ±2.2 9.9 ± 5.0 NS
Table 7.6 Mean levels of BMI, fat and lean mass, leptin and serum LBA for each 
genotype of LYS656ASN. P value is calculated by comparing those homozygous for 
the G allele with the other genotypes using the appropriate t test.
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Figure 7.10 BMI and LYS656ASN genotype: there is no significant difference in BMI 
between the genotypes.
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Figure 7.11 Levels o f fat mass (A), lean mass (B) and LYS656ASN genotype: there 
no significant difference between the genotypes.
T
n = 27 n = 38
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Figure 7.12 Serum leptin levels and LYS656ASN genotype: there is no significant 
difference between the genotypes.
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Figure 7.13 Serum LBA and LYS656ASN genotype: there is no significant difference 
in LBA between the genotypes.
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7.3.3 LYS204ARG
This SNP at codon 204 is very close to the polymorphism GLN223ARG. Other workers 
report that one allele of this SNP is extremely rare (Echwald et al., 1997), this is in 
agreement with the findings in this population of postmenopausal women. After 
genotyping 60 subjects, only 1 subject was heterozygous for this polymorphism. As 
variation with this polymorphism was so rare, it would be uninformative when assessing 
variation in BMI, serum leptin levels or serum LBA and genotype in a cohort of this 
size, therefore, the genotyping was discontinued.
7.4 Hanlotvning studies of GLN223ARG and LYS656ASN
Previous studies have reported that polymorphisms in the leptin receptor are in linkage 
disequilibrium (Thompson et al., 1997, Gotoda et al 1997). The possibility o f the SNPs 
GLN223ARG and LYS656ASN, studied in this chapter, being in linkage disequilibrium 
in this population was investigated. Analysis was carried out on 175 subjects. Phase was 
assigned to all the subjects who were not heterozygous for both of the SNPs (n = 133). 
A %2 test, to assess if carriage of the A allele of GLN223ARG was associated with 
carriage o f the G allele o f LYS656ASN, was performed.
GLN223ARG
Carriage of A allele No carriage of A allele
LYS656ASN Carriage of G allele 127 71
No carriage of G allele 41 27
Table 7.7 x2 contingency table to investigate the carriage of the common alleles of 
GLN223ARG and LYS656ASN.
%2 = 0.32 
p = NS
The x2 analysis showed that the A allele of GLN223ARG and the G allele of 
LYS656ASN were carried independently of each other. These SNPs do not appear to be 
in linkage disequilibrium in this study.
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Further analysis was carried out in order to look at the possible associations between the 
leptin receptor haplotype and measures of body mass, leptin and LBA. ANOVA with 
Bonferroni correction was used to observe any differences between each o f the 
haplotypes and the heterozygotes. Significant associations between the leptin receptor 
haplotype and BMI (Figure 7.13), fat mass (Figure 7.14), lean mass (Figure 7.15), 
serum leptin levels (Figure 7.16) and LBA (Figure 7.17) were not observed.
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Figure 7.13 Leptin receptor haplotypes and BMI: no significant difference was 
observed (GLN223ARG allele shown in bold, LYS656ASN allele shown in Italics).
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Figure 7.14 Leptin receptor haplotypes and fat mass: no significant associations were 
observed (GLN223ARG allele shown in bold, LYS656ASN allele shown in Italics).
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Figure 7.15 Leptin receptor haplotypes and lean mass: no significant associations were 
observed (GLN223ARG allele shown in bold, LYS656ASN allele shown in Italics).
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Figure 7.16 Leptin receptor haplotypes and serum leptin concentrations: no significant 
associations were observed (GLN223ARG allele shown in bold, LYS656ASN allele 
shown in Italics).
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Figure 7.17 Leptin receptor haplotypes and LBA: no significant associations were 
observed (GLN223ARG allele shown in bold, LYS656ASN allele shown in Italics).
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7.5 Conclusion
This data indicates that homozygosity of the G allele of the GLN223ARG 
polymorphism in the leptin receptor is associated with differences in BMI, fat mass and 
serum leptin levels in the Caucasian population. Homozygosity for the G allele is 
associated with serum leptin levels and associations between homozygosity for the G 
allele, BMI, fat mass and serum leptin-binding activity have been demonstrated, at least 
in postmenopausal women. There was no demonstrable difference in levels o f lean 
mass. This data also shows the absence of associations between the LYS656ASN 
polymorphism and BMI, fat mass and serum leptin levels or serum LBA. This may be 
due to the small numbers of subjects who were homozygous for the C allele. 
Investigations of the SNP LYS204ARG demonstrated, as previously described that this 
polymorphism is extremely rare and as such is unlikely to have a role in the variation of 
BMI or serum leptin levels. These studies lend weight to the hypothesis that SNPs in or 
around the leptin receptor gene are important genetic factors in regulation of BMI and 
fat mass and agrees with the work of Thompson et al. (1997) who reported an 
association between GLN223ARG genotype and BMI in a population of Pima Indians.
Other workers have reported lack of association of the SNP GLN223ARG with 
indicators o f obesity. A recent abstract by Wauters et al. (1999) describes investigation 
of GLN223ARG and other polymorphisms in obese female subjects aged 18-45 and 45- 
60 years. They did not find any associations between the GLN223ARG polymorphism 
and leptin level or BMI in either of their two cohorts. Other polymorphisms in the 
receptor, however, appeared to be associated with hip circumference (LYS109ARG) 
and waist measurements (LYS656ASN) in premenopausal, but not postmenopausal 
women. In two studies of obese males, however, associations between polymorphisms 
in the leptin receptor and BMI and leptin levels were also not detected. Echwald, et 
<z/.(1997) investigated leptin receptor polymorphisms in males with juvenile onset 
obesity (BMI > 31 Kg/m2) (n=156). They found no association between GLN223ARG 
or other markers and BMI at any age, and no significant difference in allele frequency 
between their control group and those with juvenile onset obesity. In another study of a 
British male population the frequency of the variant allele and the distribution of the 
different genotypes for GLN223ARG were not significantly different between the obese 
(n = 190) and control (n = 132) groups. The major difference in this study and the others
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in the literature is the fact that all the other studies have reported changes in obese 
populations. In contrast, a population of normal postmenopausal Caucasian women has 
been studied. Since homozygosity of the G allele of the GLN223ARG SNP is 
associated with lower BMI and lower fat mass, rather than with indicators o f obesity, it 
may simply have not been evident in the cohorts examined. In addition, it is possible 
that the association that we have demonstrated in GLN223ARG, between homozygosity 
of the G allele and leptin levels, fat mass and BMI, are found only in postmenopausal 
women: other studies have used premenopausal and perimenopausal women. A recent 
study has confirmed the associations reported here. Chagnon et al. (2000) have reported 
similar findings of associations between body mass index and fat mass and the SNP 
GLN223ARG in their cohort o f middle-aged men.
Serum leptin-binding activity was measured to determine whether the SNPs in the leptin 
receptor were associated with changes in the ligand binding. Thompson et al.{\991) 
reported that GLN223ARG is in linkage disequilibrium with three other leptin receptor 
polymorphisms. Gotoda et al., (1997) also report alleles of GLN223ARG to be in 
linkage disequilibrium with other leptin receptor SNPs at codons; 109, 343, 656 and 
1019. In this cohort, higher serum LBA levels were observed in subjects homozygous 
for the G allele than for those homozygous for the A allele and heterozygotes for 
GLN223ARG. No significant difference in serum LBA was observed in any genotypes 
of the SNP LYS656ASN, although the numbers of those who were homozygous for the 
C allele of this SNP was small. The possibility that other SNPs within the leptin 
receptor may affect this data cannot be excluded. This data may indicate a difference in 
the levels of receptor expression or changed ligand-binding capacity o f the leptin 
receptor. The leptin receptor has two cytokine binding domains (C domain). These C 
domains represent putative binding domains for leptin to bind to its receptor. A 
mutation that occurs in the Zucker rat is located in the first C domain o f the leptin 
receptor and this affects the functionality of the receptor (White et al., 1997). The SNP, 
GLN223ARG, is also located within the first C domain (Chagnon et al., 2000). It can be 
hypothesised that this polymorphism, which creates an amino acid change, may result in 
altered binding and therefore, change the signalling capacity o f the leptin receptor.
Haplotyping studies were performed on a subset of subjects where the phase of the 
alleles could be assigned. Those who were heterozygous for both the GLN223ARG and 
LYS656ASN SNPs were excluded, as phase cannot be assigned. This data suggested
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that GLN223ARG and LYS656ASN were not in linkage disequilibrium. Other workers 
have shown these polymorphisms to be in linkage disequilibrium, this was 
demonstrated using haplotypes from at least four polymorphisms. There may be a 
number of reasons as to why these polymorphisms are not observed to be in linkage 
disequilibrium. The cohort may not be large enough to see the association. Secondly, as 
the genotyping method used was SSCP, there may be some amount of error. SSCP 
relies upon the visualisation o f the conformation made by single stranded DNA. 
Although every care was taken when assessing the genotypes; the genotyping was 
confirmed by sequence analysis and the numbers of genotypes did not differ from 
Hardy-Weinberg equilibrium at the given allele frequencies, it is possible that some 
genotypes were incorrectly assigned. This is further suggested by the difference in allele 
frequencies reported in this study and the others in the literature. In future studies, other 
methods of genotyping subjects for LYS656SASN, such as mismatch primer generation 
of an artificial restriction enzyme site, will be used to compare the genotyping 
performed in these studies. Association studies performed on the leptin receptor 
haplotypes did not reveal any significant difference in BMI, fat mass, lean mass, serum 
leptin level or serum LBA. The associations observed in these studies are only seen in 
the GLN223ARG SNP. It is possible that similar associations may be observed in other 
SNP in the leptin receptor gene or may reflect another polymorphism in an alternative 
gene nearby.
These studies indicate that the polymorphic variations in the leptin receptor gene are 
associated with variation in ligand binding and, as such, inter-individual differences in 
leptin levels and BMI may reflect altered functional parameters of the leptin receptor, as 
serum LBA may reflect the binding parameters o f cell surface receptors as well. It is, 
therefore, possible that variant forms of the leptin receptor will become targets for new 
tailored, therapeutic interventions in the regulation of BMI, reproduction and other 
systems affected by leptin.
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8.1 Discussion
The present studies were performed in order to increase the body of knowledge concerning 
the role of leptin and the leptin receptor. The studies were in two parts; firstly to study leptin 
and LBA in human reproductive function, specifically in puberty, normal female 
reproductive function and the endometrium, and, secondly, to study the effect of leptin 
receptor polymorphisms on body mass regulation.
Leptin is a peripheral signal produced by the adipose tissue to inform the brain of the state 
of the body’s adiposity. In humans, the amount of leptin present is correlated with BMI and 
adiposity (Hickey et al., 1996); leptin production is determined by the adipose tissue, both in 
the numbers of adipocytes present and their ability to express leptin (Jequier and Tappy, 
1999). The signalling form of the leptin receptor is present in the hypothalamus, the body’s 
homeostatic centre, where food intake and body mass regulation are controlled. A decrease 
in body fat leads to a decrease in serum leptin concentration and this in turn, stimulates an 
increase in food intake (Friedman, 2000). In addition to regulation of BMI, leptin has a well- 
recognised role in human and animal reproduction, although the exact mechanisms of either 
system are not fully understood. On administration of recombinant leptin, both male and 
female ob/ob mice have their fertility restored (Chehab et al., 1996). Again in ob/ob mice, 
administration of leptin causes successful progression into puberty (Ahima et al., 1997). As 
well as these biological effects, leptin appears to be important in regulating sexual behaviour 
in hamsters. Wade et al. (1997) report that leptin administration to ad libertum fed female 
hamsters facilitated sexual behaviour, but decreased this behaviour in starved animals. The 
leptin system is also important in reproductive function in humans. The hypothesis that 
Frisch put forward in the 1970s, that a “pre-set” level of fat mass is required for female 
puberty to begin and ovulation and menstruation to persist is now well accepted and is 
rationally explained by the leptin system. Several studies have shown a link between serum 
leptin levels and pubertal development in both males and females. The leptin system is 
known to be important in the regulation of body mass. Leptin levels correlate well with BMI 
and also with adiposity.
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Many cytokines and hormones are bound to proteins in serum. These proteins can be 
specific binding proteins or the extracellular domain of the appropriate receptor. Two 
methods are known to exist for the creation of soluble receptors, either the extracellular 
domain can be cleaved off of the cell surface by proteolysis or it may occur by expression of 
an alternatively spliced form of the receptor by cells. It is known that leptin is bound to 
proteins in serum, with a portion of this protein attributable to the soluble leptin receptor 
(Diamond et al., 1997, Houseknecht et al., 1996). At the time of writing, the mechanism by 
which the soluble leptin receptor is created is not known. Using the method of Amit et al., 
(1990) for the measurement of GH-BP, an assay to measure leptin binding activity in serum 
was developed. Experiments to assess the appropriate conditions for sample preparation and 
for the assay themselves were performed. The most appropriate conditions were used 
subsequently for the measurement of samples for LBA. The samples required the 
endogenous leptin to be removed prior to the assay being performed, to prevent interference 
from the serum leptin in the assay. This was achieved using a dextran-coated charcoal slurry 
followed by separation by centrifugation. The assay was specific for only leptin and the 
system was tested for specificity with growth hormone (as it has a similar structure to leptin) 
and IL-6 (as the leptin receptor is similar to the IL-6 family of receptors). Scatchard analysis 
revealed a high affinity (1.0 -  1.4 x 10*9 M'1) binding protein which would be compatible 
with the expected affinity of the soluble receptor (Liu et al., 1997). This assay measures the 
activity at which leptin binds to proteins in serum. These proteins, of as yet unknown origin, 
bind leptin specifically and with high affinity: a proportion of this binding can be attributed 
to the soluble form of the leptin receptor, although it is possible that novel binding proteins 
exist for leptin. This assay does not measure low-affinity binding protein interactions, such 
as that which may exist with a-2-macroglobulin. This assay represents an important tool to 
investigate the action of leptin in serum.
This assay was employed in measuring serum LBA in subjects, both male and female, at
different ages. Emphasis was placed on the measurement of LBA in children at various
stages of puberty, as it is believed leptin may fie a permissive signal to the initiation of
puberty (Mantzoros et al., 1997, Clayton et al, 1997). These studies showed that serum
LBA was low at birth, high in early childhood, fell ffuring puberty and remained at the post
pubertal level throughout adult life. Serum LBA was negatively correlated with age,
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pubertal stage, weight and BMI. In females it is known that leptin levels increase throughout 
puberty, in response to increasing fat mass (Clayton et al., 1997). In boys, leptin appears to 
increase until Tanner stage 2 of puberty when the testosterone surge occurs, leptin then 
decreases to the low adult levels seen (Clayton et al., 1997). These levels correspond with 
adiposity and BMI. This finding, of the direct inverse relationship between LBA and 
pubertal status or age, with a fall in LBA seen at the earliest stages of puberty, suggests that 
this may be a link from leptin to the initiation and maintenance of puberty. A decrease in 
LBA could be explained by a change in leptin receptor expression, which may be the link 
between the leptin system and puberty. There is still some controversy as to whether leptin 
merely reflects the pubertal state at any given time or whether it is necessary for the 
initiation and maintenance of puberty. At a recent meeting, Farooqi et al., (2000) suggested 
that leptin is a requirement for pubertal development. They report data from an extremely 
obese female child who has a congenital leptin deficiency. At present the child is receiving 
treatment in the form of recombinant human leptin and is responding well with weight loss 
and the amelioration of her hyperphagia. It was not clear if this mutation would result in 
hypogonadism observed with other mutations in the leptin and leptin receptor genes as the 
children were not of pubertal age. After a normal peripubertal response the child's pubertal 
development ceased and there was a return to the hyperphagic state seen previously. This 
was reversed when the dose of leptin being received was increased, indicating that a certain 
level of leptin is a requirement for the onset and maintenance puberty. The change in LBA 
during puberty, described in this study, may be the mechanism by which a greater level of 
leptin is made biologically available to initiate full reproductive function.
As leptin and LBA appear to be important factors in the regulation and initiation of puberty,
and leptin has a known role in female reproduction, studies of the leptin system in normal
fertile women were undertaken. Serum leptin levels were found to increase in the luteal
phase of the menstrual cycle in two cohorts of normal, regularly cycling women. This
information is of importance in two ways; firstly menstrual date must now be controlled for
in studies of leptin in female subjects as this may affect study results and secondly, this adds
to the known role of leptin in reproduction. Leptin may have a direct and local role in the
reproductive process, as well as being a neural signal of bodily adiposity to support a
pregnancy to term. In the small study undertaken, serum LBA was not found to vary at any
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point in the menstrual cycle. Some other soluble receptors and binding-proteins for related 
cytokines and hormones do not fluctuate in the menstrual cycle. There is still controversy as 
to whether soluble IL-6 receptors and IGF-BPs fluctuate during the menstrual cycle. 
Perhaps, a larger study, with more subjects and more samples per subject will help to 
elucidate whether LBA varies in the menstrual cycle of normal women.
To complement the studies of the menstrual cycle, studies of the local effect of leptin on the 
human endometrium were performed. Cytokines have an important role in preparing the 
endometrium for implantation and subsequent pregnancy (Simon et al., 1995). The 
receptivity of the endometrium, after ovulation, is orchestrated by cytokines being up and 
down regulated. The first step in identifying a local role for leptin within the human 
endometrium was the identification of leptin receptor iso form expression. RT-PCR studies 
showed that three isoforms of the leptin receptor were present in endometrial cells in 
culture. Both the short and variant isoforms of the leptin receptor were identified in 
endometrial epithelial and stromal cells in culture; the long isoform was only detected in the 
epithelial endometrial cells. To test if these receptors were functioning in human endometrial 
cells in culture, proliferation assays were performed. In our preliminary study, both stromal 
and epithelial endometrial cells in culture proliferated in response to leptin. This suggests 
that another isoform in addition to the long form is capable of signalling. Other workers 
have suggested that the short isoform is able to signal via the mitogen-activated protein 
kinase (MAPK) pathway (Yamashita et al.} 1998) and is able to induce the early gene c-fos 
and c-jun (Murakami et al., 1997). As the receptors in the human endometrium appear to be 
functional, causing an increase in endometrial cell proliferation in response to leptin, it is 
possible that leptin, as a marker of the cytokine network, also induces effects on cytokine 
production in the endometrium. Leptin caused a concentration-dependent decrease in TNF- 
a  production in the supernatants of epithelial endometrial cells in culture. Laird et al (1996) 
showed that TNF-a production was lowest in epithelial endometrial cells cultured form 
biopsies taken after ovulation in the luteal phase of the menstrual cycle. This suggests that 
leptin has a local effect in the endometrium, possibly in creating the receptivity of the 
endometrium prior to implantation. Cytokines are important in preparing the endometrium 
for implantation (Simon et al., 1995). Leptin interacts with both TNF-a and IL-1 in other
185
human and rodent tissues (Fawcett et al., 1999, Luheshi et al., 1999). It can now be 
speculated that leptin, as part of the cytokine network, has an important function in 
preparing the endometrium for embryo implantation.
Studies of leptin during pregnancy have been performed. These studies have shown that 
levels of leptin are increased during pregnancy and fall to normal levels after birth (Butte et 
al., 1997). There is some evidence that leptin is higher in the post-partum period, in women 
who are breastfeeding compared to women who are not (Pickavance et al., 1998). Sattar et 
al (1998) report that maternal fat stores increase to a peak in the late second trimester, 
before declining towards term. The fat stores are mobilised to support the rapidly growing 
foetus. Leptin levels also decrease in the third trimester of pregnancy, this may be due to the 
decrease in maternal fat stores. Studies of leptin in pregnant human subjects with known 
pregnancy outcomes were carried out in samples taken from 2 time points in the pregnancy, 
16 and 28 weeks. These studies showed that leptin levels were higher in subjects with a 
normal pregnancy outcome than in those subjects who had a poor pregnancy outcome. Poor 
pregnancy outcome was defined as the infant being light for gestational age or being a pre­
term birth. The effect of smoking status on leptin levels in the women was also investigated. 
Previous studies have shown that leptin levels are reduced in non-pregnant smokers (Wei et 
al.,1997), this may, however, be an effect of a smokers lower BMI (Nicklas et al., 1999). In 
this cohort of pregnant subjects, leptin levels were lower in smokers than non-smokers. The 
smokers also had a lower BMI than the non-smokers. When pregnancy outcome and 
smoking status were both used together to determine leptin levels, normal outcome non- 
smokers had higher leptin levels than all the other groups. It was interesting to note a 
decrease in serum leptin concentrations between 16 and 28 weeks in subjects who were non- 
smokers but who had a poor pregnancy outcome. Leptin levels during pregnancy are 
complicated by the placental production of leptin. It is possible that in these subjects, fat 
stores were being mobilised earlier than normal in the pregnancy to support the foetus or 
that some placental dysfunction was occurring. These studies add to the knowledge of the 
leptin system during pregnancy, however, the exact function that leptin has in either 
perpetuating a pregnancy, controlling maternal fat regulation or foetal growth has not yet 
been fully elucidated.
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Inter-individual differences in LBA may reflect genetic changes within the leptin receptor 
gene. Investigations of leptin receptor SNPs were carried out to assess whether the genetic 
changes present in the gene are associated with differences in phenotype or effect ligand 
binding. A cohort of post-menopausal Caucasian women was used to minimise the hormonal 
effects on serum leptin concentrations and LBA. Two SNPs, GLN223ARG and 
LYS656ASN, both present in the extracellular domain of the leptin receptor, were 
investigated. Homozygosity of the G allele of GLN223ARG is reported to be associated 
with lower serum leptin levels in a population of Pima Indians (Thompson et al., 1997). The 
studies undertaken, indicated that homozygosity of the G allele was associated with lower 
BMI, fat mass and serum leptin levels but, not with lean mass. As this SNP is in the 
extracellular domain of the receptor, it may affect serum LBA levels, and in turn reflect the 
binding parameters of cell-surface leptin receptors. Serum LBA was significantly higher in 
those subjects who were homozygous for the G allele. This evidence suggests that 
GLN223ARG in the leptin receptor gene is an important factor in the regulation of adiposity 
and consequently BMI. None of the associations seen were independently observed with the 
SNP LYS656ASN. Haplotyping studies showed that these polymorphisms were not in 
linkage disequilibrium, and significant differences in BMI, fat mass, serum leptin levels or 
serum LBA between the haplotypes were not observed.
8.2 Further Work
As leptin is a relatively new cytokine and its full function is still being elucidated, there is 
much to investigate. To complement the work carried out in the present study, further 
experimental practises to discover the full role of leptin in the human endometrium should be 
undertaken. Workers have identified expression of leptin in the bovine uterus (Takahashi et 
al., 1998), so investigations into the possible production of leptin by the human 
endometrium should be carried out. From this point, measurement of leptin in endometrial 
flushings throughout the menstrual cycle may confirm that the increase in serum leptin, 
observed in the luteal phase of the cycle, occurs at the level of the endometrium and 
therefore may have a direct effect on cytokine production, as seen in endometrial cells in 
culture. It would be of use to investigate which signalling pathway is activated by leptin in
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both the stromal and epithelial endometrial cells. This could be assessed by investigating 
mRNA expression after treatment with leptin in endometrial cells in culture. A commercially 
prepared cDNA array treated with probes made from the cellular mRNA could then be 
utilised. In addition, investigations of the effects of leptin on endometrial cell lines, such as 
HEC-1B an endometrial carcinoma cell line, would provide interesting comparisons to the 
studies of primary endometrial cells.
There is evidence to suggest that the effect of leptin binding to its receptor influences an 
ATP-dependent potassium channel in pancreatic P-cells (Kieffer et al., 1997 , Harvey et al., 
1997). It is known that potassium channels are present in many tissues and cells where leptin 
has a role, for example T cells (Jensen et al., 1999) and the reproductive tissues (Chien et 
al., 1999). Further investigations could be carried out to identify if potassium channels were 
associated with the effect leptin has on the endometrium.
Further work on the remaining polymorphisms in the leptin receptor gene, specifically at 
codon 109 and in the leptin gene itself should be undertaken. By identifying functional 
genetic changes, this will aid in the understanding of body weight regulation. This may lead 
to future production of drugs tailored specifically to the genetic changes in individuals in the 
leptin and leptin receptor genes.
These polymorphisms could be used to examine the role of the leptin system in a number of 
situations that are associated with extremes of body weight, for example, in anorexia 
nervosa and cachexia or in obesity related disorders, such as, hypertension and heart disease. 
It would be of importance to study these polymorphisms in other population groups, such 
as, Afro-Caribbeans, Orientals and Polynesians, to see if the same associations with body 
mass index and adiposity were observed. This would allow understanding of the full effect 
the leptin receptor polymorphisms have on body mass regulation.
These polymorphisms would also be useful tools to investigate the genetic changes
associated with disorders of female reproduction such as unexplained recurrent miscarriage
and endometriosis. Unexplained recurrent miscarriage is characterised as three consecutive
miscarriages for which there is no known cause. The most common known reason for
188
miscarriage is chromosomal abnormalities of the foetus, with other explanations being the 
presence of anti-cardiolipin antibodies or abnormal uterine morphology. The polymorphic 
changes within the leptin receptor gene could also be used to investigate possible 
associations between these changes and recurrent miscarriage, as leptin and the leptin 
receptor are fundamental in female reproduction.
Another possible route of investigation of leptin and leptin receptor polymorphisms could be 
that of endometriosis. There are several theories regarding the pathogenesis of 
endometriosis. The first theory is that of "retrograde-menstruation" or "trans-tubal 
migration". This hypothesis suggests that during menstruation, endometrial tissue becomes 
loosened and the cells migrate, via the fallopian tubes, out into the pelvic and abdominal 
cavity where they implant into other tissues, such as the ovaries or the bowel and grow. This 
theory has now been superceded as it known that this migration of endometrial cells into the 
abdominal cavity occurs in women without endometriosis. The second theory is that there is 
a dysfunction in the immune system of women with endometriosis, this allows tissue that has 
migrated out of the uterine cavity to implant and grow. There is also a genetic predisposition 
to developing the disorder. Endometriosis is a heritable disorder; the risk of developing 
endometriosis increases seven-fold for women with an affected female relative. Cytokines 
are important regulators of endometrial function. It is likely that leptin, which has a role both 
in endometrial function and in the immune response, has a function in the development of 
endometriosis. By investigating, the genetic changes in the leptin and leptin receptor genes 
and in turn, identifying possible associations between certain genotypes and disease 
characteristics will enable the further elucidation of the genetic aspects of endometriosis.
This thesis has clearly shown that the leptin system has important roles in reproduction, 
specifically in the onset and maintenance of puberty and in female reproduction, and in body 
mass regulation. There is now distinct evidence for the leptin receptor to be directly 
involved in the differences observed in adiposity and BMI. There are great prospects for a 
further rapid increase in the understanding of reproductive function and body mass 
regulation, and the role which the cytokine leptin plays in these processes.
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Appendix 1
Primers used to determine the polymorphic variations in the leptin receptor
Primer Name Sequence Polymorphism Product 
size (bp)
Poly223-F
Poly223-R
5' tcc tct tta aaa gcc tat cca gta ttt 3' 
5' age tac caa ata ttt ttg taa gca at 3'
GLN223ARG 416
Poly656-F
Poly656-R
5’ gca taa gtg tgt get tea aat atg g 3’ 
5' cga aga tta ata tea gga tta acc 3'
LYS656ASN 244
Poly204-F
Poly204-R
5' tcc tct tta aaa gcc tat cca gta ttt 3' 
5* age tac caa ata ttt ttg taa gca at 3'
LYS204ARG 416
XIV
Appendix 2
RT-PCR primer sequences for the various isoforms of the leptin receptor.
Primer
Name
Receptor
Isoform
Sequence Position 
(Base No)
Product 
size (bp)
132F Ob-Rb 5’ gaa gat gtt ccg aac ccc aag aat tg 3’ 2742
132R (Long) 5 ’ eta gag cac ttg gtg act gaa c 3 ’ 3170 427
64F Ob-Ra 5’ cca ttg aga agt acc agt tea gtc ttt acc 3 ’ 2600
64R (Short) 5 ’ ggg aag ttg gca cat tgg gtt ca 3 ’ 2930 330
121F Ob-Rvar As 132F 2742
121R (variant) 5 ’ gga ttt ggc agg gtc ata gga caa 3 ’ 3053 234
7B6F
7B6R
7B6 5 ’ age cgt aga egg aac ttc gc 3 ’ 
5 ’ eta aaa cag egg aag agg 13 * 434
XV
Appendix 3
Sequencing o f  LYS656ASN PCR products to confirm genotyping by SSCP 
LYS LYS GLU
5’ 3 ’
AAA AAG GAG 
AAA AAC GAG
LYS ASN ALA
Homozygous for the C allele 
Forward
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A bstrac t: Leptin is a protein, produced by adipose tissue, which has cytokine 
and hormonal properties. Serum leptin levels can be considered as a measure 
of body fat mass, and are involved in regulation of body weight. Previous 
studies suggest that leptin may have an additional role in reproduction, and 
there is also evidence for involvement in the hypothalam ic-pituitary-gonadal 
axis. In this study, we investigate the possible changes in serum leptin concen­
tration throughout the menstrual cycle. Samples were collected from appar­
ently healthy, fertile women at different stages in their menstrual cycle, timed 
precisely according to the luteinising hormone (EH) surge. Mean serum leptin 
levels were significantly higher in the luteal phase (median 11 .4ng /m L ) than 
in the follicular phase (median lO .Ong/m L) (P <0.001). In addition, mean 
serum leptin levels correlated with body mass index (r = 0.54, P  <0.05), but 
showed no correlation with luteal-phase progesterone levels. Results showed 
that levels of serum leptin vary during the menstrual cycle, and add to the 
mounting evidence that leptin has a role in reproduction. These fluctuations 
should be taken into account whenever studies are performed using female 
subjects.
Key words: Body mass index. Leptin. M enstrual cycle. Reproduction.
Introduction
Leptin, the product o f the ob gene, is a 16 kDa adi­
pose tissue-derived protein which appears to have the 
properties of both hormone and cytokine. The effects 
of leptin appear to be pleiotropic; various studies have 
suggested a role for it in obesity, thermogenesis, body 
mass regulation1 and haematopoiesis.2 More recent 
studies have suggested that leptin has a role in female 
reproduction, although the exact nature of the role is 
not understood.2 4 Circulating leptin concentrations 
are higher in females than males, even when corrected 
for differences in body mass index (BM I).5,6
Further evidence for a role for leptin in reproduc­
tion is that pregnancy causes changes in the serum 
concentration of leptin, with levels at 36 weeks gesta­
*Correspondence to: Naomi Quinton, Sheffield Hallam University.
tion higher than at three and six months postpartum. ’ 
O ther studies have suggested that this increase in 
leptin may be brought about by the progressive 
increases in plasma progesterone, oestrogen and 
human placental lactogen in pregnancy.2,4
A num ber of studies have indicated that leptin may 
interact with the hypothalam ic-pituitary-ovarian 
axis.7 In women undergoing pituitary down- 
rcgulation and ovarian stimulation for in vitro fertilis­
ation (IVF), serum leptin levels have been shown to 
correlate with oestradiol and follicle-stimulating hor­
mone (FSI4),S and other studies have suggested that 
leptin may be involved in bringing about the ovarian 
response to gonadotrophin stimulation.4 T his hypo­
thesis is supported by the presence of leptin receptors 
in ovarian tissue2 and the presence of leptin within 
the preovulatory follicle and mature oocyte."'
T he majority of previous investigations on the role
16
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ofleptin  in female reproduction have been carried out 
in pregnant women or those undergoing IVF treat­
ment using stimulated cycles. Less is known about 
the variation in serum leptin levels throughout the 
menstrual cycle in normal fertile women. In this 
study, the levels of leptin were measured in serum 
obtained from 17 women, of proven fertility, through­
out the menstrual cycle to test the hypothesis that 
levels of leptin alter throughout the cycle.
M aterials and m ethods
Serum samples were obtained from 17 normal fertile 
women with BMI between 19.8 and 27.9 k g /m 2. 
Blood samples were collected at times in the men­
strual cycle that were convenient to the subjects 
involved, who were not required to fast before sam­
pling took place. The number of serum samples col­
lected from each subject ranged from one to three in 
the follicular phase and two to three in the luteal 
phase. The women were aged between 30 and 39 
years, with normal menstrual cycles confirmed by 
detection of luteinising hormone (LH) surge and 
luteal-phase progesterone levels. Each woman had 
had at least one successful pregnancy. The samples 
obtained were timed precisely according to the LH 
surge. From  day nine of the cycle, early morning 
urine or daily plasma samples were collected from 
each subject. An established enzyme immunoassay 
(EIA) (Serono Diagnostics L td, Surrey, UK) was 
used to measure L H  in each sample. The day on 
which the LH  surge occurred was designated L H + 0."
Each sample was prepared from 10 mL of venous 
blood. After collection, the blood sample was allowed 
to clot and then centrifuged at 3000 X g  for 10 min. 
The serum layer was removed and stored in 1 mL 
amounts at -80°C . In all, 79 samples were collected. 
Human leptin concentrations were measured in 
duplicate using a specific human leptin radioimmuno­
assay (RIA) kit (Linco Research Co, St Louis, MO, 
USA) with an inter-batch variation between 3%  and 
6% , and a detection limit of 0.5 ng /m L .
Serum progesterone was measured in samples 
taken 10 days after the L H  surge (LH+10), at the 
point where progesterone is maximal, in 14 of the 
women. T he progesterone was measured using a pro­
gesterone EIA kit (Serozyme, Welwyn Garden City, 
Herts, UK).
Differences between levels of leptin in the luteal 
phase and the follicular phase were analysed using 
non-parametric analysis (M ann-W hitney U  test). 
Correlations between BMI and leptin level were ana­
lysed using Spearman ranking.
The study had the approval of the local ethical 
committee (South Sheffield Research Ethics 
Committee) and all subjects gave informed consent.
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F ig . 1. C oncentrations o fle p tin  in serum  collected from  four sub­
jects throughout the m enstrual cycle.
Results
Fig. 1 shows the leptin levels in the serum collected 
from four representative subjects. The results for 
these four subjects are shown as they had varying 
BMI and leptin levels within the normal range (2 - 
20 ng /m L ) for women of normal weight. Levels of 
leptin gradually increased throughout the cycle and 
were maximal in the luteal phase. In 14 of the 17 
subjects, mean luteal leptin levels were arithmetically 
higher than mean follicular leptin levels. T he mean 
follicular and luteal leptin levels in the remaining 
three subjects were unchanged.
The median serum follicular and luteal leptin levels
T ab le  1. Median leptin levels for each subject in the follicular and 
luteal phases
Subject Mean leptin level (ng/m L)
Follicular phase Luteal phase
1 12.3 15.9
2 7.4 11.4
3 10.0 19.4
4 36.0 61.1
5 4.7 5.0
6 13.3 27.3
7 4.3 5.7
8 5.7 7.6
9 5.6 10.3
10 11.4 10.8
11 13.2 17.9
12 12.4 14.3
13 6.6 7.4
14 16.4 16.9
15 8.3 10.5
16 7.0 8.2
17 10.7 13.7
B r j f  Biomed S c i  1999; 56
18 N. D. Qiiinton et al.
i a
B
1 2 3 4 5 6 7 10 11 12 13 14 15 16 17
Subject
F ig . 2. Levels o f leptin for each subject in the follicular (open 
square) and luteal (black square) phases.
for each woman are shown in Table 1, and all levels 
plotted in Fig. 2. Leptin levels were significantly 
higher (P  <0.01) in serum obtained during the luteal 
phase than in serum collected during the follicular 
phase. T he overall median serum leptin levels during 
the follicular and luteal phases were 10.0 ng /m L  
(range: 4.3-32.2 ng /m L ) and 11.4 n g /m L  (range: 
4.9-66.7 ng /m L ) respectively.
BM I measurements were not obtained for subjects 
2 and 10. For the 15 subjects whose values were 
obtained, significant correlation was seen between 
leptin level and BM I (r = 0.54, P  <0.05, Fig. 3). 
Luteal-phase progesterone levels were obtained in 14 
of the 17 subjects; however, no correlation was seen 
between leptin and progesterone at the peak proges­
terone level, 10 days after the L H  surge (r = -0 .34, P  
<0.370, data not shown).
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F ig . 3. T h e  relationship betw een mean serum  leptin levels and 
BM I. A significant correlation was seen (r =  0.54, P  <0.05).
D i s c u s s i o n
T he results indicate that circulating leptin concentra­
tion increases after ovulation in the luteal phase of the 
menstrual cycle, and this was seen in 14 of the 17 
women included in the study. Levels ofleptin  showed 
no change in three women. The reason for this is 
unknown, but it may be due to differences in levels 
of reproductive hormones. This work confirmed and 
extended the work of Hardie et a l}1 who also found 
that leptin levels increased during the luteal phase of 
the menstrual cycle. Their study, however, was lim­
ited by the fact that it included only six regularly cyc­
ling women. In the present study, measurements were 
obtained in 17 women. In addition to similar changes 
seen throughout the menstrual cycle in both studies, 
the absolute levels of leptin in serum were similar in 
the present study and that of Hardie et al.12
Observation that leptin levels are higher during the 
luteal phase of the cycle would agree with suggestions 
for a role in reproduction14 and possibly implanta­
tion.10 The presence of leptin receptors in the ovary10 
also suggests that it may play a role in ovarian func­
tion, and the rise in leptin level seen during the luteal 
phase supports the hypothesis that it interacts with 
the hypothalam ic-pituitary-ovarian axis to help main­
tain the corpus luteum.
Several studies have shown that serum leptin level 
correlates well with B M I.1 In this study, significant 
correlation of BM I with serum leptin level was also 
seen. The relationship between BMI and reproductive 
ability is well established. Gymnasts, marathon run­
ners and others with low-percentage body fat often 
have amenorrhoea, and puberty is delayed in females 
with low-percentage body fat mass.14 In addition, it 
has been shown that a t Heal fat mass (> 10th centile) 
is required for ovulation in women,1’ and it has been 
suggested that leptin may serve as a signal to the 
reproductive system to indicate that stores are suffi­
cient to sustain reproduction.16
Some interpersonal variation in the leptin levels 
measured was noted. T he reason for this is unknown, 
although a study has shown that leptin levels in 
women are highly variable, even when normalised for 
BMI. However, subject 4 had a far higher serum 
leptin level than other subjects, with only a moder­
ately raised BM I of 26.5 k g /m 2. A possible explana­
tion for this anomaly is that she had eaten prior to 
having the sample taken and, hence, had a short-term  
change in metabolism. Alternative explanations may 
be the presence of a leptin receptor defect or the pres­
ence of a much greater adiposity than in the other 
subjects. BM I is not a measure of adiposity but of 
total body weight compared with height, and leptin 
levels have been shown to correlate better with meas­
ures of adiposity than with BM I.4 In addition, other
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factors such as exercise1' which may affect serum 
leptin concentrations were not controlled for in this 
study. A num ber of other factors including diurnal 
rhythms, food intake, cytokines and hormones are 
known to influence leptin levels. We can offer no clear 
explanation of the raised levels of leptin in subject 4, 
which were consistent in all her samples.
In contrast to the study by Hardie et al.,12 no cor­
relation was seen between luteal-phase progesterone 
levels and mean luteal-phase leptin levels. In our 
study, progesterone measurements were only obtained 
at one point in the cycle, whereas in the study by 
Hardie et a l}2 they were obtained throughout the 
cycle. O ther studies, in women undergoing IVF, have 
suggested that levels of leptin correlate with oestradiol 
and FSH. We did not measure these in this study; 
however, leptin may correlate better with these repro­
ductive hormones than it does with progesterone.
In summary, we have shown that serum leptin 
levels increase during the luteal phase of the men­
strual cycle, supporting the contention that leptin may 
have a role in reproduction. In addition, this fluctu­
ation should he taken into account when studies invol­
ving the measurement of leptin are performed in 
female subjects.
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ABSTRACT
The timing of the physical transition from child to adult is  deter­
mined by a biological clock that switches off the pituitary gonadal axis 
during infancy until puberty. Body composition (and in particular, fat 
mass), through leptin, are critical signals to this clock. However, no 
direct relationship between leptin and puberty has been demon­
strated. Leptin is bound in the circulation by a high-affinity binding 
protein, which has been identified as a soluble leptin receptor. We 
found circulating levels of leptin binding activity (LBA) to be low at 
birth, to be high in the prepubertal years, to fall through puberty, and
then to remain stable during adult life. LBA correlated with pubertal 
status in both boys and girls. We postulate that the fall in LBA, 
associated with increasing age and puberty, reflects a reduction in 
expression of truncated leptin receptors, and leptin is then available 
to the full-length receptor, which transm its the biological signal for 
leptin. The high levels of LBA occur during the years when the pi­
tuitary gonadal axis is quiescent. Thus, the change in LBA could 
explain how leptin regulates puberty. (J  Clin Endocrinol Metab 84: 
2336-2341, 1999)
P UBERTY, the transition from child to adult is the result 
of reactivation of the pituitary gonadal axis. Sex ste­
roids reach adult levels in late gestation, driving sexual dif­
ferentiation in the fetus, then (shortly afterbirth) the pituitary 
gonadal axis switches off and lies dormant until the onset of 
puberty. We are now beginning to define some of the met­
abolic switches that program this biological clock. The im­
portance of body composition has been recognized since the 
1970s, when Frisch (1) suggested that it was necessary for 
women to maintain a specific percentage of body fat to 
achieve menarche and fertility. The recent cloning of the 
obesity gene and characterization of its product leptin, which 
is secreted from fat cells, has provided us with a signaling 
system whereby energy stores are sensed by physiological 
systems. It is now clear that leptin has a much wider role in 
human metabolism than just the regulation of body fat mass 
(2, 3).
Leptin acts through a class 1 cytokine receptor, the leptin 
receptor, which is highly expressed in the hypothalamus (4, 
5). The biological actions of leptin include the regulation of 
appetite and energy expenditure, as well as involvement in
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the control of the hypothalamic-pituitary-gonadal axis (2,3). 
In rodents, leptin administration accelerates the onset of re­
productive function and restores fertility in the mutant 
ob/ob mouse (6, 7). Two recent reports of humans with 
mutations in the leptin receptor and leptin gene, who failed 
to progress through puberty, provide important evidence for 
the role of leptin in facilitating pubertal development (8, 9). 
However, the link between puberty and leptin is not fully 
established. Cross-sectional and longitudinal studies of lep­
tin levels before and during puberty indicate that leptin 
levels follow changes in fat mass (10-12), although a brief 
pulse of leptin may precede the onset of puberty in males 
(13). In children, age is also an independent determinant of 
leptin levels, and leptin may act as a permissive signal to 
puberty over time (12).
Binding proteins for circulating leptin have been described 
in both the human and rodents (14-16). Varying sizes of the 
binding protein have been reported but would be compatible 
with the size of the extracellular domain of the leptin receptor 
(14, 15). In humans, the leptin-binding protein can be pre­
cipitated by a leptin receptor antibody (14). In the pregnant 
mouse, the binding protein has been sequenced and con­
firmed as the extracellular domain of the leptin receptor (17), 
and expression of the extracellular domain of the human 
leptin receptor in COS7 cells results in the production of a 
binding protein in the medium (6). These results are consis­
tent with observations made for other members of the class 
I cytokine family of receptors, a number of which produce 
soluble receptors that represent the extracellular domain of 
the receptor (18).
Leptin-binding protein [or leptin binding activity (LBA)]
2336
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has only been measured in limited clinical situations. In the 
studies performed, LBA was lower in obese patients, com­
pared with lean, suggesting that the obese have higher free 
levels of leptin (14-16). We have modified an assay for GH- 
binding protein (GHBP) to measure LBA (19). The assay 
specifically measures a high-affinity binding protein; and 
using this assay, w e have measured levels of LBA through 
the ages from birth to old age. The results show that the major 
change in LBA occurs at puberty.
M aterials and Methods
LBA assay
Stripping of leptin from serum sample. To 200 pL  of serum, 500 /iL of 
prechilled 2% Norit A charcoal (American Norit Co., Atlanta, GA) 0.2% 
Dextran T70 (Amersham Life Science, Buckinghamshire, UK) in assay 
buffer was added at room temperature, vortex mixed, and immediately 
placed on ice for 5 min. The sample was centrifuged at 4 C for 12 min 
at 10,000 X  g .  The supernatant (stripped of free leptin) was removed by 
pipette and placed in a new tube.
Measurement of LBA. Fifty microliters of stripped serum was incubated 
with 150 pL  assay buffer (0.01 m ol/L  phosphate buffer (pH 7.4), 0.18 
m ol/L  MgCl2, 1% BSA), 100 pL  [125I]Leptin [135 p C i/pg (Linco Re­
search, Inc., St. Louis, MO)], in the presence (nonspecific) or absence 
(total binding) of 1 pg unlabeled leptin (R&D Systems, Abingdon, Ox­
ford, UK). For separation of bound from unbound, 1 mL prechilled 2% 
charcoal-0.2% Dextran T70 slurry in assay buffer was added to the 
overnight incubation, vortexed, placed on ice for 10 min, and centrifuged 
at 4 C for 12 min at 10,000 X g .  One milliliter of the supernatant was 
aspirated by pipette and counted in an automatic y-counter. The specific 
binding (total binding minus nonspecific binding) obtained was ex­
pressed as a percentage of the total [125I]Leptin counts per minute in­
cubated in 50 pL of serum and called the LBA. All samples were mea­
sured in duplicate.
Serum samples with high and low levels of LBA were used as control 
serum and were run in each assay at the beginning and end of the assay.
High-performance liquid chromatography (HPLC) analysis
The HPLC method was developed from a method used to measure 
GH-BP by Tar et al. (20). HPLC separations were performed using a 
liquid chromatograph (model 600, Waters Corp., Milford, MA) 
equipped with a sample injector (model U6K) fitted with a 250-pL loop 
and an analytical Protein Pak 300sw column (Waters; 0.75 X 30 cm). 
Absorbance at 280 nm was monitored with an LC spectrophotometer 
(Waters), and radioactivity was recorded on-line using a Bertold LB 504 
y-detector (E G and G, Evry, France) connected to a Compaq computer.
Serum (150 pL) was incubated overnight at 4 C with 30 pL assay 
buffer and 20 pL [125I]Leptin. A parallel incubation was carried out in 
the presence of an excess of unlabeled leptin (2 pg). After filtration 
through a 0.45-pm minifilter Millipore Corp. (Watford, UK), the entire 
incubation was placed onto an HPLC Protein Pak 300sw column. Elution 
was performed autocratically using a degassed buffer (0.1 m ol/L  
Na2S 0 4 and 0.1 m ol/L  potassium phosphate, pH 7.0) pumped at a rate 
of 0.5 mL/min.
Leptin measurement
Human leptin concentrations were measured in duplicate using a 
specific Human Leptin RIA kit (Linco Research, Inc.) with an interbatch 
variation of between 3.0 and 6.0% and a detection limit of 0.5 ng/mL.
Statistics
Statistical analysis was performed using the software package SPSS. 
Pearson product-moment correlations were calculated to test association 
among variables. One-way ANOVA was used to investigate the effect 
of pubertal status on LBA. The t test, with Bonferroni adjusted P values, 
was used to look for differences between groups. A stepwise multiple- 
regression analysis with a P value less than 0.05 for entry and less than
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0.10 for removal was used to determine which of the following possible 
explanatory variables [age, puberty, body mass index (BMI), and leptin] 
could be used to predict LBA in boys and girls.
Serum samples
All children and adults gave informed written consent or assent, and 
the studies had the approval of the local research ethics committees. 
Serum samples were taken between 0900 and 1000 h, and neonatal 
samples were from umbilical cord blood. Samples were separated and 
stored at —20 C until analysis. Pubertal staging was performed by an 
experienced pediatrician using the Tanner stages of puberty. Clinical 
details are given in Table 1.
R esults
Assay validation
Competition experiments. Displacement curves with serial di­
lutions of neat stripped serum showed parallel displacement. 
Specificity for leptin was confirmed by incubation with un­
labeled human GH and interleukin-6 (Fig. 1A), which 
showed no displacement. Scatchard analysis of competition 
experiments with human leptin showed a linear plot with a 
binding affinity of 1.0-1.4 X 109 m ol/L -1 (Fig. IB).
Serum was stripped of endogenous leptin by preincuba­
tion with dextran-coated charcoal. To establish the effect of 
the preincubation with dextran-coated charcoal, serum sam­
ples were incubated for up to 1 h, and then the leptin and LBA 
were measured. Leptin was reduced to undetectable levels 
with preincubation (n = 19), confirming that the dextran- 
coated charcoal was removing all endogenous free leptin.
The assay had a sensitivity of 0.6% specific binding (mean 
+ 2 s d  of 10 repeated measurements with zero sample). At 
12 and 6% specific binding, the intraassay coefficient of vari­
ation was 3.2 and 4.1%, and the interassay coefficient of 
variation was 6.4 and 4.8%, respectively.
Results from this assay were compared with those ob­
tained by F1PLC. A single profile is shown in Fig. 1C. HPLC 
revealed a peak at the appropriate size for a soluble receptor 
(~85 kDa). Results of specific binding were comparable, 
considering the different methodolgy for the eight samples 
analyzed; mean ± s e m  for LBA 10.5 ± 1.07% vs. HPLC 9.4 ± 
0.78%. A comparison of samples analyzed is summarized in 
Table 2; these have been corrected to allow for the difference 
in sample volume used in the two assays.
LBA through the ages
Figure 2 shows the median LBA at the different ages of life. 
LBA was lowest at birth, highest in prepubertal children, and 
fell during puberty to a mean level of between 7 and 9% in 
young men and women and remained at this level through 
to old age. There were no differences in LBA between males 
and females at any age.
In adults, there was no evidence of a relationship between 
LBA and age, BMI, or leptin levels (Table 3). In contrast, in 
children there was an inverse relationship between LBA and 
age, pubertal status, weight, and BMI (Table 3 and Fig. 3).
Multivariate stepwise regression analysis, with LBA as the 
dependent variable and age, puberty, BMI, and leptin as the 
independent variables, was performed. In boys, the model 
explained 41% of LBA, with only age significantly associated 
with LBA. In girls, the whole model explained 51% of LBA,
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Fig. 1. A, Hormonal specificity of binding of [12rT]Leptin to normal 
human serum. The specific binding of [125I]Leptin is expressed as a 
percentage of the maximal binding. Values are the mean of duplicate 
determinations from a representative experiment. IL-6, Interleu­
kin-6. B, Scatchard analysis of [125I]Leptin to normal human serum. 
B/F, Bound/Free. C, Elution profile of [125I]Leptin incubated with  
human serum. [125I]Leptin (4 X 104 cpm) was incubated with 150 p.L 
serum without (thick line) and with (thin line) excess of native leptin. 
Binding was expressed as the radioactivity in the first peak over the 
radioactivity in peak 1 and peak 2 (free [125I] Leptin. For the profile 
shown, total binding was 29.0%, and nonspecific 13.1%, radioactivity.
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with age (46%) and BMI (5%) significantly associated with 
LBA. ANOVA showed a significant effect of pubertal status 
on LBA (F = 21.2, P <  0.0001) with LBA at all stages of 
puberty being significantly lower than levels at stage 1 of 
puberty, and stage 2 being different from all stages except 
3. Pearson correlations between LBA and age, BMI, or 
leptin at each pubertal stage were performed. In girls, LBA 
was negatively correlated with age during Tanner stage 1.
TABLE 2. Comparison of results from LBA and HPLC method
Samples Specific binding (%)LBA HPLC
1 8.1 6.3
2 9.7 8.1
3 6.5 11.7
4 10.5 8.8
5 9.3 7.2
6 12.5 10.4
7 16.5 12.6
8 10.5 10.3
Mean ±  S e m 10.5 ±  1.07 9.4 ±  0.78
~  20 oU<
*  *  S ig n if ic a n tly  h ig h e r  th a n  a l l  g r o u p s
e x c e p t b o y s  (P < 0 .0 1 )
*  S ig n if ic a n tly  h ig h e r  th a n  n e o n a te s  
a n d  m e n  ( P < 0 .0 0 ! )
mm.
N= 10 
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blood
26
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9 10
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Fig. 2. LBA through the ages from birth to the elderly.
In boys, LBA was inversely correlated with serum leptin 
during stage 4.
D iscussion
Circulating soluble receptors are a feature of a number 
of members of the cytokine family of receptors (18). The 
most widely studied, with respect to the endocrine system, 
is the GHBP, which is derived (by proteolytic cleavage) 
from the extracellular domain of the GH receptor (21). In 
most studies, GHBP levels reflect the tissue-specific ex­
pression of the GH receptor; and recently, a truncated form 
of the receptor has been identified that generates large 
amounts of GHBP and acts as a dominant negative an­
tagonist of GH signaling (22,23). The leptin receptor gene 
is expressed as a number of alternatively spliced isoforms 
(Ob-Ra to Ob-Re) (24, 25) of which Ob-Ra, b, and e are the 
major splice forms (26). Ob-Rb contains all elements for 
signaling, Ob-Ra has a truncated cytoplasmic domain, and 
Ob-Re is truncated at the extracellular domain, which, 
when expressed in transfection studies, generates an LBA 
(6). The finding of a fall in high-affinity LBA may reflect 
a change in expression of truncated leptin receptors, and 
this may result in more free leptin being available at the 
hypothalamus, which expresses Ob-Rb, the full-length sig­
naling leptin receptor.
We have validated an assay for measuring LBA in human 
serum. The assay is based on a method previously described for 
the measurement of GH-binding protein activity (19). The LBA 
assay was specific, reproducible, and sensitive. It detected a 
high-affinity binding protein, Ka 1.0-1.4 X 109 M-1, which 
would be compatible with the expected affinity of the soluble 
receptor (6). Results from this assay were comparable with 
HPLC analysis of leptin-binding protein. Scatchard analysis 
suggested that the assay detected a single species of binding 
protein, although there may be lower-affinity leptin-binding 
proteins that were not detected by this assay (14). LBA has been 
reported to relate inversely to leptin levels; however, this may 
have been an artefact caused by interference in the assay by 
endogenous leptin (16). In the present study, endogenous leptin 
was removed before assaying LBA, and no statistical evidence 
of a relationship was found between leptin levels and binding 
activity except in girls. In girls, leptin increases with age and 
puberty as LBA is decreasing. The negative correlation would 
therefore be expected.
LBA was low at birth, high in early childhood, fell during
TABLE 3. Correlation analysis between different variables and LBA
Variable Umbilical cord Boys Girls Men Women
Number of subjects 10 65 67 18 23
Age NM r = -0 .6 4 r = -0 .6 6 r = -0 .0 9 r = -0 .3 5
P  = 0.0001 P  =  0.0001 P  =  0.713 P  =  0.226
Pubertal status NM r = -0 .6 2 r = -0 .6 1 NM NM
P  = 0.0001 P  = 0.0001
Testicular volume NM r = -0 .6 0 NA NM NA
P  = 0.0001
BMI NM r = -0 .3 8 r = -0 .5 1 r = -0 .1 9 r = -0 .3 5
P  =  0.002 P  = 0.0001 P  =  0.47 P  =  0.28
Leptin r = -0 .3 1 r = -0 .0 3 r = -0 .4 2 r = -0 .2 1 r = -0 .0 6
P  =  0.45 P  = 0.80 P  = 0.001 P  = 0.41 P  =  0.83
NM, Not measured; NA, not applicable.
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Fig. 3. LBA against: age (A), pubertal status (B), and testicular vol­
ume (C).
puberty, and remained at the postpubertal level throughout 
adult life. These changes in LBA parallel the known changes 
in activity of the pituitary gonadal axis, with high levels of 
LBA being present during the childhood years, when the 
pituitary gonadal axis is quiescent. There was no difference 
between boys and girls or men and women in LBA. In pu­
bertal children, LBA showed a significant relationship with 
age, pubertal status, BMI, and testicular volume in boys. 
Multivariate analysis suggested that the most important fac­
tor was age. There is an absolute requirement for leptin for 
the initiation and progression of puberty, as demonstrated by 
the hypogonadal state of leptin-resistant or -deficient human 
subjects (8, 9). However, leptin may only provide a tonic 
background signal on which other initiators act, because 
leptin levels in puberty primarily relate to fat mass (2). Our 
finding, of the direct inverse relationship between LBA and
pubertal status or age, with a fall in LBA seen at the earliest 
stages of puberty, suggests that this is a link from leptin to 
the progression of puberty.
In adult subjects, there were no differences in LBA be­
tween the sexes. This is in sharp contrast to the well- 
recognized sexual dimorphism in serum leptin levels (3). 
If the change in LBA is related to a change in leptin re­
ceptor subtype, then this may be an alteration that occurs 
at puberty and remains unaltered through adult life. We 
found no relationship between BMI and LBA in adults, 
although our studies were confined to a normal popula­
tion. Previous studies have suggested that LBA is reduced 
in obesity (14-16).
In conclusion, we have developed a simple and specific 
assay for the measurement of LBA. This assay demon­
strates an inverse relationship between age and LBA and 
a strong correlation between puberty and a fall in LBA. The 
fall in the earliest stages of puberty suggests that this is a 
primary event, not driven by changes in sex steroids. The 
fall in LBA could be explained by a change in leptin re­
ceptor expression, which may be the link between leptin 
and puberty.
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